Document:

Exhibit 10.6

 

MASTER AGREEMENT
FOR A JOINT VENTURE AND

 

INTELLECTUAL
PROPERTY PURCHASE AGREEMENT

 

by and among

 

ODYSSEY GROUP
INTERNATIONAL INC.,

 

AND

 

PREVACUS,
INC.

 

 

 

 

This
MASTER AGREEMENT FOR A JOINT VENTURE AND INTELLECTUAL PROPERTY PURCHASE AGREEMENT, dated as of June 26, 2019 (this “Agreement”),
by and among Prevacus Inc. a Delaware Corporation “Prevacus”), and, Odyssey Group International Inc., a Nevada
corporation (“Odyssey” ), whose address is 2372 Morse Ave. Irvine, CA 92614. Odyssey, and Prevacus are referred to
collectively herein as the “Parties”.

 

WHEREAS,
Odyssey is a publically traded company focused on developing and commercializing medical products, including pharmaceutical and
medical devices. (the “Business”); and

 

WHEREAS,
Prevacus desires to sell fifty percent of its interest, and Odyssey desires to purchase fifty percent of, the Purchased Assets
(as defined below) upon the terms and subject to the conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing, he mutual covenants and agreements herein contained and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties
hereby agree as follows:

 

ARTICLE
I

PURCHASE
AND SALE OF ASSETS

 

Section
1.1 Purchase and Sale of Assets.

 

On,
and subject to, the terms and conditions of this Agreement, at the Closing, Prevacus shall sell, assign, transfer, convey and deliver
to Odyssey, and Odyssey shall purchase and acquire from Prevacus, free and clear of all Encumbrances, fifty percent of Prevacus’s
right, title and interest, as of the Closing, in and to the following assets, properties and rights (collectively, the “Purchased
Assets”):

 

		a)	The world wide and USPTO Patent Numbers
		b)	The patent relates to a neurosteroid developed by Prevacus.
		c)	All the assets set forth in Exhibit “A” to this Agreement.

 

 

 

    	 	1	 

     

    

 

Section
1.2 Excluded Liabilities and Assets.

 

Prevacus
is not selling any of its assets to Odyssey other than the Purchased Assets. Odyssey does not assume any liability or obligation
of Prevacus, in connection with the Purchased Assets pursuant to Odyssey’s purchase of such assets in connection with this
Agreement.

 

Section
1.3 Purchase Consideration.

 

		a)	Equity. In partial consideration for the sale by Prevacus of the Purchased
                                                              Assets to Odyssey, at the Closing, Odyssey shall grant Prevacus two-million (2,000,000) shares of Odyssey common stock. The
                                                              Parties will execute a Stock Grant Agreement in the form attached hereto it as Exhibit “E”.

 

		b)	Joint Venture. In partial consideration for the sale by Prevacus of the Purchased
Assets to Odyssey, within 90 days after the Closing, Odyssey and Prevacus shall enter into a Joint Venture whereby the Parties
will create a limited Liability Company (LLC) in the State of Florida. The LLC will be owned equally by the Parties. Odyssey will
be responsible for raising a total of $2,500,000 for developing the Purchased Assets though a phase I clinical trial. Prevacus
will be responsible for assigning all rights and title of the Purchased Assets to the LLC.

 

		c)	Employment or Consultant Agreement.At the Closing, the LLC shall enter into an
Employment Agreement with Jake VanLandingham (“Consulting Agreement”) to oversee the development of the Purchase assets.
The annual salary will be $200,000.00 in the form attached hereto as Exhibit “B”. Payments will not begin until a minimum
of Five hundred thousand ($500,000.00) has been raised for the LLC to operate.

 

		d)	Share Exchange Agreement: In partial consideration for the Purchased Assets the Parties
will enter into a Share Exchange Agreement (“SEA”) in the form attached hereto as Exhibit “C” whereby Odyssey
will grant Prevacus three million shares (3,000,000) of Odyssey common stock and Prevacus will issue Odyssey one million shares
(1,000,000) of Prevacus stock. The SEA will have a claw back provision stating that if, within one year of the Effective Date,
Odyssey has not raised a minimum of five hundred thousand ($500,000) to fund the LLC, then each party may have their shares either
returned to the original owner or cancelled.

 

		e)	Patent Assignment. In partial consideration for the sale by Prevacus of the Purchased
Assets to Odyssey and the LLC, Prevacus shall enter a Patent Assignment Agreement (“Patent Assignment”) in the form
attached hereto as Exhibit “D” providing a recordable assignment of the US Patents described in the Purchased Assets
to Odyssey. The Patent Assignment will take place when Odyssey has funded the LLC with a minimum of five hundred thousand dollars
($500,000.00)

 

		f)	Board of Directors Agreement. An agreement appointing Jake VanLandingham to the Odyssey
Board of Directors will be executed by the Parties. Jake will become a Board member of Odyssey and the Agreement will have compensation
to as one million shares of Odyssey common stock.

 

		g)	Non Compete by Prevacus. Prevacus agrees not to assist, work for or in any way provide services
that in any way relates to the development, manufacturing, sales, marketing or distribution of a product containing the Purchased
Assets, except on behalf of Odyssey.

 

 

 

    	 	2	 

     

    

 

Section
1.4 Closing Transactions.

 

(a) Closing.
Unless this Agreement shall have been terminated in accordance with Section 8.1, and subject to the
satisfaction or, if permissible, waiver of the conditions set forth in Article VII, the closing of the
Transactions (the “Closing”) will take place at 12:00 noon, Los Angeles, California time, on a date
to be specified by the Parties but no later than July 31, 2019 (the “Closing Date”), which shall be not
later than the second Business Day after the satisfaction or, if permissible, waiver of the conditions set forth
in Article VII (other than those that by their terms are to be satisfied or waived at the Closing), at
the offices of Odyssey Group International, Inc. at 2372 Morse Ave Irvine CA , unless another time, date or place is agreed
to in writing by the Parties; provided, however, that the Parties shall use reasonable efforts to conduct the Closing by mail
and overnight delivery so as not to require the personal attendance of the parties at the Closing. If the parties agree, the
Closing may be telephonic.

 

(b) Actions
and Deliveries by Prevacus. At the Closing, Prevacus shall deliver to Odyssey:

 

(i)
the certificates and documents required to be delivered by Prevacus pursuant to Sections 7.1
and 7.2;

 

(ii)
all such other instruments of assignment and transfer as are reasonably required to effect the transfer to Odyssey of all of Prevacus’
right, title and interest in and to the Purchased Assets in accordance with this Agreement, in form and substance reasonably satisfactory
to Odyssey and Prevacus; and

 

(iii)
Duly executed copies of all the agreements referred to in this Agreement.

 

(c) Actions
and Deliveries by Odyssey (as required). At the Closing, Odyssey (as required) shall deliver to Prevacus:

 

(ii)
the Stock Grant Agreement in the form of Exhibit E  dated the Closing Date and duly executed by Odyssey;

 

(iii)
the Share Exchange Agreement in the form of Exhibit C  dated the Closing Date and duly executed by Odyssey;

 

(iv)
The Board of Directors Agreement

 

(v)
The Employment Agreement for Jake VanLandingham

 

(v)
the certificates and documents required to be delivered by Odyssey pursuant to Sections
7.1 and 7.3.

 

ARTICLE II

REPRESENTATIONS
AND WARRANTIES OF PREVACUS

 

Prevacus
hereby represents and warrants to Odyssey that, to the best of “Prevacus’s Knowledge” (as hereinafter defined)
and except as set forth in the disclosure schedule delivered by Prevacus to Odyssey and attached hereto and made a part hereof
(the “Prevacus Disclosure Schedule”). Such warranties and representation shall be true as of the date of execution
and the date of Closing:

 

 

 

    	 	3	 

     

    

 

Section
2.1 Organization.

 

Prevacus
is duly incorporated, validly existing and in good standing under the laws of Delaware and has the requisite corporate power and
authority to own, operate or lease the properties that it purports to own, operate or lease and to carry on its business as it
is now being conducted.

 

Section
2.2 Authority Relative to this Agreement and Related Matters.

 

Prevacus
have all necessary personal or corporate power and authority to enter into this Agreement and to carry out its obligations hereunder.
The execution and delivery by Prevacus of this Agreement and the consummation by Prevacus of the transactions contemplated hereby
(the “Transactions”) have been duly authorized by all necessary corporate action on the part of Prevacus. This
Agreement has been duly executed and delivered by Prevacus and, assuming the due authorization, execution and delivery hereof by
Odyssey, no further action or approval, corporate or otherwise, is required in order to constitute this Agreement as a valid and
binding obligation of Prevacus enforceable in accordance with its terms.

 

Section
2.3 No Conflict; Required Filings and Consents.

 

The
execution and delivery of this Agreement by Prevacus does not, and the consummation by Prevacus of the Transactions will not, (a) conflict
with or violate the certificate of incorporation or bylaws, each as amended to date, of Prevacus, (b) conflict with or violate
any Law or Order applicable to Prevacus or by which Prevacus or any of its properties is bound, (c) result in a breach of
or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give rise to any
right of termination, acceleration or cancellation under, or result in the creation of an Encumbrance on any of the Purchased Assets
pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license or other instrument or obligation to which
Prevacus is a party or by which Prevacus or any of its properties is bound, or (d) require Prevacus to obtain any consent,
approval, authorization or permit of, or to make any filing with or notification to, any Governmental Authority, except (i) as
set forth in Section 2.3 of the Prevacus Disclosure Schedule, or (ii) for any filings required pursuant
to the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange
Act”).

 

Section
2.4 Absence of Litigation.

 

Except
as disclosed in Section 2.4 of the Prevacus Disclosure Schedule, as of the date hereof, (a) there is
no private or governmental action, suit, proceeding, litigation, arbitration or investigation (“Action”) pending
or, to the knowledge of Prevacus, threatened against Prevacus before any Governmental Authority that, if adversely determined,
would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions, and (b) there is no legally
binding judgment, decree, order, injunction, decision or award of any Governmental Authority (“Order”) against
Prevacus that would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions.

 

Section
2.5 Purchased Assets.

 

Prevacus
owns (beneficially and of record) all right, title and interest in and to all Purchased Assets, free and clear of all Encumbrances.
Purchased Assets have been duly filed in the jurisdiction named in each such application, are being actively prosecuted and have
not been abandoned or allowed to lapse. There is no Action that is pending or, to the knowledge of Prevacus, threatened that challenges
the rights of Prevacus in respect of any Purchased Assets or the validity, enforceability or effectiveness thereof. Prevacus has
not received any written communication alleging that it has infringed the Intellectual Property rights of any third party and there
are no Actions that are pending or, to the knowledge of Prevacus, threatened against Prevacus with respect thereto. To the knowledge
of Prevacus, there is no unauthorized use, infringement or misappropriation of the Purchased Assets by any third party and there
is no Action that is pending or threatened by Prevacus with respect thereto. Notwithstanding anything to the contrary, this representation
shall not limit or restrict the transfer to Odyssey pursuant to this Agreement of all right, title and interest in and to the Purchased
Assets owned by Prevacus throughout the world; provided, however, that Prevacus does not represent, warrant or covenant that any
rights in or to the Purchased Assets exist anywhere outside of the United States of America.

 

 

 

    	 	4	 

     

    

 

Section
2.6 Prevacus’s Knowledge.

 

The
term "Prevacus' Knowledge" as used herein means the actual knowledge (and not the implied or constructive knowledge)
without any duty of investigation or inquiry of the following person: Jake Van Landingham, Prevacus.

 

ARTICLE III

REPRESENTATIONS
AND WARRANTIES OF ODYSSEY

 

Odyssey
hereby represent and warrants to Prevacus that, except as set forth in the disclosure schedule delivered by Odyssey to Prevacus
and attached hereto and made a part hereof (the “Odyssey Disclosure Schedule”). Such warranties and representation
shall be true as of the date of execution and the date of Closing:

 

Section
3.1 Organization.

 

Odyssey
is duly incorporated, validly existing and in good standing under the Laws of each of their respective jurisdictions of organization
and each has the requisite corporate power and authority to own, operate or lease the properties that it purports to own, operate
or lease and to carry on its business as it is now being conducted.

 

Section
3.2 Authority Relative to this Agreement and Related Matters.

 

Odyssey
has all necessary corporate power and authority, as the case may be, to enter into this Agreement and to carry out each of their
respective obligations hereunder. The execution and delivery by Odyssey of this Agreement and the consummation by the Odyssey of
the Transactions have been duly authorized by all necessary corporate action on the part of the Odyssey. This Agreement has been
duly executed and delivered by the Odyssey, and, assuming the due authorization, execution and delivery hereof by Prevacus, constitutes
the legal, valid and binding obligation of the Odyssey, enforceable against each the Odyssey in accordance with its terms.

 

Section
3.3 No Conflict; Required Filings and Consents.

 

The
execution and delivery of this Agreement by Odyssey does not, and the consummation of the Transactions will not, (a) conflict
with or violate the organizational or governing documents of Odyssey and/or Odyssey, (b) conflict with or violate any Law
or Order applicable to Odyssey or by which Odyssey or or any of their respective properties is bound, (c) result in a breach
of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give rise to
any right of termination, acceleration or cancellation under, any note, bond, mortgage, indenture, contract, agreement, lease,
license or other instrument or obligation to which Odyssey is a party or by which Odyssey or Odyssey or any of their respective
properties is bound, or (d) require Odyssey or Odyssey to obtain any consent, approval, authorization or permit of, or to
make any filing with or notification to, any Governmental Authority, except (i) as set forth in Section 3.3 of
the Odyssey Disclosure Schedule, or (ii) for any filings required pursuant to the Exchange Act.

 

Section 3.4 Absence of Litigation.

 

Except
as disclosed in Section 3.4 of the Odyssey Disclosure Schedule, as of the date hereof, (a) there is
no Action pending or, to the knowledge of Odyssey, threatened against Odyssey or Odyssey before any Governmental Authority that,
if adversely determined, would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions, and (b) there
is no Order against Odyssey that would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions
contemplate hereby.

 

 

 

    	 	5	 

     

    

 

ARTICLE
IV

COVENANTS
OF PREVACUS

 

Section
4.1 Conduct of Prevacus Pending the Closing.

 

Prevacus
shall not, between the date of this Agreement and the Closing Date or the earlier termination of this Agreement, do or agree to
do any of the following without the prior written consent of Odyssey:

 

(a)
take or fail to take, or agree to take or fail to take, any action which would make any representation or warranty made by Prevacus
herein untrue or incorrect in any material respect as of the date of this Agreement or the date of the Closing;

 

(b)
sell, lease, license, encumber, transfer or otherwise dispose of any Purchased Assets; and

 

(c)
agree to do any of the foregoing.

 

Section
4.2 Notification of Certain Events.

 

Prevacus
shall give prompt notice to Odyssey if any of the following occurs after the date of this Agreement: (i) there has been a
material failure of Prevacus to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by
it hereunder; (ii) receipt by Prevacus of any material notice or other communication from any Governmental Authority in connection
with the Transactions; (iii) the occurrence of an event which would cause a condition in Section 7.2 not
to be satisfied; or (iv) the commencement or threat, in writing, of any Action against Prevacus, or any of its properties,
with respect to the Transactions and/or any of the Purchased Assets. No such notice to Odyssey shall have any effect on the determination
of whether or not any of the conditions to Closing or to the consummation of the Transactions have been satisfied or in determining
whether or not any of the representations, warranties or covenants contained in this Agreement have been breached.

 

ARTICLE V

COVENANTS
OF ODYSSEY

 

Section
5.1 Representations and Warranties.

 

Odyssey
covenants and agrees that, except as otherwise contemplated by this Agreement or unless Prevacus shall give its prior written consent,
Odyssey shall not, between the date of this Agreement and the Closing Date or the earlier termination of this Agreement, take or
fail to take, or agree to take or fail to take, any action which would make any representation or warranty made by Odyssey herein
untrue or incorrect in any material respect.

 

Section
5.2 Notification of Certain Events.

 

Odyssey
shall give prompt notice to Prevacus if any of the following occurs after the date of this Agreement: (i) there has been a
material failure of Odyssey to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by
it hereunder; (ii) receipt by Odyssey of any material notice or other communication from any Governmental Authority in connection
with the Transactions; (iii) the occurrence of an event which would cause a condition in Section 7.3 not
to be satisfied; or (iv) the commencement or threat, in writing, of any Action against Odyssey, or any of its properties,
with respect to the Transactions. No such notice to Prevacus shall have any effect on the determination of whether or not any of
the conditions to Closing or to the consummation of the Transactions have been satisfied or in determining whether or not any of
the representations, warranties or covenants contained in this Agreement have been breached.

 

 

 

    	 	6	 

     

    

 

Section
5.3 Condition of Purchased Assets.

 

ODYSSEY
ACKNOWLEDGES THAT IT IS A SOPHISTICATED INVESTOR IN ASSET PURCHASES OF THE TYPE CONTEMPLATED BY THIS AGREEMENT AND THAT ITS VALUATION
OF AND DECISION TO PURCHASE THE PURCHASED ASSETS IS BASED UPON ITS OWN INDEPENDENT EXPERT EVALUATIONS OF SUCH FACTS AND MATERIALS
DEEMED RELEVANT BY ODYSSEY. ODYSSEY ACKNOWLEDGES AND AGREES THAT, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION 2 ABOVE,
PREVACUS HAS NOT MADE, AND PREVACUS HEREBY SPECIFICALLY DISCLAIMS, ANY REPRESENTATION, WARRANTY, GUARANTY, PROMISE, COVENANT OR
AGREEMENT, IN EACH CASE WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, PAST, PRESENT OR FUTURE, OF, AS TO, CONCERNING, OR WITH RESPECT
TO THE PURCHASED ASSETS. ODYSSEY ACKNOWLEDGES AND AGREES THAT, HAVING BEEN GIVEN THE OPPORTUNITY TO INSPECT THE PURCHASED ASSETS,
ODYSSEY IS RELYING SOLELY ON ITS OWN INVESTIGATION OF THE PURCHASED ASSETS, AND NOT ON ANY MATERIALS AND OTHER INFORMATION PROVIDED
OR TO BE PROVIDED BY PREVACUS EXCEPT FOR THE REPRESENTATIONS SET FORTH IN THIS AGREEMENT. ODYSSEY FURTHER ACKNOWLEDGES THAT ANY
INFORMATION PROVIDED AND TO BE PROVIDED WITH RESPECT TO THE PURCHASED ASSETS WAS OBTAINED FROM A VARIETY OF SOURCES AND PREVACUS
(i) HAS NOT MADE ANY INDEPENDENT INVESTIGATION OR VERIFICATION OF SUCH INFORMATION; AND (ii) MAKES NO REPRESENTATIONS OR WARRANTIES
AS TO THE ACCURACY OR COMPLETENESS OF SUCH INFORMATION. EXCEPT AS OTHERWISE EXPRESSLY SPECIFIED HEREIN, ODYSSEY AGREES TO ACCEPT
THE PURCHASED ASSETS AND ACKNOWLEDGES THAT THE SALE OF THE PURCHASED ASSETS AS PROVIDED FOR HEREIN IS CONDITIONED ON THE FACT THAT
THE PROPERTY IS "AS IS, WHERE IS AND WITH ALL FAULTS". WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, ODYSSEY EXPRESSLY
ACKNOWLEDGES THAT, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, PREVACUS MAKES NO WARRANTY OR REPRESENTATION OF ANY
KIND OR CHARACTER WHATSOEVER, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, PAST, PRESENT OR FUTURE, OF, AS TO, CONCERNING OR WITH
RESPECT TO (A) THE VALUE, NATURE, QUALITY OR CONDITION OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (B) THE INCOME TO BE DERIVED
FROM THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (C) THE SUITABILITY OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF) FOR ANY
AND ALL ACTIVITIES AND USES WHICH ODYSSEY MAY CONDUCT THEREWITH, (D) THE COMPLIANCE OF OR BY THE PURCHASED ASSETS (OR ANY PORTION
THEREOF) OR ITS USE WITH ANY LAWS, RULES, ORDINANCES OR REGULATIONS OF ANY APPLICABLE GOVERNMENTAL AUTHORITY OR BODY, (E) THE MERCHANTABILITY,
MARKETABILITY, PROFITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (F) THE MANNER
OR QUALITY OF THE OPERATIONSENABLED BY THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (G) THE MANNER, QUALITY, OR STATE OF THE
PURCHASED ASSETS (OR ANY PORTION THEREOF), (H) THE PAST, PRESENT OR FUTURE USE OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF),
(I) THE RELIABILITY, ACCURACY OR COMPLETENESS OF ANY OF THE PURCHASED ASSETS FOR THE USES INTENDED BY ODYSSEY; AND ODYSSEY HEREBY
WAIVES ANY RIGHT TO MAKE ANY CLAIM BASED ON ANY OF THE FOREGOING.

 

ARTICLE
VI

ADDITIONAL
AGREEMENTS OF THE PARTIES

 

Section
6.1 Commercially Reasonable Efforts.

 

(a)
Upon the terms and subject to the conditions hereof, each of the Parties agrees to use its commercially reasonable efforts to take,
or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to consummate and make
effective as promptly as practicable the Transactions and to vest in Odyssey (and any transferee of Odyssey) good and marketable
title to the Purchased Assets, including obtaining all consents, waivers, authorizations and approvals from Governmental Authorities
and other third parties required for the consummation of the Transactions.

 

 

 

    	 	7	 

     

    

 

(b)
From time to time after the Closing, at the request of Odyssey (or any transferee of Odyssey) and at such requesting party’s
expense, and without further consideration, Prevacus agrees on its own behalf, as well as on behalf of its subsidiaries, affiliates,
successors, assigns and legal representatives, to execute and deliver to Odyssey any further documents or instruments and perform
any further acts that may reasonably be deemed necessary to vest, record, perfect, support and/or confirm the rights herein conveyed,
or intended so to be, to Odyssey (and any transferee of Odyssey) with respect to the Purchased Assets, including without limitation
such assignments, agreements and limited powers of attorney as may be needed for recording or effectuating the transfer of the
Purchased Assets in the United States. Nothing herein shall be deemed a waiver by Odyssey of its right to receive at the Closing
an effective assignment of such rights by Prevacus as otherwise set forth in this Agreement. Without limiting the generality of
the foregoing, Prevacus shall execute and deliver to Odyssey or obtain for delivery to Odyssey, at the request of Odyssey and at
Odyssey’s expense, and without further consideration, any documents required to update record title to the owned Purchased
Assets to reflect Odyssey (and any transferee of Odyssey) as the record owner in each jurisdiction in which such Purchased Assets
exists. At the request of Odyssey and at Odyssey’s expense, and without further consideration, Prevacus shall reasonably
cooperate with Odyssey (and any transferee of Odyssey) in connection with the registration of the Purchased Assets in jurisdictions
outside of the United States.

 

(c)
From time to time after the Closing, at the request of Odyssey and at Odyssey’s expense, and without further consideration,
Prevacus shall assist Odyssey (and any transferee of Odyssey) to the extent reasonably necessary for the defense or prosecution
of any claim by or against any third party with respect to the ownership, validity, enforceability, infringement or other violation
of or by the Purchased Assets, so long as Prevacus is not named as a party adverse to the Odyssey in any such proceeding.

 

Section
6.2 Public Announcements.

 

Each
of the Parties agrees that a press release or announcement concerning this Agreement or the Transactions shall be issued by it.
Such release or announcement may also be required by applicable Law or the rules or regulations of any securities exchange.

 

ARTICLE
VII

CONDITIONS
TO THE CLOSING

 

Section
7.1 Conditions to Obligations of Each Party.

 

The
respective obligations of each Party to consummate the Transactions shall be subject to the condition that no Governmental Authority
shall have enacted, issued, promulgated, enforced, initiated, or entered any Law or Order (whether temporary, preliminary or permanent)
that is then in effect and has the effect of making the Transactions illegal or otherwise preventing or prohibiting consummation
of the Transactions.

 

Section
7.2 Additional Conditions to Obligations of Odyssey.

 

The
obligation of Odyssey to consummate the Transactions shall also be subject to the satisfaction or waiver (where permissible), on
or prior to the Closing Date, of each of the following conditions:

 

(a)
The representations and warranties of Prevacus set forth in Article II of this Agreement (i) that are
qualified by the words “material” or “material adverse effect” shall be true and correct in all
respects on and as of the Closing Date as if made on and as of such date and (ii) that are not so qualified shall be
true and correct in all material respects on and as of the Closing Date as if made on and as of such date, except in any such
case (x) for changes contemplated by this Agreement and by the Prevacus Disclosure Schedule, and (y) to the extent
that any such representation or warranty is made as of a specified date, in which case such representation or warranty shall
remain true and correct (in all material respects, as the case may be) as of such date.

 

 

 

    	 	8	 

     

    

 

(b)
Prevacus shall in all material respects have performed or complied with each obligation and covenant to be performed or complied
with by Prevacus hereunder on or prior to the Closing Date, including the deliveries under Section 1.4(b).

 

(c)
Odyssey shall have received a certificate of Prevacus, dated the Closing Date, signed by an officer of Prevacus, to the effect
that the conditions specified in Sections 7.2(a) and (b) have been satisfied.

 

Section
7.3 Additional Conditions to Obligations of Prevacus.

 

The
obligation of Prevacus to consummate the Transactions shall also be subject to the satisfaction or waiver (where permissible),
on or prior to the Closing Date, of each of the following conditions:

 

(a)
The representations and warranties of Odyssey set forth in Article III of this Agreement shall be true and correct
in all material respects on and as of the Closing Date as if made on and as of such date, except in any such case (x) for
changes contemplated by this Agreement and by the Odyssey Disclosure Schedule, and (y) to the extent that any such representation
or warranty is made as of a specified date, in which case such representation or warranty shall remain true and correct (in all
material respects, as the case may be) as of such date.

(b)
Odyssey shall in all material respects have performed or complied with each obligation and covenant to be performed or complied
with by it hereunder on or prior to the Closing Date, including the deliveries under Section 1.4(c).

 

(c)
Prevacus shall have received a certificate of Odyssey, dated the Closing Date, signed by an executive officer of Odyssey, to the
effect that the conditions specified in Sections 7.3(a) and (b) have been satisfied.

 

ARTICLE
VIII

TERMINATION

 

Section
8.1 Termination.

 

This
Agreement may not be terminated at any time prior to the Closing Date except:

 

(a)
By mutual written consent of Odyssey and Prevacus;

 

(b)
by either Prevacus or Odyssey, if the Closing shall not have occurred on or before July 31, 2019 (the “Outside Date”); provided, however,
that the right to terminate this Agreement under this Section 8.1(b) shall not be available to any Party
whose failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, the failure of the Transactions
to be consummated on or before the Outside Date;

 

(c)
by either Prevacus or Odyssey if any Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Law
or Order that is, in each case, then in effect and is final and non-appealable and has the effect of making the Transactions illegal
or otherwise preventing or prohibiting consummation of the Transactions; provided, however, that the right to
terminate this Agreement under this Section 8.1(c) shall not be available to any Party whose failure to fulfill
any obligation under this Agreement has been the cause of, or resulted in, any such Law or Order to have been enacted, issued,
promulgated, enforced or entered;

 

 

 

    	 	9	 

     

    

 

(d)
by Odyssey (if Odyssey is not in material breach of any of the terms or conditions of this Agreement), if there has been a material
breach by Prevacus of any terms or conditions of this Agreement, or if any representation or warranty of Prevacus shall have become
inaccurate, in either case that would result in a failure of a condition set forth in Section 7.2(a) or 7.2(b) (a
“Terminating Prevacus Breach”); provided, that if such Terminating Prevacus Breach is reasonably
curable by Prevacus, within 30 days after Prevacus has received written notice from Odyssey of such Terminating Prevacus Breach,
through the exercise of its commercially reasonable efforts and for as long as Prevacus continues to exercise such commercially
reasonable efforts, Odyssey may not terminate this Agreement under this Section 8.1(d) until the earlier
of the expiration of such 30-day period and the Outside Date; and

 

(e)
by Prevacus (if Prevacus is not in material breach of any of its representations, warranties, covenants or agreements under
this Agreement), if there has been a material breach by Odyssey of any of terms or conditions of this Agreement, or if any
representation or warranty of Odyssey shall have become inaccurate, in either case that would result in a failure of a
condition set forth in Section 7.3(a) or 7.3(b) (a “Terminating Odyssey
Breach”); provided, that if such Terminating Odyssey Breach is reasonably curable by Odyssey, within 30
days after Odyssey has received written notice from Prevacus of such Terminating Odyssey Breach, through the exercise of its
commercially reasonable efforts and for as long as Odyssey continues to exercise such commercially reasonable efforts,
Prevacus may not terminate this Agreement under this Section 8.1(e) until the earlier of the expiration
of such 30-day period and the Outside Date.

 

Section
8.2 Effect of Termination.

 

In
the event of the termination of this Agreement pursuant to Section 8.1, this Agreement shall forthwith
become void, and there shall be no liability on the part of any Party hereto or any of their respective Affiliates or the
directors, officers, partners, members, managers, employees, agents or other representatives of any of them, and all rights
and obligations of each Party hereto shall cease, except that nothing herein shall relieve any Party from liability for any
breach of this Agreement committed before such termination. Without limiting the foregoing, Section 6.2, this Section
8.2  and Article X shall survive the termination of this Agreement. Notwithstanding anything to the contrary
contained in this Agreement, nothing shall limit or prevent any Party from exercising any rights or remedies it may have
under Section 10.9 hereof in lieu of terminating this Agreement pursuant to Section 8.1.
Notwithstanding anything to the contrary contained in this Agreement, nothing shall limit or prevent any Party from
exercising any rights or remedies it may have under any of the agreements attached as Exhibits to this Agreement, whether or
not this Agreement has been terminated.

 

ARTICLE
IX

INDEMNIFICATION
PROVISIONS

 

Section
9.1 Prevacus Indemnification Obligation.

 

Prevacus
agrees that, from and after the Closing, it shall indemnify, defend and hold harmless Odyssey and their respective officers, directors,
Affiliates, partners, members, managers, employees, agents and other representatives (“Odyssey Indemnified Parties”)
from and against any damages, claims, losses, liabilities, costs and expenses (including, without limitation, reasonable attorneys’
fees) (each, a “Liability” and, collectively, “Liabilities”) incurred by any of the foregoing
Persons arising out of (a) any misrepresentation in or breach of any representation or warranty of Prevacus contained in Article
II of this Agreement and/or (b) any breach of any covenant or agreement of Prevacus contained in this Agreement,
and/or (c) any action, suit, litigation, proceeding at law or in equity, arbitration or governmental investigation against, or
threatened against, Odyssey relating to any pre-Closing matter regarding the Purchased Assets, except in all cases to the extent
any Liabilities arise out of any breach of the Odyssey's representations, warranties, covenants or agreements set forth in this
Agreement.

 

 

 

    	 	10	 

     

    

 

Section
9.2 Odyssey’s Indemnification Obligation.

 

Odyssey
agrees that, from and after the Closing, it shall indemnify, defend and hold harmless Prevacus and its officers, directors, Affiliates,
partners, members, managers, employees, agents and other representatives (“Prevacus Indemnified Parties”) from
and against any Liabilities incurred by any of the foregoing Persons arising out of (a) any misrepresentation in or breach
of any representation or warranty of Odyssey contained in Article III of this Agreement, (b) any breach of
any covenant or agreement of Odyssey contained in this Agreement, or (c)  any action, suit, litigation, proceeding at law
or in equity, arbitration or governmental investigation against, or threatened against, Prevacus relating to any post-Closing matter
regarding the Purchased Assets, except in all cases to the extent any Liabilities arise out of any breach of the Prevacus's representations,
warranties, covenants or agreements set forth in this Agreement.

 

Section
9.3 Procedures for Indemnification for Third Party Claims.

 

For
purposes of this Article IX, any Party entitled to be indemnified under Article IX is referred to
herein as an “Indemnified Party,” and any Party obligated to provide indemnification under Article IX is
referred to herein as an “Indemnifying Party.” The obligations and liabilities of the Parties under this Article
IX with respect to, relating to or arising out of claims of third parties (individually, a “Third Party Claim”
and, collectively, the “Third Party Claims”) shall be subject to the following terms and conditions:

 

(a)
The Indemnified Party shall give the Indemnifying Party prompt written notice of any Liability regarding which it seeks indemnification.
In the event a Liability is the result of a Liability asserted against the Indemnified Party by a third-party to this Agreement
(a “Third Party Claim”), the Indemnifying Party may undertake the defense of that claim by representatives chosen by
it with the written consent of the Indemnified Party, which consent may not be unreasonably withheld, conditioned or delayed, provided,
that, in such event, the Indemnified Party will have the right to participate in such defense through counsel of its own choice.
Any such notice of a Liability shall identify with reasonable specificity the basis for the indemnification claimed, the facts
giving rise to the Liability and the amount of the Liability (or, if such amount is not yet known, a reasonable estimate of the
amount of the Liability). The Indemnified Party shall make available to the Indemnifying Party copies of all relevant documents
and records in its possession at the expense of the Indemnifying Party. Failure of an Indemnified Party to give prompt notice shall
not relieve the Indemnifying Party of its obligation to indemnify, except to the extent that the failure to so notify materially
prejudices the Indemnifying Party’s ability to defend such claim against a third party.

 

(b)
If the Indemnifying Party, within ten (10) days after notice from the Indemnified Party of any such Liability, notifies the Indemnified
Party in writing of its election not to, or fails to, assume the defense thereof in accordance with Section 9.3(a) of
this Agreement, the Indemnified Party shall have the right (but not the obligation) to undertake the defense of the Liability.
Any failure on the part of the Indemnifying Party to notify the Indemnified Party within the time period provided above regarding
its election shall be deemed an election by the Indemnifying Party not to assume and control the defense of the Liability.

 

(c)
Anything in this Section 9.3 to the contrary notwithstanding, the Indemnifying Party shall not, and does
not have any authority to, without the prior written consent of the Indemnified Party, settle or compromise any Liability or consent
to the entry of judgment which does not include as an unconditional term thereof the unconditional release of the Indemnified Party,
or consent to the entry of judgment with respect thereto, any Liability regarding which it has delivered notice of a claim for
indemnification to the Indemnifying Party, without first obtaining the written consent of the Indemnifying Party (which shall not
be unreasonably withheld or delayed). An Indemnifying Party shall be deemed to have consented to a settlement, compromise, payment
or judgment by the Indemnified Party if it does not respond to written notice from the Indemnified Party seeking such consent within
ten (10) days after delivery of such notice to the Indemnifying Party.

 

Section
9.4 Indemnification Limitations.

 

(a) Time
Limits On Indemnification. No claim on account of a breach or inaccuracy of a representation or warranty shall be made after
the expiration of the survival periods referred to in Section 10.1 of this Agreement. Notwithstanding the
foregoing, if a written claim or written notice is given under Article IX with respect to any representation or
warranty prior to the expiration of its survival period, the claim with respect to such representation or warranty shall continue
until such claim is finally resolved.

 

 

 

    	 	11	 

     

    

 

(b) Limitations
on Damages.

 

(i)
In no event shall Prevacus be liable for indemnification pursuant to Section 9.1(a) unless and until the
aggregate of all Liabilities which are incurred or suffered by the Odyssey Indemnified Parties exceeds $50,000 (the “Basket”),
in which case the Odyssey Indemnified Parties shall be entitled to indemnification for all such Liabilities including the Basket
(subject to Section 9.4(b)(ii)). In no event shall Odyssey be liable for indemnification pursuant to Section 9.2(a) unless
and until the aggregate of all Liabilities which are incurred or suffered by the Prevacus Indemnified Parties exceeds the Basket,
in which case the Prevacus Indemnified Parties shall be entitled to indemnification for all such Liabilities including the Basket
(subject to Section 9.4(b)(ii)).

 

(ii)
Notwithstanding anything to the contrary in this Agreement, the maximum aggregate liability of Prevacus pursuant to Section 9.1(a) shall
not exceed (1) the amount of money actually paid to and received by the Prevacus from the Odyssey and Odyssey or their Affiliates
pursuant to the terms of this Agreement and any of the Agreements attached as Exhibits hereto as of the date the notice of requested
indemnification is delivered to the Prevacus, less (2) any amounts of money currently due the Prevacus from the Odyssey,
Odyssey or their Affiliates pursuant to the terms of this Agreement and any of the Agreements attached as Exhibits hereto. For
purposes of this provision, the right to purchase Odyssey stock at its par value or the shares, if purchased, shall be valued at
the greater of its book value or its then current market price.

 

The
maximum aggregate liability of Odyssey pursuant to Section 9.2(a) shall not exceed $7,500,000.

 

(iii)
Notwithstanding anything to the contrary contained in this Agreement or otherwise, no Party to this Agreement shall be liable to
any Indemnified Party for any special, incidental, punitive, consequential or similar damages except, in the event a Third
Party Claim results in a judgment against an Indemnified Party by the third-party claimant, then such damages shall be included
in the amount of indemnification due the Indemnified Party.

 

Section 9.5 Exclusive
Remedy.

 

The
remedies provided in this Article IX shall be the sole and exclusive remedies of the Parties with respect to the
matters arising from or related to this Agreement or the Transactions, except that nothing herein shall prevent a Party from seeking
specific performance pursuant to Section 10.9, subject to the provisions thereof, including with respect to the
obligations in Section 6.1.

 

ARTICLE
X

GENERAL
PROVISIONS

 

Section
10.1 Survival of Representations and Warranties.

 

The
representations and warranties made by Prevacus in Article II of this Agreement shall survive until the 
date that is fifteen (15) months after the Closing Date. The representations and warranties made by Odyssey in Article
III of this Agreement shall survive until the date that is fifteen (15) months after the Closing Date.

 

Section
10.2 Notices.

 

All
notices and other communications under this Agreement shall be in writing and shall be deemed given (a) when delivered personally
by hand (with written confirmation of receipt) or (b) one Business Day following the day sent by nationally-recognized overnight
courier (with written confirmation of receipt), in each case at the following addresses (or to such other address as a Party may
have specified by notice given to the other Party pursuant to this provision)

 

 

 

    	 	12	 

     

    

 

	 	(a)	if to Odyssey:
	 	 	 
	 	 	Odyssey
Group International, Inc.

                                                                          1327
Morse Ave

                                                                          Irvine,
CA 90401

                                                                          Attention: Michael Redmond

	 	 	 
	 	(b)	Prevacus
	 	 	 
	 	 	Jake
VanLandingham.

 

with
a copy to:

 

Any
notice or other communication that has been given or made as of a date that is not a Business Day shall be deemed to have been
given or made on the next succeeding day that is a Business Day.

 

Section 10.3 Headings.

 

The
headings contained in this Agreement and the disclosure schedules are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement or the disclosure schedules. Unless the context of this Agreement otherwise requires,
words of any gender are deemed to include each other gender and words using the singular or plural number also include the plural
or singular number, respectively.

 

Section 10.4 Entire
Agreement.

 

This
Agreement, together with the exhibits and schedules attached hereto, constitutes the entire agreement, and supersede all prior
agreements and undertakings, both written and oral, between the Parties with respect to the subject matter hereof. There are no
agreements, commitments, promises, or representations that are not contained herein.

 

Section 10.5 Assignment:
Parties in Interest.

 

This
Agreement and any rights or obligations hereunder can be assigned by any Party without the prior written consent of the other Party.
This Agreement shall be binding upon and inure solely to the benefit of each Party hereto and its successors and permitted assigns,
and nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature
whatsoever under this Agreement, other than Article IX hereof (which is intended to be for the benefit of the
Persons covered thereby and may be enforced by such Persons).

 

Section 10.6 Governing
Law; Consent to Jurisdiction.

 

This
Agreement shall be governed by, and construed in accordance with, the Laws of the State of Florida applicable to contracts executed
in and to be performed entirely in that State, without regard to conflicts of Laws principles thereof to the extent that the general
application of the Laws of another jurisdiction would be required thereby.

 

 

 

    	 	13	 

     

    

 

Section 10.7 Counterparts.

 

This
Agreement may be executed and delivered (including by facsimile transmission or .pdf) in one or more counterparts, and by the Parties
hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together
shall constitute one and the same agreement.

 

Section 10.8 Severability.

 

In
case any provision in this Agreement shall be held invalid, illegal or unenforceable in a jurisdiction, such provision shall be
modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable,
and the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby
nor shall the validity, legality or enforceability of such provision be affected thereby in any other jurisdiction.

 

Section 10.9 Specific
Performance.

 

The
Parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed
in accordance with their specific terms or were otherwise breached. Accordingly, the Parties further agree that each Party shall
be entitled to seek an injunction or restraining order to prevent breaches of this Agreement and to seek to enforce specifically
the terms and provisions hereof, this being in addition to any other right or remedy to which such Party may be entitled under
this Agreement, at law or in equity.

 

Section 10.10 Fees
and Expenses.

 

All
fees, costs and expenses incurred in connection with this Agreement and the Transactions shall be paid by the Party incurring the
same, regardless of the termination, if any, of this Agreement pursuant to Section 8.1. Notwithstanding the foregoing,
in the event the Parties engage in litigation relating to or arising out of this Agreement or the performance thereof, the Parties
agree that the Court shall be asked to determine which Party is the prevailing Party to the proceeding or proceedings, and the
non-prevailing Party or Parties shall, jointly and severally, be liable to the prevailing Party in the amount of all reasonable
attorney’s fees, court costs, and all other expenses, incurred by the prevailing Party to the proceeding in addition to any
other relief to which the prevailing Party may be entitled.

 

Section 10.11 Amendment.

 

This
Agreement may not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed
by Odyssey, Odyssey, and Prevacus.

 

Section 10.12 Waiver.

 

At
any time prior to the Closing Date, any Party hereto may (a) extend the time for the performance of any of the obligations
or other acts of the other Party hereto, (b) waive any inaccuracies in the representations and warranties contained herein
or in any document delivered pursuant hereto and (c) waive compliance with any of the agreements or conditions contained herein.
Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the Parties hereto. The failure
of any Party hereto to assert any of its rights hereunder shall not constitute a waiver of such rights.

 

 

 

    	 	14	 

     

    

 

ARTICLE
XI

CERTAIN
DEFINITIONS

For
purposes of this Agreement, the term:

 

“Action”
shall have the meaning ascribed to it in Section 2.4.

 

“Affiliate”
of a Person means a person that directly, or indirectly through one or more intermediaries,
controls or is controlled by, or is under common control with, the person specified. “Agreement” shall
have the meaning ascribed to it in the preamble.

 

“Business
Day” means any calendar day which is not a Saturday, Sunday or federal holiday.

 

“Odyssey”
shall have the meaning ascribed to it in the Preamble.

 

“Odyssey
Disclosure Schedule” shall have the meaning ascribed to it in the preamble to Article III.

 

“Closing”
shall have the meaning ascribed to it in Section 1.4(a).

 

“Closing
Date” shall have the meaning ascribed to it in Section 1.4(a).

 

“Control”
(including the terms “Controlled by” and “under common Control with”) means the possession, directly or
indirectly or as trustee or executor, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, as trustee or executor, by contract or credit arrangement or otherwise.

 

“Data”
means all information gathered in the use or operation of any of the Purchased Assets that identifies or describes an individual
or an individual’s record of behavior or action, including without limitation, name, telephone, postal address, phone number,
email, date of birth, gender, or any other information identifiable to a specific person, including “personal health information”
as that term is defined in the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended,
to the extent such information exists as of the Closing Date.

 

“Encumbrance”
means any charge, claim, community property interest, condition, easement, covenant, warrant, demand, encumbrance, equitable interest,
lien, mortgage, option, purchase right, pledge, security interest, right of first refusal or other right of third parties or restriction
of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.

 

“Exchange
Act” shall have the meaning ascribed to it in Section 2.3.

 

“Governmental
Authority” means any United States federal, state or local government, governmental, regulatory or administrative authority,
agency, self-regulatory body, instrumentality or commission, and any court, tribunal or judicial or arbitral body (including private
bodies) and any political or other subdivision, department or branch of any of the foregoing.

 

 

 

    	 	15	 

     

    

 

“Indemnified
Party” shall have the meaning ascribed to it in Section 9.3.

 

“Indemnifying
Party” shall have the meaning ascribed to it in Section 9.3.

 

“Intellectual
Property” means all United States and foreign intellectual property and all other similar proprietary rights, including
all (i) patents and patent applications, including divisionals, continuations, continuations-in-part, reissues, reexaminations
and extensions thereof and counterparts claiming priority therefrom; utility models; invention disclosures; and statutory invention
registrations and certificates; (ii) registered, pending and unregistered trademarks, service marks, trade dress, logos,
trade names, corporate names and other source identifiers, domain names, Internet sites and web pages; and registrations and applications
for registration for any of the foregoing, together with all of the goodwill associated therewith; (iii) registered copyrights,
and registrations and applications for registration thereof; rights of publicity; and copyrightable works; (iv) all inventions
and design rights (whether patentable or unpatentable) and all categories of trade secrets as defined in the Uniform Trade Secrets
Act, including business, technical and financial information; and (v) confidential and proprietary information, including
know-how.

 

“Prevacus’s
Knowledge” shall have the meaning ascribed to it in Section 2.6.

 

“Laws”
means any federal, state or local statute, law, rule, ordinance, code or regulation of any Governmental Authority.

 

“Liability”
and, collectively, “Liabilities” shall have the meaning ascribed to it in Section 9.1.

 

“Order”
shall have the meaning ascribed to it in Section 2.4.

 

“Outside
Date” shall have the meaning ascribed to it in Section 8.1(b).

 

“Parties”
shall have the meaning ascribed to it in the preamble.

 

“Patent(s)
means: The patents and Patent Applications described on Exhibit “A”.

 

“Patent
Assignment” means the Patent Assignment Agreement whereby, as part of this Agreement, Prevacus assigns Patent and Patent
applications described on Exhibit “A”.

 

“Permitted
Encumbrance” means: (i) statutory liens for Taxes, assessments and governmental charges or levies not yet due and
payable or that are being contested in good faith by appropriate proceedings; (ii) mechanics’, materialmen’s,
carriers’, warehousemen’s or similar statutory liens for amounts not yet due or being diligently contested in good
faith in appropriate proceedings; and (iii) pledges or deposits to secure obligations under workers’ compensation laws
or similar legislation or to secure public or statutory obligations.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, unincorporated organization or other
entity.

 

“Purchase
Price” shall have the meaning ascribed to it in Section 1.3.

 

 

 

    	 	16	 

     

    

 

“Purchased
Assets” shall have the meaning ascribed to it in Section 1.1.

 

“Prevacus”
shall have the meaning ascribed to it in the Preamble.

 

“Prevacus
Disclosure Schedule” shall have the meaning ascribed to it in the preamble to Article II.

 

“Subsidiary”
means any Person with respect to which a specified Person directly or indirectly (A) owns a majority of the equity interests,
(B) has the power to elect a majority of that Person’s board of directors or similar governing body, or (C) otherwise
has the power, directly or indirectly, to direct the business and policies of that Person.

 

“Tax”
or “Taxes” means any and all taxes, fees, levies, duties, tariffs, imposts and other charges of any kind (together
with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any Governmental
Authority, including: taxes or other charges on or with respect to income, franchise, windfall or other profits, gross receipts,
property, sales, use, equity interests, payroll, employment, social security, workers’ compensation, unemployment compensation
or net worth; taxes or other charges in the nature of excise, withholding, ad valorem, stamp, transfer, value-added or gains taxes;
license, registration and documentation fees; and customers’ duties, tariffs and similar charges.

 

“Terminating
Odyssey Breach” shall have the meaning ascribed to it in Section 8.1(e).

 

“Terminating
Prevacus Breach” shall have the meaning ascribed to it in Section 8.1(d).

 

“Third
Party Claim” and, collectively, “Third Party Claims” shall have the meaning ascribed to it in Section 9.3.

 

“Transactions”
shall have the meaning ascribed to it in Section 2.2.

 

 

 

[Signature
page follows]

 

 

    	 	17	 

     

    

 

IN
WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be duly executed as of the date first written above.

 

	 	PREVACUS:
	 	 
	 	By:	/s/ Jake VanLandingham
	 	Name:

        Title:
	Jake VanLandingham
President
	 	 	 
	 	 	 
	 	 	 
	 	ODYSSEY:
	 	 	 
	 	By:	/s/ J. Michael Redmond
	 	Name:	J. Michael Redmond
	 	Title:	President

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	18	 

     

    

 

Exhibit “A”

PURCHASED ASSETS

 

	

Families	Matter-No	Case	Appl	Publish Patent 	Appl	Country Name Filing Date	Publ Date	Inventor 
	 	 	Type	Number	Number	Status	 	 	 

 

		(1)	PROPHYLACTIC AND POST-ACUTE USE OF PROGESTERONE IN CONJUNCTION WITH ITS ENANTIOMER FOR USE

IN TREATMENT OF TRAUMATIC
BRAIN INJURIES

 

		(2)	SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF

 

	FSURF/	48691-504/P01	PRO	61/790,366	 	Converted	USA	15-Mar-2013	
         

        CRAN

	PREVACUS	48691-504/001	ORD	14/214,864	US-2014-0275572-A1	Published	USA	15-Mar-2014	18-Sept-2014HAN
	 	48691-504/001	ORD	PCT/US2014/030040	WO 2014/145302	Inactive	PCT	15-Mar-2014	
        18-Sept-2014

        ZHANG

	 	48691-504/C01	CON	14/855,072	 	Pending	USA	15-Sep-2015	 
	 	48691-504/N01	PCT	14/777,267	 	Pending	USA	15-Sep-2015	 
	 	48691-504/N01	PCT	2014-233156	 	Pending	Australia	15-Mar-2014	 
	 	48691-504/N01	PCT	BR112015022794-5	 	Pending	Brazil	15-Mar-2014	 
	 	48691-504N01	PCT	2907320	 	Pending	Canada	15-Mar-2014	 
	 	48691-504/N01	PCT	201502766	 	Pending	Chile	15-Mar-2014	 
	 	48691-504/N01	PCT	2014-80026814.0	 	Pending	China	15-Mar-2014	 
	 	48691-504/N01	PCT	201591790	 	Pending	Eurasia	15-Mar-2014	 
	 	48691-504/N01	PCT	14764927.1	2968576	Published	EPO	15-Mar-2014	20-Jan-2016
	 	48691-504/N01	PCT	5408/CHENP/2015	 	Pending	India	15-Mar-2014	 
	 	48691-504/N01	PCT	241348	 	Pending	Israel	15-Mar-2014	 
	 	48691-504/N01	PCT	 	 	Pending	Japan	15-Mar-2014	 
	 	48691-504/N01	PCT	10-2015-7029352	 	Pending	Korea	15-Mar-2014	 
	 	48691-504/N01	PCT	MX/a/2015/012902	 	Pending	Mexico	15-Mar-2014	 
	 	48691-504/N01	PCT	712624	 	Pending	New Zealand	15-Mar-2014	 
	 	48691-504/N01	PCT	2009-2015	 	Pending	Peru	15-Mar-2014	 
	 	48691-504/N01	PCT	2015/06787	 	Pending	South Africa	15-Mar-2014	 

 

 

 

    	 	19	 

     

    

 

Exhibit “B”

FORM OF EMPLOYMENT AGREEMENT

 

This Employment Agreement
(“Agreement”), dated as of ______ (the “Effective Date”), is made by and among Jacob VanLandingham (“Executive”)
with an address at _________________ and LLC. a Florida Company with an address at________________________________ or any successor
company, (the “Company”).

 

WHEREAS, Executive
will be employed by the Company as its President and will maintain a position on the Company’s Board; and

 

WHEREAS, the
Company desires to enter into an employment agreement with Executive, which employment agreement will have a term from ______
through ______; and

 

WHEREAS, the agreed
upon terms and conditions of Executive’s continued employment are embodied in this Agreement.

 

NOW THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive do hereby
agree as follows:

 

Section 1. Employment and Duties. On the terms and subject
to the conditions set forth in this Agreement, the Company agrees to employ Executive and Executive agrees to render such services
as would be customary in developing an orphan drug.

 

Section 2. Performance.

 

(a) Executive accepts the employment as set
forth in Section 1 herein and agrees to concentrate such time, attention and skill as may be necessary to assure the full performance
of the services described therein.

 

Section 3. Term/Termination.

 

3.1 Term. The term of employment under
this Agreement (the “Employment Period”) shall commence on ______ and terminate on July 31, 2022, unless earlier terminated
pursuant to the termination provisions set forth herein. Notwithstanding anything to the contrary herein, the parties acknowledge
and agree that the Company may only terminate Executive’s employment for Due Cause (as hereinafter defined).

 

3.2 Termination for Due Cause. The Company
may only terminate the Employment Period for Due Cause. The Company, by a vote of a majority of the Board of Directors (a “Termination
Vote”) may terminate the Employment Period for Due Cause, effective upon written notice of such termination to Executive
only in the event of Due Cause as defined by (i) the dissolving, recession or bankruptcy of the LLC;

(ii) violations of the law by Executive for
theft or embezzlement of property of the Company and/or conviction by Executive of a felony crime resulting in a material injury
to the businesses, properties of the Company or any of its affiliates; (iii) violations of any laws or regulations relating to
the Securities and Exchange Commission. All compensation paid to Executive shall immediately cease upon termination for Due Cause
hereunder except accrued and unpaid compensation and all unvested Stock Options shall immediately expire.

 

3.3 Termination Due to Death. The Employment
Period shall be terminated upon the death of Executive. All compensation paid to Executive shall immediately cease upon such termination
except for accrued and unpaid compensation pursuant to Section 4.1 herein and earned but unpaid bonus payments pursuant to Section
4.2 herein. All unvested Stock Options shall immediately become vested.

 

 

 

    	 	20	 

     

    

 

3.4 Termination Due to Permanent Total Disability.
The Employment Period shall be terminated upon the Permanent Total Disability (as defined in this Section 3.4) of Executive following
written notice from the Company. Permanent Total Disability is defined as an inability by Executive to perform substantially all
of the services required pursuant to this Agreement for a continuous period of one hundred eighty (180) days when such inability
is caused by illness or a physical or mental disability. Such Permanent Total Disability shall be determined by a physician selected
jointly by the parties hereto.

 

3.5 Termination Other Than Due Cause, Death, Disability or Resignation.
In the event that Executive’s employment is terminated for reasons other than Due Cause, death, Permanent Total Disability
or resignation, then all Stock grants not fully vested are immediately vested. The Company shall pay severance compensation, to
Executive equal to twelve months salary compensation at his then annual salary compensation rate. Any severance compensation paid
to Executive shall be paid ratably over the remaining payment period following termination.

 

3.6 Termination by Executive. Executive
may terminate the Employment Period at Executive’s convenience upon thirty days written notice.

 

3.7 Surrender of Position and Properties.
Upon termination of Executive’s employment with the Company, regardless of the cause therefore, Executive shall promptly
be deemed to have resigned from the Company’s Board of Directors and as an officer and director of any of the Company’s
affiliates, if serving as such at that time, and shall surrender to the Company or its affiliates all property provided to him
by the Company.

 

3.8 Survival of Covenants. The covenants
of Executive set forth in Section 5 and 6 herein shall survive the termination of the Employment Period or termination of this
Agreement.

 

Section 4. Compensation/Expenses.

 

4.1 Salary. In exchange for the services
to be rendered by Executive hereunder, the Company agrees to pay, after raising a minimum of $500,000.00 for the LLC to operate,
a salary at a rate of;

 

Salary:

$300,000 per year

Salary will be paid bi-weekly.

 

4.2 Business Expenses. Executive shall
be reimbursed for business-related expenses that Executive incurs pursuant to employment with the Company, such expenses to be
timely submitted with supporting documentation and other substantiation of such expenses that conform to the reporting requirements
of the Company and requirements of the Internal Revenue Service. Company will reimburse expenses to Executive within thirty days
of receipt.

 

Section 5. Confidentiality.

 

5.1 Confidentiality. At any time during
the Term of this Agreement , Executive shall not disclose or make any use of, for his own benefit or for the benefit of a business
or entity other than the Company or its affiliates, any secret or Confidential Information, lists of customers and prospective
customers or any other information of or pertaining to the Company or its affiliates that is not generally known within the trade
of the Company or its affiliates or which is not publicly available.

 

Confidential Information. For
purposes of this Agreement, the term "Confidential Information" shall mean Information regarding Company's business including,
Information regarding cardiac related medical device products for determining EKG, processing and manufacturing capabilities of
the EKG device.

 

Exceptions to Confidentiality Obligations.
The obligations of this Agreement shall not apply to Confidential Information which:

 

1.     is
or becomes publicly available

 

 

 

    	 	21	 

     

    

 

Section 6. Indemnification. In addition
to any rights Executive may have under the Company's charter or by-laws, the Company agrees to indemnify Executive and hold Executive
harmless, both during the Term and thereafter, against all costs, expenses (including, without limitation, fines, excise taxes
and attorneys' and accountants’ fees) and liabilities (other than settlements to which the Company does not consent, which
consent shall not be unreasonably withheld) (collectively, "Losses") reasonably incurred by Executive in connection with
any claim, action, proceeding or investigation brought against or involving Executive with respect to, arising out of or in any
way relating to Executive's employment with the Company or Executive's service as a director of the Company; provided, however,
that the Company shall not be required to indemnify Executive for Losses incurred as a result of Executive's intentional misconduct
or gross negligence (other than matters where Executive acted in good faith and in a manner he reasonably believed to be in and
not opposed to the Company's best interests). Executive shall promptly notify the Company of any claim, action, proceeding or investigation
under this paragraph and the Company shall be entitled to participate in the defense of any such claim, action, proceeding or investigation
and, if it so chooses, to assume the defense with counsel selected by the Company; provided that Executive shall have the right
to employ counsel to represent him (at the Company's expense) if Company counsel would have a "conflict of interest"
in representing both the Company and Executive. The Company shall not settle or compromise any claim, action, proceeding or investigation
without Executive's consent, which consent shall not be unreasonably withheld; provided, however, that such consent shall not be
required if the settlement entails only the payment of money and the Company fully indemnifies Executive in connection therewith.
The Company further agrees to advance any and all expenses (including, without limitation, the fees and expenses of counsel) reasonably
incurred by the Executive in connection with any such claim, action, proceeding or investigation. The Company, as soon as reasonably
possible, will maintains a policy of directors' and officers' liability insurance covering Executive and, notwithstanding the expiration
or earlier termination of this Agreement, the Company shall maintain a directors' and officers' liability insurance policy covering
Executive for a period of time following such expiration or earlier termination equal to the statute of limitations for any claim
that may be asserted against Executive for which coverage is available under such directors' and officers' liability insurance
policy. The provisions of this paragraph shall survive the termination of this Agreement for any reason.

 

Section 7. Notice. Any notice required
or permitted hereunder shall be made in writing (i) either by actual delivery of the notice into the hands of the party hereunder
entitled, or (ii) by the mailing of the notice in the United States mail, certified mail, return receipt requested, Federal Express,
United Parcel Service with all postage prepaid and addressed to the party to whom the notice is to be given at the party’s
respective address set forth below, or such other address as the parties may from time to time designate by written notice as provided
herein and (iii) via email to the email addresses provided by the Parties below. Notice will hereby be deemed to be satisfied via
the delivery of any of the methods listed above.

 

If to the Company:

Attn: LLC

 

If to Executive:

Jacob VanLandingham

 

The notice shall be deemed to be received in
case (i) on the date of actual receipt by the party and in case (ii) three days following the date of the mailing.

 

Section 8. Amendment and Waiver. No
amendment or modification of this Agreement shall be valid or binding upon: (i) the Company unless made in writing and signed by
an officer of the Company, duly authorized by the Board of Directors of the Company or; (ii) Executive unless made in writing and
signed by him. The waiver by the Company or Executive of the breach of any Provision of this Agreement by the other party shall
not operate or be construed as a waiver of any subsequent breach of such party.

 

Section 9. Governing Law. (a) The validity
and effect of this Agreement and the rights and obligations of the parties hereto shall be governed by, and construed in accordance
with, the laws of the State of Florida.

 

 

 

    	 	22	 

     

    

 

Section 10. Entire Agreement. This Agreement
contains all of the terms agreed upon by the parties with respect to the subject matter hereof and supersedes all prior agreements,
arrangements and communications between the parties dealing with such subject matter, whether oral or written, but limited to the
Employment Period.

 

Section 11. Binding Effect. This Agreement
shall be binding upon and shall inure to the benefit of the transferees, successors and assigns of the Company, including any company
or entity with which the Company may merge or consolidate.

 

Section 12. Headings. Numbers and titles
to paragraphs hereof are for information purposes only and, where inconsistent with the text, are to be disregarded.

 

Section 13. Severability – General.
If any provision of this Agreement or the application of any such provision to any person or circumstance shall be held invalid,
illegal or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall
not affect any other provision hereof

 

Section 14. Counterparts. This Agreement
may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original and
all of which together shall be deemed to be one and the same agreement.

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be executed on the date first set forth above.

 

	Company	 	Executive
	 	 	 
	By: ______________________	 	By: ______________________
	 	 	 
	Printed:	 	Printed:
	 	 	 
	Title:	 	 
	 	 	 
	Date:
_____________________	 	Date:
_____________________
	 	 	 

 

 

 

 

 

 

    	 	23	 

     

    

 

Exhibit “C”

SHARE EXCHANGE AGREEMENT

 

This Share Exchange Agreement (this
"Agreement") is entered into as of June 26 2019, by and among Odyssey, Inc., a Nevada corporation ("Odyssey"),
and Prevacus, Inc. a Delaware corporation, ("Prevacus") Odyssey, are sometimes hereinafter referred
to individually as a “Party” and together as the “Parties.”

 

RECITALS

 

A.       Whereas,
Prevacus is a Delaware corporation that is engaged in the business of identifying, developing and commercializing chemical
drug compounds for treatment of brain related medical issues.

 

B.       Whereas,
Prevacus Stockholders hold all of the issued and outstanding capital stock of Prevacus.

 

C.       Whereas,
Odyssey is a reporting corporation presently subject to the reporting requirements as provided by Section 13 and 15(d) of the
Securities Exchange Act of 1934 (the “Exchange Act”). The common stock of Odyssey is presently quoted on the OTC Bulletin
Board under the symbol “ODYY.”

 

D.       Whereas,
Odyssey and Prevacus have each agreed to the acquisition by Odyssey of the equitable and other legal rights, title and interests
in and to one-million (1,000,000) shares of Prevacus stock and by Prevacus of the equitable and other legal rights, title and interests
in three-million (3,000,000) shares of Odyssey stock pursuant to a voluntary share exchange transaction (the "Share Exchange"),
and the other transactions provided herein and have adopted this Agreement, in each case after determining that the Share Exchange
and the consummation of the other transactions contemplated herein are advisable, fair to, and in the best interests of Odyssey,
Prevacus and, their respective stockholders;

 

E.       Whereas,
in order to implement their common long-term business and financial goals, the Parties to this Agreement desire to implement a
strategy through which the drug development of a chemical compound known as a neurosteroid will become the asset of a joint venture
company owned equally by Prevacus and Odyssey,

 

F.       Whereas,
in furtherance thereof, the Board of Directors of Odyssey has approved the Share Exchange in accordance with the applicable
provisions of the Nevada Revised Statutes (“NRS”) and upon the terms and subject to the conditions set forth herein;

 

G.       Whereas,
in furtherance thereof, the Board of Directors and the Prevacus have approved the Share Exchange in accordance with the applicable
provisions of the laws of the State of Delaware and upon the terms and subject to the conditions set forth herein; and

 

H.       Whereas,
for United States federal income tax purposes, the parties intend that the Share Exchange shall constitute a tax-free reorganization
within the meaning of Sections 368 and 1032 of the Code.

 

AGREEMENT

 

NOW, THEREFORE, in consideration
of the premises, and the mutual covenants and agreements contained herein, the parties do hereby agree as follows:

 

 

 

    	 	24	 

     

    

 

a)

 

DEFINITIONS

 

a)         Defined Terms. When used in this Agreement, the following terms shall have the respective meanings specified below.

 

"Affiliate" shall
mean, as to any Person, any other Person controlled by, under the control of, or under common control with, such Person. As used
in this definition, "control" shall mean possession, directly or indirectly, of the power to direct or cause the direction
of management or policies (whether through ownership of securities or partnership or other ownership interests, by contract or
otherwise), provided that, in any event, any Person which owns or holds directly or indirectly five per cent (5%) or more of the
voting securities or five per cent (5%) or more of the partnership or other equity interests of any other Person (other than as
a limited partner of such other Person) will be deemed to control such other Person.

 

"Agreement" means
this Share Exchange Agreement.

 

"Odyssey" means
Odyssey, Inc., a Nevada corporation.

 

"Odyssey Balance Sheet"
has the meaning set forth in Section 5.6.

 

"Odyssey Balance Sheet
Date" has the meaning set forth in Section 5.6

 

"Odyssey Business"
the development and commercialization of life saving medical products.

 

"Odyssey Common Stock"
means the common stock, par value $0.001 per share, of Odyssey.

 

"Odyssey Financial Information"
has the meaning set forth in Section 5.6.

 

"Odyssey SEC Reports"
has the meaning set forth in Section 5.13.

 

"Applicable Law" or
"Applicable Laws" means any and all laws, ordinances, constitutions, regulations, statutes, treaties, rules, codes,
licenses, certificates, franchises, permits, principles of common law, requirements and Orders adopted, enacted, implemented, promulgated,
issued, entered or deemed applicable by or under the authority of any Governmental Body having jurisdiction over a specified Person
or any of such Person's properties or assets.

 

"Best Efforts"
means the efforts that a prudent Person desirous of achieving a result would use in similar circumstances to achieve that result
as expeditiously as possible, provided, however, that a Person required to use Best Efforts under this Agreement will not be thereby
required to take actions that would result in a Material Adverse Effect in the benefits to such Person of this Agreement and the
Share Exchange.

 

"Breach" means
any breach of, or any inaccuracy in, any representation or warranty or any breach of, or failure to perform or comply with, any
covenant or obligation, in or of this Agreement or any other Contract.

 

 

 

    	 	25	 

     

    

 

"Business Day"
means any day other than (a) Saturday or Sunday or (b) any other day on which banks in Tallahassee, FL are permitted or required
to be closed.

 

“CGCL” means
the California General Corporation Law, as amended from time to time, and the rules and regulations promulgated thereunder. Section
references to the CGCL are to the CGCL as in effect at the date of this Agreement.

 

"Closing" shall
mean the completion of the Share Exchange and the consummation of the transactions set forth herein.

 

"Closing Date"
shall mean the date on which the Closing is completed.

 

"Code" shall mean
the Internal Revenue Code of 1986, as amended.

 

"Confidential Information"
means any information pertaining to the business, operations, marketing, customers, financing, forecasts and plans of any Party
provided to or learned by any other Party during the course of negotiation of the Share Exchange. Information shall be treated
as Confidential Information whether such information has been marked "confidential" or in a similar manner.

 

"Consent" means
any approval, consent, license, permits, ratification, waiver or other authorization.

 

"Contract" means
any agreement, contract, lease, license, consensual obligation, promise, undertaking, understanding, commitment, arrangement, instrument
or document (whether written or oral and whether express or implied), whether or not legally binding.

 

“DGCL” means
the Delaware General Corporation Law, as amended from time to time, and the rules and regulations promulgated thereunder. Section
references to the DGCL are to the DGCL as in effect at the date of this Agreement.

 

"Encumbrance"
means and includes:

 

with respect to any personal property,
any security or other property interest or right, claim, lien, pledge, option, charge, security interest, contingent or conditional
sale, or other title claim or retention agreement or lease or use agreement in the nature thereof, interest or other right or claim
of third parties, whether voluntarily incurred or arising by operation of law, and including any agreement to grant or submit to
any of the foregoing in the future; and

 

with respect to any Real Property
(whether and including owned real estate or Real Estate subject to a Real Property Lease), any mortgage, lien, easement, interest,
right-of-way, condemnation or eminent domain proceeding, encroachment, any building, use or other form of restriction, encumbrance
or other claim (including adverse or prescriptive) or right of Third Parties (including Governmental Bodies), any lease or sublease,
boundary dispute, and agreements with respect to any real property including: purchase, sale, right of first refusal, option, construction,
building or property service, maintenance, property management, conditional or contingent sale, use or occupancy, franchise or
concession, whether voluntarily incurred or arising by operation of law, and including any agreement to grant or submit to any
of the foregoing in the future.

 

"Exchange Act"
means the Securities Exchange Act of 1934, as amended.

 

 

 

    	 	26	 

     

    

 

"GAAP" means at
any particular time generally accepted accounting principles in the United States, consistently applied on a going concern basis,
using consistent audit scope and materiality standards.

 

"Governing Documents"
means with respect to any particular entity, the articles or certificate of incorporation and the bylaws (or equivalent documents
for entities of foreign jurisdictions); all equity holders' agreements, voting agreements, voting trust agreements, joint venture
agreements, registration rights agreements or other agreements or documents relating to the organization, management or operation
of any Person or relating to the rights, duties and obligations of the equity holders of any Person; and any amendment or supplement
to any of the foregoing.

 

"Governmental Authorization"
means any Consent, license, registration or permit issued, granted, given or otherwise made available by or under the authority
of any Governmental Body or pursuant to any Applicable Law.

 

"Governmental Body"
means any instrumentality, subdivision, court, administrative agency, commission, official or other authority of the United States
or any other country or any state, province, prefect, municipality, locality or other government or political subdivision thereof,
or any quasi-governmental or private body exercising any regulatory, taxing, importing or other governmental or quasi-governmental
authority.

 

"IRS" means the
United States Internal Revenue Service and, to the extent relevant, the United States Department of the Treasury.

 

"Knowledge" means
actual knowledge without independent investigation.

 

"Land" means all
parcels and tracts of land in which any Person has an ownership or leasehold interest.

 

"Material Adverse Effect"
or "Material Adverse Change" means:

 

with respect to Prevacus or the Major
Stockholders, an effect that is or would reasonably be expected to be materially adverse (A) to the Prevacus Business, results
of operations or financial condition of Prevacus; or (B) to Prevacus’ or the Major Stockholders’ ability to perform
any of their respective obligations under this Agreement or to consummate the transactions contemplated in this Agreement; or

 

with respect to the Odyssey, an effect
that is or would reasonably be expected to be materially adverse (A) to the Odyssey Business, results of operation or financial
condition of the Odyssey considered as a whole; or (B) to the ability of the Odyssey to perform any of their respective obligations
under this Agreement or to consummate the transactions contemplated in the Agreement;

 

provided, however, that in determining
whether a Material Adverse Effect has occurred there shall be excluded any effect on the referenced party the cause of which is:
(A) general changes in the financial markets or in the global or United States economy so long as any such change does not materially
effect the referenced party to a materially different extent than other similarly situated Persons, (B) any action or omission
of the parties permitted or required by the Agreement, and (C) the announcement of the transactions contemplated hereby.

 

"NRS" shall mean
the Nevada Revised Statutes, as amended.

 

 

 

    	 	27	 

     

    

 

"Order" means
any writ, directive, order, injunction, judgment, decree, ruling, assessment or arbitration award of any Governmental Body or arbitrator.

 

"Ordinary Course of Business"
means an action taken by a Person will be deemed to have been taken in the Ordinary Course of Business only if that action: (i)
is consistent in nature, scope and magnitude with the past practices of such Person and is taken in the ordinary course of the
normal, day-to-day operations of such Person; (ii) does not require authorization by the board of directors or Stockholders of
such Person (or by any Person or group of Persons exercising similar authority) and does not require any other separate or special
authorization of any nature; and (iii) is similar in nature, scope and magnitude to actions customarily taken, without any separate
or special authorization, in the ordinary course of the normal, day-to-day operations of other Persons that are in the same line
of business as such Person.

 

"Party" or "Parties"
means Prevacus, the Prevacus Stockholders, the Major Stockholders and/or Odyssey.

 

"Person" means
and includes an individual, a partnership, a joint venture, a corporation, a limited liability company, a limited liability partnership,
a trust, an incorporated organization or a Governmental Body.

 

"Proceeding" means
any action, arbitration, audit, hearing, investigation, litigation or suit (whether civil, criminal, administrative, judicial or
investigative, whether formal or informal, whether public or private) commenced, brought, conducted or heard by or before, or otherwise
involving, any Governmental Body or arbitrator.

 

"Real Property"
means any Land and Improvements and all privileges, rights, easements, hereditaments and appurtenances belonging to or for the
benefit of any Land.

 

"Real Property Lease"
means any lease, rental agreement or rights to use any Land or Real Property.

 

"Representative"
means with respect to a particular Person, any director, officer, manager, employee, agent, consultant, advisor, accountant, financial
advisor, legal counsel or other Representative of that Person.

 

"Prevacus" has
the meaning set forth in the preamble.

 

"Prevacus Balance Sheet"
has the meaning set forth in Section 5.6.

 

"Prevacus Balance Sheet
Date" has the meaning set forth in Section 5.6.

 

"Prevacus Board"
has the meaning set forth in Section 5.4.

 

"Prevacus Business"
means the biotechnology business as presently conducted by Prevacus.

 

"Prevacus Financial Information"
has the meaning set forth in Section 5.6.

 

"SEC" means the
United States Securities and Exchange Commission.

 

"Securities Act"
means the Securities Act of 1933, as amended.

 

 

 

    	 	28	 

     

    

 

"Security Interest"
means any mortgage, pledge, security interest, Encumbrance, charge, claim, or other lien, other than: (a) mechanic's, materialmen's
and similar liens; (b) liens for Taxes not yet due and payable or for Taxes that the taxpayer is contesting in good faith through
appropriate Proceedings; (c) liens arising under worker's compensation, unemployment insurance, social security, retirement and
similar legislation; (d) liens arising in connection with sales of foreign receivables; (e) liens on goods in transit incurred
pursuant to documentary letters of credit; (f) purchase money liens and liens securing rental payments under capital lease
arrangements; and (g) other liens arising in the Ordinary Course of Business and not incurred in connection with the borrowing
of money.

 

"Share Exchange"
has the meaning set forth in the preamble.

 

"Shares" has the
meaning set forth in Section 2.1

 

"Subsidiary" means
with respect to any Person (the "Owner"), any corporation or other Person of which securities or other interests having
the power to elect a majority of that corporation's or other Person's board of directors or similar governing body, or otherwise
having the power to direct the business and policies of that corporation or other Person (other than securities or other interests
having such power only upon the happening of a contingency that has not occurred), are held by the Owner or one or more of its
Subsidiaries.

 

"Tangible Personal Property"
means all machinery, equipment, tools, furniture, office equipment, computer hardware, supplies, materials, vehicles and other
items of tangible personal property of every kind owned or leased by a Party (wherever located and whether or not carried on a
Party's books), together with any express or implied warranty by the manufacturers or sellers or lessors of any item or component
part thereof and all maintenance records and other documents relating thereto.

 

"Tax" or "Taxes"
means all taxes, assessments, charges, duties, fees, levies or other similar governmental charges, including all U.S. and
non-U.S. federal, state, local and other income, franchise, profits, capital gains, capital stock, transfer, sales, use,
occupation, property, excise, severance, windfall profits, stamp, license, payroll, withholding and other taxes, assessments, charges,
duties, fees, levies or other similar governmental charges (whether payable directly or by withholding and whether or not requiring
the filing of a Tax Return), all estimated taxes, deficiency assessments, additions to tax, penalties and interest and shall include
any liability for such amounts as a result either of being a member of a combined, consolidated, unitary or affiliated group or
of a contractual obligation to indemnify any Person or other entity.

 

"Tax Return" means
any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule
or attachment thereto, and including any amendment thereof.

 

"Third Party"
means a Person that is not a Party to this Agreement.

 

b)

 

THE SHARE EXCHANGE

 

a)          The Share Exchange. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with
the NRS, at the Closing, the parties shall cause the Share Exchange to be consummated by taking all appropriate actions to ensure
that all equitable and legal rights, title and interests in and to the one-million shares of capital stock of Prevacus is assigned,
delivered and transferred to Odyssey, in exchange for the issuance of an aggregate of three-million restricted shares of Odyssey
Common Stock (the "Shares") to escrow until $500k is raised.

 

b)          Closing.
The Closing will occur via e-mail and facsimile on such date and time to be agreed upon by the parties (the "Closing Date"),
following satisfaction or waiver of the conditions set forth in Article VII.

 

 

 

    	 	29	 

     

    

 

c)

 

 

d)

 

COVENANTS, REPRESENTATIONS AND

WARRANTIES OF PREVACUS STOCKHOLDERS

 

a)          Investment Purpose.  Prevacus acknowledges and agree that they are acquiring the Shares for investment purposes and
will not offer, sell or otherwise transfer, pledge or hypothecate any of the Shares issued to them (other than pursuant to an effective
Registration Statement under the Securities Act) directly or indirectly unless:

 

The sale is to Odyssey;

 

the sale is made pursuant to the exemption
from registration under the Securities Act, provided by Rule 144 thereunder; or

 

the Shares are sold in a transaction
that does not require registration under the Securities Act, or any applicable United States state laws and regulations governing
the offer and sale of securities, and the vendor has furnished to Odyssey an opinion of counsel to that effect or such other written
opinion as may be reasonably required by Odyssey.

 

b)          Share Legend. The Prevacus Stockholders acknowledge and agree that the certificates representing the Shares shall bear
the following legend:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE
BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. WITHOUT SUCH REGISTRATION, SUCH SECURITIES MAY NOT BE SOLD
OR OTHERWISE TRANSFERRED AT ANY TIME WHATSOEVER UNLESS IN THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY REGISTRATION IS NOT
REQUIRED FOR SUCH TRANSFER AND THAT SUCH TRANSFER WILL NOT BE IN VIOLATION OF THE APPLICABLE FEDERAL AND STATE SECURITIES LAWS
OR ANY RULE OR REGULATION PROMULGATED THEREUNDER.

 

c)          Acknowledgements.

 

Prevacus acknowledge that the shares
being issued hereunder are subject to significant restrictions on transfer as imposed by state and federal securities laws, including
but not limited to a minimum holding period of six (6) months before such shares can be sold pursuant to Rule 144; and

 

Prevacus are not aware of any advertisement
of any of the shares being issued hereunder.

 

The Prevacus Stockholders acknowledge and agree that Odyssey
will refuse to register any transfer of the shares not made pursuant to an effective registration statement under the Securities
Act or pursuant to an available exemption from the registration requirements of the Securities Act and in accordance with applicable
state and provincial securities laws;

 

 

 

    	 	30	 

     

    

 

The Prevacus Stockholders acknowledge
and agree that offers and sales of any of the Shares, after six (6) months but prior to the expiration of a period of one year
from the date of Closing (the “Distribution Compliance Period”), shall only be made pursuant to Rule 144, the registration
provisions of the Securities Act or an exemption therefrom, and that all offers and sales after one year shall be made only in
compliance with the registration provisions of the Securities Act or an exemption therefrom and in each case only in accordance
with all applicable securities laws;

 

Prevacus acknowledges and agrees not
to engage in any hedging transactions involving the Shares prior to the end of the Distribution Compliance Period unless such transactions
are in compliance with the provisions of the Securities Act; and

 

Prevacus hereby acknowledge and agree
to Odyssey making a notation on its records or giving instructions to the registrar and transfer agent of Odyssey in order to implement
the restrictions on transfer set forth and described herein.

 

e)

 

REPRESENTATIONS AND WARRANTIES OF PREVACUS

 

As a material inducement for Odyssey to enter
into this Agreement and to consummate the transactions contemplated hereby, Prevacus makes the following representations and warranties
as of the date hereof and as of the Closing Date, each of which is relied upon by Odyssey regardless of any investigation made
or information obtained by Odyssey (unless and to the extent specifically and expressly waived in writing by Odyssey on or before
the Closing Date):

 

a)           Organization and Good Standing.

 

Prevacus is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware. Prevacus is duly qualified to do business
in each jurisdiction in which it conducts business activities and is in good standing under the laws of each jurisdiction in which
either the ownership or use of the properties owned or used by it, or the nature of the activities conducted by it, requires such
qualification and the failure to be so qualified would have a Material Adverse Effect on Prevacus.

 

Prevacus has no Subsidiaries and
does not own any shares of capital stock or other securities of any other Person.

 

b)           Capitalization
of Prevacus. The entire authorized capital stock of Prevacus consists of ____________ shares of common stock no par value,
of which ____________ shares are issued and outstanding. All issued and outstanding shares of common stock have been duly authorized,
are validly issued, fully paid and nonassessable.

 

c)           Authorization
of Transaction.

 

Prevacus has full power and authority
to execute and deliver this Agreement and the Related Agreements and to perform its obligations hereunder. On the Closing Date,
this Agreement shall be duly and validly authorized by all necessary action on the part of Prevacus in accordance with Applicable
Laws and Prevacus' Governing Documents. This Agreement constitutes the valid and legally binding obligation of Prevacus, enforceable
in accordance with its terms and conditions. The Board of Directors of Prevacus (the "Prevacus Board") has duly
and validly authorized the execution and delivery of this Agreement and approved the consummation of the transactions contemplated
hereby.

 

 

 

    	 	31	 

     

    

 

d)           Noncontravention.
Neither the execution nor delivery of this Agreement,
nor consummation of the Share Exchange, by Prevacus will:

 

violate any Applicable Law, Order,
stipulation, charge or other restriction of any Governmental Body to which Prevacus is subject or any provision of its Governing
Documents; or

 

conflict with, result in a Breach
of, constitute a default under, result in the acceleration of, create in any Person the right to accelerate, terminate, modify
or cancel, or require any notice under any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement
or mortgage for borrowed money, instrument of indebtedness, Security Interest or other arrangement to which Prevacus is a party
or by which it is bound or to which any of its assets is subject (or result in the imposition of any Security Interest upon any
of its assets), except where the violation, conflict, Breach, default, acceleration, termination, modification, cancellation, failure
to give notice, or Security Interest would not have a Material Adverse Effect on the financial condition of Prevacus or on the
ability of the Parties to consummate the Share Exchange.

 

e)           Events
Subsequent to Prevacus Balance Sheet. Since the Prevacus Balance Sheet Date, and except as disclosed on Schedule 5.7,
there has not been, occurred or arisen, with respect to Prevacus:

 

any change or amendment in its
Governing Documents;

 

any reclassification, split up
or other change in, or amendment of or modification to, the rights of the holders of any of its capital stock;

 

any direct or indirect redemption,
purchase or acquisition by any Person of any of its capital stock or of any interest in or right to acquire any such stock;

 

any issuance, sale, or other disposition
of any capital stock, or any grant of any options, warrants, or other rights to purchase or obtain (including upon conversion,
exchange, or exercise) any capital stock;

 

any declaration, set aside, or
payment of any dividend or any distribution with respect to its capital stock (whether in cash or in kind) or any redemption, purchase,
or other acquisition of any of its capital stock;

 

the organization of any Subsidiary
or the acquisition of any shares of capital stock by any Person or any equity or ownership interest in any business;

 

any damage, destruction or loss
of any of its properties or assets whether or not covered by insurance;

 

any material sale, lease, transfer,
or assignment of any of its assets, tangible or intangible, other than for a fair consideration in the Ordinary Course of Business;

 

the execution of, or any other
commitment to any agreement, contract, lease, or license (or series of related agreements, contracts, leases, and licenses) outside
the Ordinary Course of Business;

 

any acceleration, termination,
modification, or cancellation of any agreement, contract, lease, or license (or series of related agreements, contracts, leases,
and licenses) involving more than $10,000 to which it is a party or by which it is bound;

 

 

 

    	 	32	 

     

    

 

any Security Interest or Encumbrance
imposed upon any of its assets, tangible or intangible;

 

any grant of any license or sublicense
of any rights under or with respect to any material Prevacus Intellectual Property;

 

any sale, assignment or transfer
(including transfers to any employees, Affiliates or Stockholders) of any material Prevacus Intellectual Property;

 

any capital expenditure (or series
of related capital expenditures) involving more than $25,000 and outside the Ordinary Course of Business;

 

any delay or postponement of the
payment of accounts payable or other liabilities, other than those being contested in good faith;

 

any cancellation, compromise, waiver,
or release of any right or claim (or series of related rights and claims) involving more than $25,000 and outside the Ordinary
Course of Business;

 

any loan to, or any entrance into
any other transaction with, any of its directors, officers, and employees either involving more than $1,000 individually or $5,000
in the aggregate;

 

the adoption, amendment, modification,
or termination of any bonus, profit-sharing, incentive, severance, or other plan, contract, or commitment for the benefit of any
of its directors, officers, and employees (or taken any such action with respect to any other Employee Benefit Plan);

 

any employment contract or collective
bargaining agreement, written or oral, or modified the terms of any existing such contract or agreement;

 

any increase in the base compensation
of any of its directors, officers, and employees that is greater than $25,000 per annum;

 

any charitable or other capital
contribution in excess of $2,500;

 

any taking of other action or entrance
into any other transaction other than in the Ordinary Course of Business, or entrance into any transaction with any insider of
Prevacus, except as disclosed in this Agreement and the Disclosure Schedules;

 

any other event or occurrence that
may have or could reasonably be expected to have a Material Adverse Effect on Prevacus (whether or not similar to any of the foregoing);
or

 

any agreement or commitment, whether
in writing or otherwise, to do any of the foregoing.

 

f)            Tax
Matters.

 

Except as set forth on Schedule 5.8
Prevacus:

 

 

 

    	 	33	 

     

    

 

has timely paid or caused to be paid
all material Taxes required to be paid by it though the date hereof and as of the Closing Date (including any Taxes shown due on
any Tax Return);

 

has filed or caused to be filed in
a timely and proper manner (within any applicable extension periods) all Tax Returns required to be filed by it with the appropriate
Governmental Body in all jurisdictions in which such Tax Returns are required to be filed; and all tax returns filed on behalf
of Prevacus were complete and correct in all material respects; and

 

has not requested or caused to be
requested any extension of time within which to file any Tax Return, which Tax Return has not since been filed.

 

has not been notified since January 1,
2019 by any Governmental Body that any material issues have been raised (and no such issues are currently pending) by any Governmental
Body in connection with any Tax Return filed by or on behalf of Prevacus; there are no pending Tax audits and no waivers of statutes
of limitations have been given or requested with respect to Prevacus; no Tax liens have been filed against Prevacus or unresolved
deficiencies or additions to Taxes have been proposed, asserted or assessed against Prevacus;

 

has made full and adequate accrual
(A) on the Prevacus Balance Sheet, and the books and records of Prevacus for all income taxes currently due and all accrued Taxes
not yet due and payable by Prevacus for all periods ending on or prior to the Prevacus Balance Sheet Date, and (B) on the books
and records of Prevacus for all Taxes payable by Prevacus for all periods beginning after the Prevacus Balance Sheet Date;

 

has not incurred any liability for
Taxes from and after the Prevacus Balance Sheet Date other than Taxes incurred in the Ordinary Course of Business and consistent
with past practices;

 

has complied in all material respects
with all Applicable Laws relating to the collection or withholding of Taxes (such as Taxes or withholding of Taxes from the wages
of employees); and

 

does not have any liability in respect
of any Tax sharing agreement with any Person;

 

Prevacus has incurred any liability
to make any payments either alone or in conjunction with any other payments that would constitute a "parachute payment"
within the meaning of Section 280G of the Code (or any corresponding provision of state local or foreign Applicable Law related
to Taxes);

 

No claim has been made within the
last three years by any taxing authority in a jurisdiction in which Prevacus does not file Tax Returns that Prevacus is or may
be subject to taxation by that jurisdiction;

 

The consummation of the Share Exchange
will not trigger the realization or recognition of intercompany gain or income to Prevacus or any Affiliate of Prevacus under the
Federal consolidated return regulations with respect to Federal, state or local taxes; and

 

Prevacus is not currently, nor
has it been at any time during the previous five years, a "U.S. real property holding corporation" and, therefore, the
Shares are not "U.S. real property interests," as such terms are defined in Section 897 of the Code.

 

 

 

    	 	34	 

     

    

 

g)           Title
to Assets. Prevacus has good and marketable title to, or a valid leasehold interest in, the properties and assets owned
or leased and used by it to operate the Prevacus Business in the manner presently operated by it, as reflected in the Prevacus
Financial Information.

 

h)           Real
Property.

 

Except as set forth in Schedule
5.10(a) Prevacus does not own or hold an ownership interest in any Real Property.

 

Leased Real Property. Except
as set forth in Schedule 5.10(b) Prevacus does not own or a leasehold interest in any Real Property.

 

i)            Condition
of Facilities.

 

To the knowledge of Prevacus, the
use of the Real Property of Prevacus for the various purposes for which it is presently being used is permitted as of right under
all Applicable Laws related to zoning and is not subject to "permitted nonconforming" use or structure classifications.
To the knowledge of the Prevacus, all Improvements are in compliance with all Applicable Laws, including those pertaining to zoning,
building and the disabled, are in good repair and in good condition, ordinary wear and tear excepted, and are free from latent
and patent defects. To the knowledge of the Prevacus, no part of any Improvement encroaches on any real property not included in
the Real Property of Prevacus or the Prevacus, and there are no buildings, structures, fixtures or other Improvements primarily
situated on adjoining property which encroach on any part of the Land.

 

Each item of Tangible Personal
Property is in good repair and good operating condition, ordinary wear and tear excepted, is suitable for immediate use in the
Ordinary Course of Business and is free from latent and patent defects. No item of Tangible Personal Property is in need of repair
or replacement other than as part of routine maintenance in the Ordinary Course of Business. All Tangible Personal Property used
in the Prevacus Business is in the possession of Prevacus.

 

j)            Powers
of Attorney. There are no outstanding powers of attorney executed on behalf of Prevacus.

 

k)           Litigation.
Except as set forth on Schedule 5.16:

 

there is no pending or, to Prevacus'
Knowledge, threatened Proceeding:

 

by or against
Prevacus or that otherwise relates to or may affect the Prevacus Business which, if adversely determined, would have a Material
Adverse Effect; or

 

that challenges,
or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Share Exchange.

 

to the Knowledge
of Prevacus, no event has occurred or circumstance exists that is reasonably likely to give rise to or serve as a basis for the
commencement of any such Proceeding. Prevacus has delivered to Odyssey copies, if any, of all pleadings, correspondence and other
documents relating to each Proceeding.

 

there is no material Order to which
Prevacus or the Prevacus Business is subject; and

 

 

 

    	 	35	 

     

    

 

To the knowledge of the Prevacus,
no officer, director, agent or employee of Prevacus is subject to any Order that prohibits such officer, director, agent or employee
from engaging in or continuing any conduct, activity or practice relating to the Prevacus Business.

 

Prevacus has been and is in compliance
with all of the terms and requirements of each Order to which it or the Prevacus Business is or has been subject;

 

no event has occurred or circumstance
exists that is reasonably likely to constitute or result in (with or without notice or lapse of time) a violation of or failure
to comply with any term or requirement of any Order to which Prevacus or the Prevacus Business is subject; and

 

Prevacus has not received any notice
or other communication (whether oral or written) from any Governmental Body or any other Person regarding any actual, alleged,
possible or potential violation of, or failure to comply with, any term or requirement of any Order to which Prevacus or the Prevacus
Business is subject.

 

l)            Legal Compliance. Prevacus is in material compliance with all Applicable Laws (including rules and regulations thereunder)
of any Governmental Bodies having jurisdiction over Prevacus , including any requirements relating to antitrust, consumer protection,
currency exchange, equal opportunity, health, occupational safety, pension and securities matters.

 

m)          Brokers'
Fees. Prevacus has no liability or obligation to pay any fees or commissions to any broker, finder or agent with respect
to the Share Exchange for which Prevacus could become liable or obligated.

 

n)           Disclosure.
The representations and warranties of Prevacus contained in this Agreement do not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements and information contained herein not misleading.

 

f)

 

REPRESENTATIONS AND WARRANTEES
OF ODYSSEY

 

As a material inducement for Prevacus
to enter into this Agreement and to consummate the transactions contemplated hereby, Odyssey hereby makes the following representations
and warranties as of the date hereof and as of the Closing Date, each of which is relied upon by Prevacus regardless of any investigation
made or information obtained by Prevacus (unless and to the extent specifically and expressly waived in writing by Prevacus on
or before the Closing Date):

 

a)           Organization and Good Standing.

 

Odyssey is a corporation duly organized,
validly existing and in good standing under the laws of State of Nevada. Odyssey is duly qualified to do business as a foreign
corporation and is in good standing under the laws of each state or other jurisdiction in which either the ownership or use of
the properties owned or used by it, or the nature of the activities conducted by it, requires such qualification and the failure
to be so qualified would have a Material Adverse Effect on Odyssey.

 

Except as set forth on Schedule
6.1(b), Odyssey has no Subsidiary and does not own any shares of capital stock or other securities of any other Person.

 

 

 

    	 	36	 

     

    

 

b)           Capitalization
of Odyssey. The entire authorized capital stock of Odyssey consists of 250,000,000 shares of common stock having a par
value of $0.001 per share.

 

c)           Authorization
of Transaction. Odyssey has the corporate power to execute, deliver and perform this Agreement, the Related Agreements,
and, subject to the satisfaction of the conditions precedent set forth herein, has taken all action required by law, its Governing
Documents or otherwise, to authorize the execution, delivery, and performance of this Agreement and such related documents. The
execution and delivery of this Agreement has been approved by the Board of Directors of Odyssey. This Agreement is a valid obligation
of Odyssey and is legally binding on Odyssey in accordance with its terms.

 

d)           Noncontravention.
Neither the execution nor delivery of this Agreement, nor consummation of the Share Exchange, will:

 

violate any Applicable Law, Order,
stipulation, charge or other restriction of any Governmental Body to which Odyssey is subject or any provision of its Governing
Documents; or

conflict with, result in a Breach
of, constitute a default under, result in the acceleration of, create in any Person the right to accelerate, terminate, modify
or cancel, or require any notice under any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement
or mortgage for borrowed money, instrument of indebtedness, Security Interest, or other arrangement to which Odyssey is a party
or by which it is bound or to which any of its assets is subject (or result in the imposition of any Security Interest upon any
of its assets), except where the violation, conflict, Breach, default, acceleration, termination, modification, cancellation, failure
to give notice, or Security Interest would not have a Material Adverse Effect on the financial condition of Odyssey or on the ability
of the Parties to consummate the Share Exchange.

 

e)           Affiliate
Transactions. No officer, director, or employee of Odyssey or any member of the immediate family of any such officer,
director or employee, or any entity in which any of such persons owns any beneficial interest (other than any publicly-held corporation
whose stock is traded on a national securities exchange or in the over-the-counter market and less than one percent of the stock
of which is beneficially owned by any of such Persons), has any agreement with Odyssey or any interest in any of their property
of any nature, used in or pertaining to the Odyssey Business. None of the foregoing Persons has any direct or indirect interest
in any competitor, supplier or customer of Odyssey or in any Person from whom or to whom Odyssey leases any property or transacts
business of any nature.

 

f)            Odyssey
Financial Information.

 

The audited balance sheet and statements
of income, changes in Stockholders' equity and cash flow as of and for the fiscal years ended 2018 for Odyssey (collectively, the
“Odyssey Financial Information”) are set forth in its Annual Reports on Form 10-K as filed with the Securities
and Exchage Commission. The audited balance sheet as of July 31, 2018, as set forth in its Form 10-K, shall be referred to herein
as the "Odyssey Balance Sheet" and July 31, 2018 shall be sometimes referred to herein as the "Odyssey
Balance Sheet Date." Odyssey Financial Information presents fairly the financial condition of Odyssey as of such dates
and the results of operations of Odyssey for such periods, in accordance with GAAP and are consistent with the books and records
of Odyssey (which books and records are correct and complete).

 

g)           Tax Matters.

 

Except as set forth on Schedule
6.8, Odyssey:

 

has timely paid or caused to be paid
all Taxes required to be paid by it though the date hereof and as of the Closing Date (including any Taxes shown due on any Tax
Return);

 

 

 

    	 	37	 

     

    

 

has filed or caused to be filed in
a timely and proper manner (within any applicable extension periods) all Tax Returns required to be filed by it with the appropriate
Governmental Body in all jurisdictions in which such Tax Returns are required to be filed; and all tax returns filed on behalf
of Odyssey and each Odyssey Tax Affiliate were completed and correct in all material respects; and

 

has not requested or caused to be
requested any extension of time within which to file any Tax Return, which Tax Return has not since been filed.

 

has previously delivered true, correct
and complete copies of all Federal Tax Returns filed by or on behalf of Odyssey through the date hereof for the periods ending
after December 31, 2018.

 

since June 1, 2019 has not been notified
by the IRS or any other Governmental Body that any issues have been raised (and no such issues are currently pending) by the IRS
or any other Governmental Body in connection with any Tax Return filed by or on behalf of Odyssey or any Odyssey Tax Affiliate;
there are no pending Tax audits and no waivers of statutes of limitations have been given or requested with respect to Odyssey
or any present or former Affiliate of Odyssey (for years that it was an Affiliate); no Tax liens have been filed against Odyssey
or unresolved deficiencies or additions to Taxes have been proposed, asserted or assessed against Odyssey or any present or former
Affiliate (for the years that it was an Affiliate);;

 

has made full and adequate accrual
(i) on the Odyssey Balance Sheet, and the books and records of Odyssey for all income Taxes currently due and all accrued Taxes
not yet due and payable by Odyssey for all periods ending on or prior to the Odyssey Balance Sheet Date, and (ii) on the books
and records of Odyssey and for all Taxes payable by Odyssey for all periods beginning after the Odyssey Balance Sheet Date;

 

has not incurred any liability for
Taxes from and after the Odyssey Balance Sheet Date other than Taxes incurred in the Ordinary Course of Business and consistent
with past practices;

 

has not (i) made an election (or
had an election made on its behalf by another person) to be treated as a “consenting corporation” under Section 341(f)
of the Code or (ii) a “personal holding company” within the meaning of Section 542 of the Code;

 

has complied in all material respects
with all Applicable Laws relating to the collection or withholding of Taxes (such as Taxes or withholding of Taxes from the wages
of employees);

 

does not have any liability in respect
of any Tax sharing agreement with any Person and all Tax sharing agreements to which Odyssey has been bound have been terminated;

 

has not incurred any Liability to
make any payments either alone or in conjunction with any other payments that:

 

shall be non-deductible under,
or would otherwise constitute a “parachute payment” within the meaning of Section 280G of the Code (or any corresponding
provision of state local or foreign income Tax Law); or

 

are or may be subject to the imposition
of an excise Tax under Section 4999 of the Code;

 

 

 

    	 	38	 

     

    

 

has not agreed to (nor has any other
Person agreed to on its behalf) and is not required to make any adjustments or changes on, before or after the Closing Date, to
its accounting methods pursuant to Section 481 of the Code, and the Internal Revenue Service has not proposed any such adjustments
or changes in the accounting methods of Odyssey; and

 

No claim has been made within the
last three years by any taxing authority in a jurisdiction in which Odyssey does not file Tax Returns that Odyssey is or may be
subject to taxation by that jurisdiction;

 

The consummation of the Share Exchange
will not trigger the realization or recognition of intercompany gain or income to Odyssey under the Federal consolidated return
regulations with respect to Federal, state or local Taxes;

 

Odyssey is not is not currently,
nor has it been at any time during the previous five years, a “U.S. real property holding corporation” and, therefore,
the Odyssey Common Stock is not “U.S. real property interests,” as such terms are defined in Section 897 of the
Code.

 

h)           Condition of Facilities. 

 

Use of the Real Property of Odyssey
for the various purposes for which it is presently being used is permitted as of right under all Applicable Laws related to zoning
and is not subject to “permitted nonconforming” use or structure classifications. All Improvements are in compliance
with all Applicable Laws, including those pertaining to zoning, building and the disabled, are in good repair and in good condition,
ordinary wear and tear excepted, and are free from latent and patent defects. To the Knowledge of Odyssey, no part of any Improvement
encroaches on any real property not included in the Real Property of Odyssey, and there are no buildings, structures, fixtures
or other Improvements primarily situated on adjoining property which encroach on any part of the Land.

 

Each item of Tangible Personal
Property is in good repair and good operating condition, ordinary wear and tear excepted, is suitable for immediate use in the
Ordinary Course of Business and is free from latent and patent defects. No item of Tangible Personal Property is in need of repair
or replacement other than as part of routine maintenance in the Ordinary Course of Business.

 

i)            SEC Reports and Financial Statements. Odyssey has filed with the SEC all reports and other filings required to be filed
by Odyssey in accordance with the Securities Act and the Exchange Act and the rules and regulations promulgated thereunder (the
“Odyssey SEC Reports”). As of their respective dates, Odyssey SEC Reports complied in all material respects
with the applicable requirements of the Securities Act, the Exchange Act and the respective rules and regulations promulgated thereunder
applicable to such Odyssey SEC Reports and, except to the extent that information contained in any Odyssey SEC Report has been
revised or superseded by a later Odyssey SEC Report filed and publicly available prior to the date of this Agreement, none of the
Odyssey SEC Reports contained any untrue statement of a material fact or omitted to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
The financial statements of Odyssey included in Odyssey SEC Reports were prepared from and are in accordance with the accounting
books and other financial records of Odyssey, were prepared in accordance with GAAP (except, in the case of unaudited statements,
as permitted by the rules of the SEC) applied on a consistent basis during the periods involved (except as may be indicated in
the notes thereto) and presented fairly the consolidated financial position of Odyssey and its consolidated subsidiaries as of
the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in the case
of unaudited statements, to normal year-end audit adjustments). Except as set forth in the Odyssey SEC Reports, Odyssey has no
liabilities or obligations of any nature (whether accrued, absolute, contingent or otherwise) other than liabilities or obligations
incurred in the Ordinary Course of Business since the Odyssey Balance Sheet Date. The Odyssey SEC Reports accurately disclose (i)
the terms and provisions of all stock option plans, (ii) transactions with Affiliates, and (iii) all material contracts required
to be disclosed pursuant to Item 601(b)(10) of Regulation S-K promulgated by the SEC.

 

 

 

    	 	39	 

     

    

 

j)            Powers
of Attorney. There are no outstanding powers of attorney executed on behalf of Odyssey.

 

k)           Litigation.
Except as set forth in Schedule 6.16:

 

There is no pending or, to Odyssey’s
Knowledge, threatened Proceeding:

 

by or against Odyssey or that otherwise
relates to or may affect the Odyssey Business which, if adversely determined, would have a Material Adverse Effect; or

 

that challenges, or that may have
the effect of preventing, delaying, making illegal or otherwise interfering with, the Share Exchange.

 

To the Knowledge of Odyssey, no event
has occurred or circumstance exists that is reasonably likely to give rise to or serve as a basis for the commencement of any such
Proceeding.

 

l)            Legal
Compliance. To the knowledge of Odyssey, Odyssey is in material compliance with all Applicable Laws of any Governmental
Bodies having jurisdiction over Odyssey, including any requirements relating to antitrust, consumer protection, currency exchange,
equal opportunity, health, occupational safety, pension and securities matters.

 

m)          Brokers'
Fees. Odyssey has no liability or obligation to pay any fees or commissions to any broker, finder or agent with respect
to the Share Exchange for which Odyssey could become liable or obligated.

 

n)           Disclosure.
The representations and warranties of Odyssey contained in this Agreement do not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements and information contained herein not misleading.

 

g)

 

COVENANTS

 

a)           Preservation
of Business.

 

Prior to the Closing or the termination
of this Agreement, Prevacus will use its Best Efforts to preserve the Prevacus Business, to keep available to Odyssey the services
of the present employees of Prevacus, and to preserve for Odyssey the goodwill of the suppliers, customers and others having business
relations with Prevacus. Prevacus shall conduct its Business only in the Ordinary Course of Business, including, without limitation,
its policies and practices relating to the collection of accounts receivable and the payment of accounts payable and other liabilities,
and not introduce any new methods of management, operations or accounting, without Odyssey’s prior written consent (which
shall not be unreasonably withheld); maintain its assets in as good working order and condition as at present, ordinary wear and
tear excepted; perform all material obligations under material agreements and leases relating to or affecting it, and keep in full
force and effect present insurance policies.

 

Prior to the Closing or the termination
of this Agreement, Odyssey will use its Best Efforts to preserve the Odyssey Business, to keep available to Odyssey the services
of the present employees of Odyssey, and to preserve for Odyssey the goodwill of the suppliers, customers and others having business
relations with Odyssey. Odyssey shall conduct the Odyssey Business only in the Ordinary Course of Business, including, without
limitation, its policies and practices relating to the collection of accounts receivable and the payment of accounts payable and
other liabilities, and not introduce any new methods of management, operations or accounting, without the prior written consent
of Prevacus (which shall not be unreasonably withheld); maintain its assets in as good working order and condition as at present,
ordinary wear and tear excepted; perform all material obligations under material agreements and leases relating to or affecting
it, and keep in full force and effect present insurance policies.

 

 

 

    	 	40	 

     

    

 

b)           Current
Information.

 

During the period from the date
of this Agreement to the Closing, each Party hereto shall promptly notify each other Party of any (i) significant change in the
normal course of business or operations of its business, (ii) Proceeding (or communications indicating that the same may be contemplated),
or the institution or threat or settlement of Proceedings, in each case involving such Party, the outcome of which, if adversely
determined, could reasonably be expected to have a Material Adverse Effect on the Party, taken as a whole or (iii) event which
such Party reasonably believes could be expected to have a Material Adverse Effect on the ability of any Party to consummate the
Share Exchange.

 

During the period from the date
of this Agreement to the Closing, Odyssey shall promptly notify Prevacus of any correspondence received from the SEC and shall
deliver a copy of such correspondence to Prevacus within one (1) Business Day of receipt.

 

c)           Public
Disclosures. Odyssey and Prevacus will consult with each other before issuing any press release or otherwise making any
public statement with respect to the transactions contemplated by this Agreement, and shall not issue any such press release or
make any such public statement prior to such consultation except as may be required by Applicable Law. The Parties shall issue
a joint press release, mutually acceptable to Prevacus and Odyssey, promptly upon execution and delivery of this Agreement.

 

d)           Confidentiality.
Odyssey and Prevacus shall hold, and shall use their Best Efforts to cause their respective auditors, attorneys, financial advisors,
bankers and other consultants and advisors to hold, in strict confidence, unless compelled to disclose by judicial or administrative
process or by other requirements of law, all Confidential Information, and each Party shall not release or disclose such Confidential
Information to any other Person, except its auditors, attorneys, financial advisors, bankers and other consultants and advisors
in connection with the transactions contemplated by this Agreement.

 

h)

 

CONDITIONS TO CLOSING

 

a)           Mutual
Conditions. The respective obligations of each Party to effect the Share Exchange shall be subject to the satisfaction,
at or prior to the Closing Date, of the following conditions (any of which may be waived in writing by Odyssey and Prevacus:

 

None of Odyssey, or Prevacus shall
be subject to any Order by a court of competent jurisdiction which (i) prevents or materially delays the consummation of the Share
Exchange or (ii) would impose any material limitation on the ability of Odyssey effectively to exercise full rights of ownership
of the common stock of Prevacus or any material portion of the assets or Business, taken as a whole.

 

No statute, rule or regulation,
shall have been enacted by any Governmental Body that makes the consummation of the Share Exchange illegal.

 

Odyssey and Prevacus shall have
received all Consents of Third Parties that are required of such Third Parties prior to the consummation of the Share Exchange,
in form and substance acceptable to Odyssey or Prevacus, as the case may be, except where the failure to obtain such consent, approval
or authorization would not have a Material Adverse Effect.

 

 

 

    	 	41	 

     

    

 

b)           Conditions
to the Obligations of Odyssey to Close. The obligations of Odyssey under this Agreement are subject to the satisfaction,
at or before the Closing, of each of the following conditions:

 

Prevacus shall have performed and
complied in all material respects with all covenants, agreements, obligations and conditions required by this Agreement to be performed
or complied with by Prevacus at or prior to the Closing.

 

There shall not be threatened,
instituted or pending any Proceeding by or before any court or Governmental Body requesting or looking toward an Order that (a)
restrains or prohibits the consummation of the Share Exchange, (b) could have a Material Adverse Effect on Odyssey's ability to
exercise control over or manage the Prevacus after the Closing or (c) could have a Material Adverse Effect on Prevacus.

 

On the Closing Date, there shall
be no effective Order issued by a court of competent jurisdiction restraining or prohibiting the consummation of the Share Exchange.

 

All Consents of all Third Parties
and Governmental Bodies shall have been obtained that are necessary, in the opinion of Odyssey Counsel, in connection with (a)
the execution and delivery by Prevacus of this Agreement and the Related Agreements to which it is a Party or (b) the consummation
by Prevacus of the Share Exchange and copies of all such Consents shall have been delivered to Odyssey.

 

c)           Conditions
to the Obligations of Prevacus. The obligations of Prevacus and the Prevacus Stockholders under this Agreement are subject
to the satisfaction, at or before the Closing, of each of the following conditions:

 

The representations and warranties
of Odyssey contained herein that are qualified as to materiality shall be true in all respects on and as of the Closing Date (except
for such representations and warranties made as of a specific date which shall be true as of such date) with the same force and
effect as though made on and as of such date, and each of the representations and warranties of Odyssey that are not so qualified
shall be true in all material respects on and as of the Closing Date (except for such representations and warranties made as of
a specific date which shall be true in all material respects as of such date).

 

Odyssey shall have performed and
complied in all material respects with all covenants, agreements, obligations and conditions required by this Agreement to be so
performed or complied with by Odyssey at or prior to the Closing.

 

There shall not be threatened,
instituted or pending any Proceeding by or before any court or Governmental Body requesting or looking toward an Order, that (a)
restrains or prohibits the consummation of the Share Exchange or (b) could have a Material Adverse Effect on Odyssey.

 

On the Closing Date, there shall
be no effective Order issued by a court of competent jurisdiction restraining or prohibiting the consummation of the Share Exchange.

 

All Consents of all Third Parties
and Governmental Bodies shall have been obtained that are necessary, in the opinion of counsel to Prevacus, in connection with
(a) the execution and delivery by Odyssey of this Agreement to which either of them is a party, and (b) the consummation by Odyssey
of the transactions contemplated hereby or thereby, and copies of all such Consents shall have been delivered to Prevacus.

 

Odyssey shall deliver to Prevacus
or place in escrow a certificate evidencing ownership of the Shares described in Section 2.1.

 

The Stockholders of Odyssey shall
have given all necessary approvals and consents required under NRS.

 

 

 

    	 	42	 

     

    

 

i)

 

TERMINATION, AMENDMENT, CLAWBACK
AND WAIVER

 

a)           Termination.
This Agreement may be terminated at anytime prior to the Closing:

 

by mutual written consent of Odyssey
and Prevacus;

 

by Odyssey or Prevacus:

 

if the Share Exchange shall not have
been consummated on or before July 31, 2019, unless the failure to consummate the Share Exchange is the result of a willful and
material Breach of this Agreement by the Party seeking to terminate this Agreement;

 

if any court of competent jurisdiction
or other Governmental Body shall have issued an Order or taken any other action permanently enjoining, restraining or otherwise
prohibiting the Share Exchange and such order, decree, ruling or other action shall have become final and non-appealable;

 

in the event of a Breach by the other
Party of any representation, warranty, covenant or other agreement contained in this Agreement which cannot be or has not been
cured within ten (10) days after the giving of written notice to the breaching Party of such Breach (provided that the terminating
Party is not then in Breach of any representation, warranty, covenant or other agreement contained in this Agreement);

 

if there shall have occurred prior
to the Closing changes in Applicable Law that, in the aggregate, shall have a Material Adverse Effect on either Party.

 

(v) if within
one year, Odyssey has not funded the LLC (as defined in the Master Agreement) to the minimum amount of $500,000.00.

 

b)           Effect
of Termination. In the event of termination of this Agreement as provided in Section 11.1, this Agreement shall forthwith
become void and have no effect, without any liability or obligation on the part of any Party except to the extent that such termination
results from the willful and material Breach by a Party of any of its representations, warranties, covenants or other agreements
set forth in this Agreement, in which case the terminating Party shall have the right to pursue any remedies available to it at
law or in equity. If this Agreement is terminated under provision 9.1(v) in the preceding paragraph then Prevacus will cancel
or return the Odyssey common stock in its entirety and Odyssey will return or cancel the Prevacus stock in its entirety.

 

c)           Amendment.
This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties.

 

d)           Extension;
Waiver. At any time prior to the Closing, the Parties may (i) extend the time for the performance of any of the obligations
or other acts of the other Parties, (ii) waive any inaccuracies in the representations and warranties contained in this Agreement
or in any document delivered pursuant to this Agreement or (iii) waive compliance with any of the agreements or conditions contained
in this Agreement. Any agreement on the part of a Party to any such extension or waiver shall be valid only if set forth in an
instrument in writing signed on behalf of such Party.

 

 

 

    	 	43	 

     

    

 

j)

 

MISCELLANEOUS

 

a)           Notices.
All notices, requests, demands and other communications under this Agreement, shall be in writing and shall be deemed to have
been duly given on the date of service if served personally on the party to whom notice is to be given or within five (5) business
days if mailed to the party to whom notice is to be given, by first-class mail, registered, or certified, postage prepaid and
properly addressed as follows:

 

If to Odyssey:

Odyssey, Inc.

Attn: Michael redmond

2375 Morse Ave

Irvine, CA

 

 

If to Prevacus:

Prevacuss

Attn: _____________

__________________

__________________

 

b)           Further
Assurances. Each Party hereby agrees to perform any further acts and to execute and deliver any documents, which may be
reasonably necessary to carry out the provisions of this Agreement.

 

c)           Governing
Law; Venue. This Agreement is being executed and delivered, and is intended to be performed, in the State of Florida,
and to the extent permitted by law, the execution, validity, construction, and performance of this Agreement shall be construed
and enforced in accordance with the laws of the State of Florida without giving effect to conflict of law principles.

 

d)           Entire
Agreement. This Agreement including all Exhibits and Disclosure Schedules attached hereto and thereto contain the entire
agreement of the Parties and supersede any and all prior or contemporaneous agreements between the Parties, written or oral, with
respect to the transactions contemplated hereby. Such agreement may not be changed or terminated orally, but may only be changed
by an agreement in writing signed by the Party or Parties against whom enforcement of any waiver, change, modification, extension,
discharge or termination is sought.

 

e)           Expenses.
Except as expressly provided otherwise, each party hereto will bear its own costs and expenses (including fees and expenses of
auditors, attorneys, financial advisors, bankers, brokers and other consultants and advisors) incurred in connection with this
Agreement, the Related Agreements and the transactions contemplated hereby and thereby.

 

f)            Counterparts.
This Agreement may be executed in several counterparts, each of which, when so executed, shall be deemed to be an original, and
such counterparts shall together constitute and be one and the same instrument. Facsimile signatures shall be sufficient for execution
of this Agreement.

 

g)           Binding
Effect. This Agreement shall be binding on, and shall inure to the benefit of, the Parties hereto, and their respective
successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No Party may
assign any right or obligation hereunder without the prior written consent of the other Parties.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK]

 

 

 

    	 	44	 

     

    

 

SIGNATURE PAGE OF ODYSSEY AND PREVACUS
TO

SHARE EXCHANGE AGREEMENT

 

IN WITNESS WHEREOF,
Odyssey and Prevacus have caused this Share Exchange Agreement to be executed by their respective duly authorized officers,
all as of the day and year first above written.

 

	 	ODYSSEY, INC.
	
         

         

        Dated: 06-25-19
	
         

         

        /s/ J. Michael Redmond 

        By: J. Michael Redmond

        Its: President and CEO

	 	 
	 	 
	 	 
	 	 
	 	PREVACUSS
	
         

         

        Dated: 06-25-19
	
         

         

        /s/ Jake Vanlandingham

        By: Jake Vanlandingham

        Its: President and CEO

 

 

 

 

 

 

 

 

 

 

 

    	 	45	 

     

    

 

Exhibit “D”

FORM OF ASSIGNMENT OF PATENT 

 

Effective _____,
202_ (the “Effective Date”) Prevacus, Inc. whose address is _______________________________ (“Assignor”),
with its principal address at and Odyssey Group International, Inc., a Nevada corporation (“Assignee”) with its principle
address at 2372 Morse Ave Irvine, CA 92614.

 

ARTICLE I

BACKGROUND

 

WHEREAS, Assignor
has developed and deployed a certain technology and known as “________________________________________ (the “Platform”);
and

 

		a)	WHEREAS, Assignor is the owner of all intellectual property rights in or to US Patents, __________________________

 

 

WHEREAS, Assignee
is engaged in the development of medical products for commercial use and application, and desires to own the Platform and Assignor’s
intellectual property rights in and to the same; and

 

WHEREAS, Assignor
and Assignee, are parties to that certain Intellectual Property Purchase Agreement whereby Assignor agreed to assign ___________________,
and

 

In consideration
of the Mater Agreement for a Joint Venture and Intellectual Property Purchase Agreement and other good and valuable consideration,
the receipt and adequacy of which is hereby acknowledged, Assignor does hereby transfer and assign to Assignee, its successors,
assigns and legal representatives all its right, title and interest in and to the patents and the invention entitled:

 

“______________________________________”

 

Invented
by __________________and described in the:

 

_____________________________________________________________________________

 

and all United
States Letters Patent which may be granted therefor, and all divisions, reissues, continuations and extensions thereof, the said
interest being the entire ownership of the said Patents when granted, to be held and enjoyed by the said Assignee, its successors,
assigns or other legal representatives, to the full end of the term for which said Patent may be granted, as fully and entirely
as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made;

 

And I hereby authorize and request
the Commissioner of Patents and Trademarks to transfer and assign said Patent to the said Assignee.

 

ASSIGNOR

 

Prevacus, Inc.

 

By: /s/ Jake Vanlandingham

Jake Vanlandingham                       Date

 

 

 

 

    	 	46	 

     

    

 

STATE OF FLORIDA:

: to wit:

CITY OF ___________:

 

I HEREBY CERTIFY
that on this ____ day of _____, 20__, before me, the undersigned Notary Public of the jurisdiction aforesaid personally appeared
___________, and acknowledged himself to be the individual owner of the Platform and that he, being authorized so to do, executed
the foregoing instrument for the purposes therein contained.

 

IN WITNESS MY Hand and
Notarial Seal.

 

	 	                                             (SEAL)
	 	Notary Public
	Notary Public, state of Florida

NO. _____________________

Qualified in _____________ Counties

My Commission expires: _________

	Registration # : ______________
	 	 
	 	 
	ACKNOWLEDGED AND ACCEPTED:	 
	 	 
	Odyssey Group International, Inc.	 
	 	 
	By: /s/J. Michael Redmond

J. Michael Redmond

President/CEO

Odyssey Group international Inc.

	 

         
Date

 

 

 

 

 

 

 

 

 

 

 

 

    	 	47	 

     

    

 

Exhibit “E”

STOCK GRANT AGREEMENT

 

THIS AGREEMENT is made and entered into this
25TH day June 2019, by and between Odyssey Group International, Inc., a Nevada corporation ("Grantor'') and Prevacus,
Inc. a Delaware Corporation ("Prevacus").

 

WHEREAS, Grantor is the record owner and holder
of the issued and outstanding shares of the capital stock of Odyssey Group International, Inc. ("Corporation"), a Nevada
corporation, which Corporation has authorized two hundred and fifty million (250,000,000) shares of Common stock and; and

 

WHEREAS, Prevacus desires to acquire the number
of shares of said stock as specified in Exhibit "A" hereto (the "Granted Shares") and the Grantor desires to
Grant the Granted Shares, upon the terms and subject to the conditions hereinafter set forth;

 

NOW, THEREFORE, in consideration of the mutual
covenants and agreements contained in the Agreement, and in order to consummate the purchase and the sale of the Purchased Shares,
it is hereby agreed as follows:

 

		1.	Grant of Shares: Subject to the terms and conditions hereinafter set forth, at the closing of the
transaction contemplated hereby, Grantor shall convey, transfer, and deliver to Prevacus certificates representing the Granted
Shares, in consideration of the Purchased Assets set forth in the Master Agreement.

 

		2.	NUMBER OF PURCHASED SHARES. The number of Granted Shares and total consideration for the purchase
of the Purchased Shares are fully set out in Exhibit "A" attached hereto and made a part hereof.

 

		3.	REPRESENTATIONS AND WARRANTIES OF GRANTOR. Grantor hereby warrants and represent:

 

		a.	Organization and Standing. Corporations is a corporation duly organized, validly existing and in
good standing under the laws of the State Nevada and has the corporate power and authority to carry on its business as it is now
being conducted.

 

		b.	Restrictions on Stock.

 

		i.	Seller is not a party to any agreement, written or oral, creation rights in respect to the Granted
Shares in any third person or relation to the voting of the Corporation's Stock.
	 	 	 
	 	ii.	Granter is the lawful owner of the
Granted Shares, free and clear of all security interests, liens, encumbrances, equities and other charges.
	 	 	 
	 	iii.	there are no existing warrants, options,
stock purchase agreements, redemption agreements, restrictions of any nature, calls or rights to subscribe of any character relating
to the Granted Shares, nor are there any securities convertible into such stock.

 

		4.	REPRESENTATIONS AND WARRANTIES OF GRANTOR AND PREVACUS. Grantor and Prevacus hereby represent and
warrant that there has been no act or omission by Grantor, Prevacus or the Corporation which would give rise to any valid claim
against any of the parties hereto for a brokerage commission, finder's fee, or other like payment in connection with the transaction
contemplated hereby.

 

 

 

    	 	48	 

     

    

 

		5.	GENERAL PROVISIONS

 

		a.	Entire Agreement. This agreement (including the exhibits hereto and any written agreements hereof
executed by the parties) constitutes the entire Agreement and supersedes all prior agreements and understandings, oral and written,
between the parties hereto with respect to the subject matter hereof.

 

		b.	Section and Other Heading. The section and other headings contained in this Agreement are for reference
purposes only and shall not affect the meaning or interpretation of this Agreement.

 

		c.	Governing Law. This agreement and all transactions contemplated hereby, shall be governed by, construed
and enforced in accordance with the laws of the State of Florida.

 

		d.	Amendment. This Agreement shalt only be amended, modified, or supplemented by a writing signed
by all parties hereto.

 

 

 

 

 

 

 

(The remainder of the page left intentionally
blank)

 

 

 

 

 

 

 

 

 

 

 

    	 	49	 

     

    

 

IN WITNESS WHEREOF, This Agreement has been
executed by each of the individual parties hereto on the date first above written.

 

 

Signed:

 

 

	By: /s/Joseph Michael Redmond

        Joseph Michael Redmond

        President/CEO

        Odyssey Group International,
Inc.

	6-25-19

                           Date

	 	 
	By: /s/ Jake Vanlandingham

        Jake Vanlandingham

        President

        Prevacus, Inc.

 	6-25-19

        Date

 

 

'

 

 

 

 

 

 

 

 

 

 

 

 

    	 	50	 

     

    

 

EXHIBIT "A"

 

NUMBER OF SHARES TO BE PURCHASED

 

 

 

 

a.       Two
Million (2,000,000) shares of common stock of Odyssey Group International Inc., trading on the OTCQB under the symbol "ODYY".

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	51Exhibit 10.7

 

INTELLECTUAL
PROPERTY PURCHASE AGREEMENT

 

by and among

 

ODYSSEY GROUP
INTERNATIONAL INC.,

 

DE LUCA AND

 

MURDOCK CAPITAL
PARTNERS INC.

 

 

 

 

This
INTELLECTUAL PROPERTY PURCHASE AGREEMENT, dated as of June 26, 2019 (this “Agreement”), by and among James
De Luca an individual whose address is 15 Wendover Road, Forest Hills Gardens, NY 11375 (“De Luca” or “Seller”),
on the one hand, and Murdock Capital Partners, Inc., whose address is 15 West 53rd Street, 24th Floor, New
York, NY 10019 (“MCP” or “Seller”), and, Odyssey Group International Inc., a Nevada corporation
(“Odyssey” or “Buyer”), whose address is 2372 Morse Ave. Irvine, CA 92614. Odyssey/Buyer, and Seller are
referred to collectively herein as the “Parties.” De Luca and MCP together may be referred to collectively as
“Sellers”.

 

WHEREAS,
Buyer is a publically traded company focused on developing and commercializing medical products, including medical devices. (the
“Business”); and

 

WHEREAS,
Seller desires to sell, and Buyer desires to purchase, the Purchased Assets (as defined below) upon the terms and subject to the
conditions set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the foregoing, he mutual covenants and agreements herein contained and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties
hereby agree as follows:

 

ARTICLE
I

 

PURCHASE
AND SALE OF ASSETS

 

Section 1.1 Purchase
and Sale of Assets.

 

On,
and subject to, the terms and conditions of this Agreement, at the Closing, Seller shall sell, assign, transfer, convey and deliver
to Buyer, and Buyer shall purchase and acquire from Seller, free and clear of all Encumbrances, all of Seller’s right, title
and interest, as of the Closing, in and to the following assets, properties and rights (collectively, the “Purchased Assets”):

 

 

 

    	 	1	 

     

    

 

		a)	United States Letters Patent No. 7,559,921, entitled “Device for Removing a Lodged Mass”
which issued on July 14, 2009 and which was Reissued on June 2, 2015 and received U.S. Reissue Patent No. Re 45,535 and U. S. Patent
No.8,454,624 also entitled “Device for Removing a Lodged Mass” which issued on June 4, 2013

 

		b)	“Second Chance” is
an anti choking device in prototype form developed by Seller.

 

Section 1.2 Excluded Liabilities and Assets.

 

Seller
is not selling any of its assets to Buyer other than the Purchased Assets. Buyer does not assume any liability or obligation of
Seller, in connection with the Purchased Assets pursuant to Buyer’s purchase of such assets in connection with this Agreement.

 

Section 1.3 Purchase
Consideration.

 

		a)	Equity. In partial consideration for the sale by Seller of the Purchased Assets
                                                                to Buyer, at the Closing, Odyssey shall grant Seller the equivalent of twenty five thousand dollars ($25,000) in free selling
                                                                shares of Odyssey common stock. The stock certificate will be delivered to De Luca within 60 days after the Closing. In
                                                                addition, Odyssey will grant Seller an option to purchase a total of six hundred thousand (600,000) shares of Odyssey common
                                                                stock and will enter into a Common Stock Purchase Agreement (“Stock Purchase”) in the form attached as Exhibit
                                                                “A” to this Agreement. The strike price of the options will be the closing price of Odyssey common stock on the
                                                                day immediately preceding the Closing. The options will vest as follows: two-hundred fifty thousand on the day of the
                                                                Closing; one hundred thousand (100,000) one year from the Effective Date at the strike price of the stock on the day of
                                                                closing and two hundred fifty thousand (250,000) two (2) years from the Effective Date or upon the FDA submission for
                                                                approval, whichever occurs first. The Equity portion of the consideration detailed above will be split between De Luca and
                                                                MCP, sixty (60) percent will go to De Luca and forty (40) percent will go to MCP.
	 	 	 
	 	b)	Royalty Agreement. In partial consideration for the sale by Seller
                          of the Purchased Assets to Buyer, at the Closing, Buyer shall enter into a Royalty Agreement (“Seller
                          Royalty”) with Seller in the form attached as Exhibit “B” to this Agreement providing
                          for payment of three percent (3%) of the net profits from the commercial sale of products that contain
                          the Purchased Assets in perpetuity, collected by Buyer on the terms and conditions set forth therein.
                          Net profits will be determined according to GAAP. The Royalty portion of the consideration will be split
                          between De Luca and MCP, sixty (60) percent will go to De Luca and forty (40) percent will go to MCP.
	 	 	 
		c)	Consulting Agreement. In partial consideration for the sale by Seller of the
                    Purchased Assets to Buyer, at the Closing, Buyer shall enter into a Consulting Agreement (“Consulting Agreement”)
                    with De Luca and Murdock Capital Partners in the form attached hereto as Exhibit “C” to this Agreement.
	 	 	 
		d)	Cash Payment: A onetime cash payment totaling two hundred fifty thousand dollars
($250,000) will be paid to Sellers upon FDA clearance of the product containing the Intellectual Property. The total payment will
be split between the Sellers, De Luca will be paid sixty (60) percent of the total and MCP will be paid forty (40) percent of the
total.
	 	 	 
		e)	Patent Assignment. In partial consideration for the sale by Seller of the Purchased
Assets to Buyer, at the Closing, Seller shall enter a Patent Assignment Agreement (“Patent Assignment”) in the form
attached hereto as Exhibit “D,” providing a recordable assignment of the US Patents described in the Purchased Assets
to Buyer.

 

 

 

    	 	2	 

     

    

 

		f)	Security Interest. Buyer shall grant to De LUCA, a security interest in the Purchased Assets
as collateral security for the prompt and complete payment and performance when due of Odyssey’s obligations as defined herein.
If Buyer fails to make any of the above payments, whether cash or equity, then the ownership of the Purchased Assets will revert
back to Sellers. However, any improvements to the Purchased Assets made after the Closing will remain the property of Buyer.
	 	 	 
		g)	Non-Compete by Seller. Seller agrees not to assist, work for or in any way provide services
that in any way relates to the development, manufacturing, sales, marketing or distribution of an anti-choking device or any device
that rescues a person from choking except on behalf of Buyer.

 

Section 1.4 Closing
Transactions.

 

(a) Closing.
Unless this Agreement shall have been terminated in accordance with Section 8.1, and subject to the satisfaction
or, if permissible, waiver of the conditions set forth in Article VII, the closing of the Transactions (the “Closing”)
will take place at 12:00 noon, Los Angeles, California time, on a date to be specified by the Parties but no later than June
30, 2019 (the “Closing Date”), which shall be not later than the second Business Day after the satisfaction
or, if permissible, waiver of the conditions set forth in Article VII (other than those that by their terms
are to be satisfied or waived at the Closing), at the offices of Odyssey Group International, Inc. at 2372 Morse Ave Irvine CA
, unless another time, date or place is agreed to in writing by the Parties; provided, however, that the Parties shall use reasonable
efforts to conduct the Closing by mail and overnight delivery so as not to require the personal attendance of the parties at the
Closing. If the parties agree, the Closing may be telephonic.

 

(b) Actions
and Deliveries by Seller. At the Closing, Seller shall deliver to Buyer and Odyssey:

 

(i)
the Patent Assignment in the form of Exhibit D  dated the Closing Date and duly executed by Seller;

 

(iii)
the Consulting Agreement in the form of Exhibit C dated the Closing Date and duly executed by De Luca and Murdock ;

 

(iv)
the certificates and documents required to be delivered by Seller pursuant to Sections 7.1 and 7.2;

 

(v)
all such other instruments of assignment and transfer as are reasonably required to effect the transfer to Buyer of all of Seller’s
right, title and interest in and to the Purchased Assets in accordance with this Agreement, in form and substance reasonably satisfactory
to Buyer and Seller; and

 

(vi)
Duly executed copies of all the agreements referred to in this Agreement.

 

(c) Actions
and Deliveries by Buyer and/or Odyssey (as required). At the Closing, Buyer and/or Odyssey (as required) shall deliver to Seller:

 

(ii)
the Stock Option Agreement in the form of Exhibit A dated the Closing Date and duly executed by Buyer;

 

(iii)
the Seller Royalty Agreement in the form of Exhibit B dated the Closing Date and duly executed by Buyer;

 

(iv)
the certificates and documents required to be delivered by Buyer pursuant to Sections
7.1 and 7.3.

 

 

 

    	 	3	 

     

    

 

ARTICLE II

 

REPRESENTATIONS
AND WARRANTIES OF SELLER

 

Seller
hereby represents and warrants to Buyer that, to the best of “Seller’s Knowledge” (as hereinafter defined) and
except as set forth in the disclosure schedule delivered by Seller to Buyer and attached hereto and made a part hereof (the “Seller
Disclosure Schedule”). The De Luca Seller makes no representation or warranty as to MCP and MCP makes no representation
or warranty as to De Luca. Such respective warranties and representations shall be true as of the date of execution and the date
of Closing:

 

Section 2.1 Organization.

 

MCP
is duly incorporated, validly existing and in good standing under the Laws of the Commonwealth of New York and has the requisite
corporate power and authority to own, operate or lease the properties that it purports to own, operate or lease and to carry on
its business as it is now being conducted.

 

Section 2.2 Authority
Relative to this Agreement and Related Matters.

 

Sellers
respectively have all necessary personal or corporate power and authority to enter into this Agreement and to carry out its obligations
hereunder. The execution and delivery by Sellers of this Agreement and the consummation by Sellers of the transactions contemplated
hereby (the “Transactions”) have been duly authorized by all necessary corporate action on the part of each
Seller. This Agreement has been duly executed and delivered by Sellers and, assuming the due authorization, execution and delivery
hereof by Buyer, no further action or approval, corporate or otherwise, is required in order to constitute this Agreement as a
valid and binding obligation of Seller enforceable in accordance with its terms.

 

Section 2.3 No
Conflict; Required Filings and Consents.

 

The
execution and delivery of this Agreement by Sellers does not, and the consummation by Sellers of the Transactions will not, (a) conflict
with or violate the certificate of incorporation or bylaws, each as amended to date, of each respective Seller, (b) conflict
with or violate any Law or Order applicable to Seller or by which Seller or any of its properties is bound, (c) result in
a breach of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give
rise to any right of termination, acceleration or cancellation under, or result in the creation of an Encumbrance on any of the
Purchased Assets pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license or other instrument or obligation
to which Seller is a party or by which Seller or any of its properties is bound, or (d) require Seller to obtain any consent,
approval, authorization or permit of, or to make any filing with or notification to, any Governmental Authority, except (i) as
set forth in Section 2.3 of the Seller Disclosure Schedule, or (ii) for any filings required pursuant
to the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange
Act”).

 

Section 2.4 Absence
of Litigation.

 

Except
as disclosed in Section 2.4 of the Seller Disclosure Schedule, as of the date hereof and with respect to
each Seller separately, (a) there is no private or governmental action, suit, proceeding, litigation, arbitration or investigation
(“Action”) pending or, to the knowledge of Seller, threatened against Seller before any Governmental Authority
that, if adversely determined, would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions,
and (b) there is no legally binding judgment, decree, order, injunction, decision or award of any Governmental Authority (“Order”)
against Seller that would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions.

 

 

 

    	 	4	 

     

    

 

Section 2.5 Purchased
Assets.

 

Seller
owns (beneficially and of record) all right, title and interest in and to all Purchased Assets, free and clear of all Encumbrances.
Purchased Assets have been duly filed in the jurisdiction named in each such patents , have each been prosecuted to issuance as
a patent and have not been abandoned or allowed to lapse. There is no Action that is pending or, to the knowledge of Seller, threatened
that challenges the rights of Seller in respect of any Purchased Assets or the validity, enforceability or effectiveness thereof.
Seller has not received any written communication alleging that it has infringed the Intellectual Property rights of any third
party and there are no Actions that are pending or, to the knowledge of Seller, threatened against Seller with respect thereto.
To the knowledge of Seller, there is no unauthorized use, infringement or misappropriation of the Purchased Assets by any third
party and there is no Action that is pending or threatened by Seller with respect thereto. Notwithstanding anything to the contrary,
this representation shall not limit or restrict the transfer to Buyer pursuant to this Agreement of all right, title and interest
in and to the Purchased Assets owned by Seller throughout the world; provided, however, that Seller does not represent, warrant
or covenant that any rights in or to the Purchased Assets exist anywhere outside of the United States of America.

 

Section
2.6 Seller’s Knowledge.

 

The
term "Seller's Knowledge" as used herein means the actual knowledge (and not the implied or constructive knowledge)
without any duty of investigation or inquiry of the following person: James De Luca, Seller.

 

ARTICLE III

 

REPRESENTATIONS
AND WARRANTIES OF BUYER

 

Buyer
hereby represent and warrants to Seller that, except as set forth in the disclosure schedule delivered by Buyer to Seller and attached
hereto and made a part hereof (the “Buyer Disclosure Schedule”). Such warranties and representation shall be
true as of the date of execution and the date of Closing:

 

Section 3.1 Organization.

 

Buyer
is duly incorporated, validly existing and in good standing under the Laws of each of their respective jurisdictions of organization
and each has the requisite corporate power and authority to own, operate or lease the properties that it purports to own, operate
or lease and to carry on its business as it is now being conducted.

 

Section 3.2 Authority
Relative to this Agreement and Related Matters.

 

Buyer
has all necessary corporate power and authority, as the case may be, to enter into this Agreement and to carry out each of their
respective obligations hereunder. The execution and delivery by Buyer of this Agreement and the consummation by the Buyer of the
Transactions have been duly authorized by all necessary corporate action on the part of the Buyer. This Agreement has been duly
executed and delivered by the Buyer, and, assuming the due authorization, execution and delivery hereof by Seller, constitutes
the legal, valid and binding obligation of the Buyer, enforceable against each the Buyer in accordance with its terms.

 

 

 

    	 	5	 

     

    

 

Section 3.3 No
Conflict; Required Filings and Consents.

 

The
execution and delivery of this Agreement by Buyer does not, and the consummation of the Transactions will not, (a) conflict
with or violate the organizational or governing documents of Buyer and/or Odyssey, (b) conflict with or violate any Law or
Order applicable to Buyer or by which Buyer or or any of their respective properties is bound, (c) result in a breach of or
constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give rise to any
right of termination, acceleration or cancellation under, any note, bond, mortgage, indenture, contract, agreement, lease, license
or other instrument or obligation to which Buyer is a party or by which Buyer or Odyssey or any of their respective properties
is bound, or (d) require Buyer or Odyssey to obtain any consent, approval, authorization or permit of, or to make any filing
with or notification to, any Governmental Authority, except (i) as set forth in Section 3.3 of the Buyer
Disclosure Schedule, or (ii) for any filings required pursuant to the Exchange Act.

 

Section 3.4 Absence of Litigation.

 

Except
as disclosed in Section 3.4 of the Buyer Disclosure Schedule, as of the date hereof, (a) there is no
Action pending or, to the knowledge of Buyer, threatened against Buyer or Odyssey before any Governmental Authority that, if adversely
determined, would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions, and (b) there
is no Order against Buyer that would prohibit, prevent, enjoin, restrict or materially impair or delay any of the Transactions
contemplate hereby.

 

ARTICLE
IV

 

COVENANTS
OF SELLER

 

Section 4.1 Conduct
of Seller Pending the Closing.

 

Seller
shall not, between the date of this Agreement and the Closing Date or the earlier termination of this Agreement, do or agree to
do any of the following without the prior written consent of Buyer:

 

(a)
take or fail to take, or agree to take or fail to take, any action which would make any representation or warranty made by Seller
herein untrue or incorrect in any material respect as of the date of this Agreement or the date of the Closing;

 

(b)
sell, lease, license, encumber, transfer or otherwise dispose of any Purchased Assets; and

 

(c)
agree to do any of the foregoing.

 

Section 4.2 Notification
of Certain Events.

 

Seller
shall give prompt notice to Buyer if any of the following occurs after the date of this Agreement: (i) there has been a material
failure of Seller to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder;
(ii) receipt by Seller of any material notice or other communication from any Governmental Authority in connection with the
Transactions; (iii) the occurrence of an event which would cause a condition in Section 7.2 not to be
satisfied; or (iv) the commencement or threat, in writing, of any Action against Seller, or any of its properties, with respect
to the Transactions and/or any of the Purchased Assets. No such notice to Buyer shall have any effect on the determination of whether
or not any of the conditions to Closing or to the consummation of the Transactions have been satisfied or in determining whether
or not any of the representations, warranties or covenants contained in this Agreement have been breached.

 

 

 

    	 	6	 

     

    

 

ARTICLE V

 

COVENANTS
OF BUYER

 

Section 5.1 Representations
and Warranties.

 

Buyer
covenants and agrees that, except as otherwise contemplated by this Agreement or unless Seller shall give its prior written consent,
Buyer shall not, between the date of this Agreement and the Closing Date or the earlier termination of this Agreement, take or
fail to take, or agree to take or fail to take, any action which would make any representation or warranty made by Buyer herein
untrue or incorrect in any material respect.

 

Section 5.2 Notification
of Certain Events.

 

Buyer
shall give prompt notice to Seller if any of the following occurs after the date of this Agreement: (i) there has been a material
failure of Buyer to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder;
(ii) receipt by Buyer of any material notice or other communication from any Governmental Authority in connection with the
Transactions; (iii) the occurrence of an event which would cause a condition in Section 7.3 not to be
satisfied; or (iv) the commencement or threat, in writing, of any Action against Buyer, or any of its properties, with respect
to the Transactions. No such notice to Seller shall have any effect on the determination of whether or not any of the conditions
to Closing or to the consummation of the Transactions have been satisfied or in determining whether or not any of the representations,
warranties or covenants contained in this Agreement have been breached.

 

Section
5.3 Condition of Purchased Assets.

 

BUYER
ACKNOWLEDGES THAT IT IS A SOPHISTICATED INVESTOR IN ASSET PURCHASES OF THE TYPE CONTEMPLATED BY THIS AGREEMENT AND THAT ITS VALUATION
OF AND DECISION TO PURCHASE THE PURCHASED ASSETS IS BASED UPON ITS OWN INDEPENDENT EXPERT EVALUATIONS OF SUCH FACTS AND MATERIALS
DEEMED RELEVANT BY BUYER. BUYER ACKNOWLEDGES AND AGREES THAT, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION 2 ABOVE,
SELLER HAS NOT MADE, AND SELLER HEREBY SPECIFICALLY DISCLAIMS, ANY REPRESENTATION, WARRANTY, GUARANTY, PROMISE, COVENANT OR AGREEMENT,
IN EACH CASE WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, PAST, PRESENT OR FUTURE, OF, AS TO, CONCERNING, OR WITH RESPECT TO THE
PURCHASED ASSETS. BUYER ACKNOWLEDGES AND AGREES THAT, HAVING BEEN GIVEN THE OPPORTUNITY TO INSPECT THE PURCHASED ASSETS, BUYER
IS RELYING SOLELY ON ITS OWN INVESTIGATION OF THE PURCHASED ASSETS, AND NOT ON ANY MATERIALS AND OTHER INFORMATION PROVIDED OR
TO BE PROVIDED BY SELLER EXCEPT FOR THE REPRESENTATIONS SET FORTH IN THIS AGREEMENT. BUYER FURTHER ACKNOWLEDGES THAT ANY INFORMATION
PROVIDED AND TO BE PROVIDED WITH RESPECT TO THE PURCHASED ASSETS WAS OBTAINED FROM A VARIETY OF SOURCES AND SELLER (i) HAS NOT
MADE ANY INDEPENDENT INVESTIGATION OR VERIFICATION OF SUCH INFORMATION; AND (ii) MAKES NO REPRESENTATIONS OR WARRANTIES AS TO THE
ACCURACY OR COMPLETENESS OF SUCH INFORMATION. EXCEPT AS OTHERWISE EXPRESSLY SPECIFIED HEREIN, BUYER AGREES TO ACCEPT THE PURCHASED
ASSETS AND ACKNOWLEDGES THAT THE SALE OF THE PURCHASED ASSETS AS PROVIDED FOR HEREIN IS CONDITIONED ON THE FACT THAT THE PROPERTY
IS "AS IS, WHERE IS AND WITH ALL FAULTS". WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, BUYER EXPRESSLY ACKNOWLEDGES
THAT, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, SELLER MAKES NO WARRANTY OR REPRESENTATION OF ANY KIND OR CHARACTER
WHATSOEVER, WHETHER EXPRESS OR IMPLIED, ORAL OR WRITTEN, PAST, PRESENT OR FUTURE, OF, AS TO, CONCERNING OR WITH RESPECT TO (A)
THE VALUE, NATURE, QUALITY OR CONDITION OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (B) THE INCOME TO BE DERIVED FROM THE
PURCHASED ASSETS (OR ANY PORTION THEREOF), (C) THE SUITABILITY OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF) FOR ANY AND ALL
ACTIVITIES AND USES WHICH BUYER MAY CONDUCT THEREWITH, (D) THE COMPLIANCE OF OR BY THE PURCHASED ASSETS (OR ANY PORTION THEREOF)
OR ITS USE WITH ANY LAWS, RULES, ORDINANCES OR REGULATIONS OF ANY APPLICABLE GOVERNMENTAL AUTHORITY OR BODY, (E) THE MERCHANTABILITY,
MARKETABILITY, PROFITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (F) THE MANNER
OR QUALITY OF THE OPERATIONSENABLED BY THE PURCHASED ASSETS (OR ANY PORTION THEREOF), (G) THE MANNER, QUALITY, OR STATE OF THE
PURCHASED ASSETS (OR ANY PORTION THEREOF), (H) THE PAST, PRESENT OR FUTURE USE OF THE PURCHASED ASSETS (OR ANY PORTION THEREOF),
(I) THE RELIABILITY, ACCURACY OR COMPLETENESS OF ANY OF THE PURCHASED ASSETS FOR THE USES INTENDED BY BUYER; AND BUYER HEREBY WAIVES
ANY RIGHT TO MAKE ANY CLAIM BASED ON ANY OF THE FOREGOING.

 

 

 

    	 	7	 

     

    

 

Section
5.4 Maintenance of the Purchased Assets

 

Buyer
represents and warrants that it will take all steps to pay any and all of the periodic maintenance fees due and owing to the United
States Patent and Trademark Office to keep the Patents in force and effect. If Buyer fails to make such payment, when due the ownership
of the Patents will automatically revert back to De Luca if De Luca makes the payments and is not reimbursed by Seller within 10
days of notice of the payment.

 

ARTICLE
VI

 

ADDITIONAL
AGREEMENTS OF THE PARTIES

 

Section 6.1 Commercially
Reasonable Efforts.

 

(a)
Upon the terms and subject to the conditions hereof, each of the Parties agrees to use its commercially reasonable efforts to take,
or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to consummate and make
effective as promptly as practicable the Transactions and to vest in Buyer (and any transferee of Buyer) good and marketable title
to the Purchased Assets, including obtaining all consents, waivers, authorizations and approvals from Governmental Authorities
and other third parties required for the consummation of the Transactions.

 

(b)
From time to time after the Closing, at the request of Buyer (or any transferee of Buyer) and at such requesting party’s
expense, and without further consideration, Seller agrees on its own behalf, as well as on behalf of its subsidiaries, affiliates,
successors, assigns and legal representatives, to execute and deliver to Buyer any further documents or instruments and perform
any further acts that may reasonably be deemed necessary to vest, record, perfect, support and/or confirm the rights herein conveyed,
or intended so to be, to Buyer (and any transferee of Buyer) with respect to the Purchased Assets, including without limitation
such assignments, agreements and limited powers of attorney as may be needed for recording or effectuating the transfer of the
Purchased Assets in the United States. Nothing herein shall be deemed a waiver by Buyer of its right to receive at the Closing
an effective assignment of such rights by Seller as otherwise set forth in this Agreement. Without limiting the generality of the
foregoing, Seller shall execute and deliver to Buyer or obtain for delivery to Buyer, at the request of Buyer and at Buyer’s
expense, and without further consideration, any documents required to update record title to the owned Purchased Assets to reflect
Buyer (and any transferee of Buyer) as the record owner in each jurisdiction in which such Purchased Assets exists. At the request
of Buyer and at Buyer’s expense, and without further consideration, Seller shall reasonably cooperate with Buyer (and any
transferee of Buyer) in connection with the registration of the Purchased Assets in jurisdictions outside of the United States,
in the event such registration is available.

 

(c)
From time to time after the Closing, at the request of Buyer and at Buyer’s expense, and without further consideration, Seller
shall assist Buyer (and any transferee of Buyer) to the extent reasonably necessary for the defense or prosecution of any claim
by or against any third party with respect to the ownership, validity, enforceability, infringement or other violation of or by
the Purchased Assets, so long as Seller is not named as a party adverse to the Buyer in any such proceeding.

 

Section 6.2 Public
Announcements.

 

Each
of the Parties agrees that a press release or announcement concerning this Agreement or the Transactions shall be issued by it.
Such release or announcement may also be required by applicable Law or the rules or regulations of any securities exchange.

 

 

 

    	 	8	 

     

    

 

ARTICLE
VII

 

CONDITIONS
TO THE CLOSING

 

Section 7.1 Conditions
to Obligations of Each Party.

 

The
respective obligations of each Party to consummate the Transactions shall be subject to the condition that no Governmental Authority
shall have enacted, issued, promulgated, enforced, initiated, or entered any Law or Order (whether temporary, preliminary or permanent)
that is then in effect and has the effect of making the Transactions illegal or otherwise preventing or prohibiting consummation
of the Transactions.

 

Section 7.2 Additional
Conditions to Obligations of Buyer.

 

The
obligation of Buyer to consummate the Transactions shall also be subject to the satisfaction or waiver (where permissible), on
or prior to the Closing Date, of each of the following conditions:

 

(a)
The representations and warranties of Seller set forth in Article II of this Agreement (i) that are qualified
by the words “material” or “material adverse effect” shall be true and correct in all respects on and as
of the Closing Date as if made on and as of such date and (ii) that are not so qualified shall be true and correct in all
material respects on and as of the Closing Date as if made on and as of such date, except in any such case (x) for changes
contemplated by this Agreement and by the Seller Disclosure Schedule, and (y) to the extent that any such representation or
warranty is made as of a specified date, in which case such representation or warranty shall remain true and correct (in all material
respects, as the case may be) as of such date.

 

(b)
Seller shall in all material respects have performed or complied with each obligation and covenant to be performed or complied
with by Seller hereunder on or prior to the Closing Date, including the deliveries under Section 1.4(b).

 

(c)
Buyer shall have received a certificate of Seller, dated the Closing Date, signed by an officer of Seller, to the effect that the
conditions specified in Sections 7.2(a) and (b) have been satisfied.

 

Section 7.3 Additional
Conditions to Obligations of Seller.

 

The
obligation of Seller to consummate the Transactions shall also be subject to the satisfaction or waiver (where permissible), on
or prior to the Closing Date, of each of the following conditions:

 

(a)
The representations and warranties of Buyer set forth in Article III of this Agreement shall be true and correct
in all material respects on and as of the Closing Date as if made on and as of such date, except in any such case (x) for
changes contemplated by this Agreement and by the Buyer Disclosure Schedule, and (y) to the extent that any such representation
or warranty is made as of a specified date, in which case such representation or warranty shall remain true and correct (in all
material respects, as the case may be) as of such date.

 

 

 

    	 	9	 

     

    

 

(b)
Buyer shall in all material respects have performed or complied with each obligation and covenant to be performed or complied with
by it hereunder on or prior to the Closing Date, including the deliveries under Section 1.4(c).

 

(c)
Seller shall have received a certificate of Buyer, dated the Closing Date, signed by an executive officer of Buyer, to the effect
that the conditions specified in Sections 7.3(a) and (b) have been satisfied.

 

ARTICLE
VIII

 

TERMINATION

 

Section 8.1 Termination.

 

After
the Closing, this Agreement may be terminated at any time by Buyer by giving thirty (30) days written notice to Sellers.

 

This
Agreement may not be terminated at any time prior to the Closing Date except:

 

(a)
By mutual written consent of Buyer and Seller;

 

(b)
by either Seller or Buyer, if the Closing shall not have occurred on or before June 30, 2019 (the “Outside Date”); provided, however,
that the right to terminate this Agreement under this Section 8.1(b) shall not be available to any Party
whose failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, the failure of the Transactions
to be consummated on or before the Outside Date;

 

(c)
by either Seller or Buyer if any Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Law or
Order that is, in each case, then in effect and is final and non-appealable and has the effect of making the Transactions illegal
or otherwise preventing or prohibiting consummation of the Transactions; provided, however, that the right to
terminate this Agreement under this Section 8.1(c) shall not be available to any Party whose failure to fulfill
any obligation under this Agreement has been the cause of, or resulted in, any such Law or Order to have been enacted, issued,
promulgated, enforced or entered;

 

(d)
by Buyer (if Buyer is not in material breach of any of the terms or conditions of this Agreement), if there has been a material
breach by Seller of any terms or conditions of this Agreement, or if any representation or warranty of Seller shall have become
inaccurate, in either case that would result in a failure of a condition set forth in Section 7.2(a) or 7.2(b) (a
“Terminating Seller Breach”); provided, that if such Terminating Seller Breach is reasonably curable
by Seller, within 30 days after Seller has received written notice from Buyer of such Terminating Seller Breach, through the exercise
of its commercially reasonable efforts and for as long as Seller continues to exercise such commercially reasonable efforts, Buyer
may not terminate this Agreement under this Section 8.1(d) until the earlier of the expiration of such 30-day
period and the Outside Date; and

 

(e)
by Seller (if Seller is not in material breach of any of its representations, warranties, covenants or agreements under this Agreement),
if there has been a material breach by Buyer of any of terms or conditions of this Agreement, or if any representation or warranty
of Buyer shall have become inaccurate, in either case that would result in a failure of a condition set forth in Section 7.3(a) or 7.3(b) (a
“Terminating Buyer Breach”); provided, that if such Terminating Buyer Breach is reasonably curable
by Buyer, within 30 days after Buyer has received written notice from Seller of such Terminating Buyer Breach, through the exercise
of its commercially reasonable efforts and for as long as Buyer continues to exercise such commercially reasonable efforts, Seller
may not terminate this Agreement under this Section 8.1(e) until the earlier of the expiration of such 30-day
period and the Outside Date.

 

 

 

    	 	10	 

     

    

 

Section 8.2 Effect of Termination.

 

In
the event of the termination of this Agreement pursuant to Section 8.1, this Agreement shall forthwith become
void, and there shall be no liability on the part of any Party hereto or any of their respective Affiliates or the directors, officers,
partners, members, managers, employees, agents or other representatives of any of them, and all rights and obligations of each
Party hereto shall cease, except that nothing herein shall relieve any Party from liability for any breach of this Agreement committed
before such termination. Without limiting the foregoing, Section 6.2, this Section 8.2 and Article
X shall survive the termination of this Agreement. Notwithstanding anything to the contrary contained in this Agreement,
nothing shall limit or prevent any Party from exercising any rights or remedies it may have under Section 10.9 hereof
in lieu of terminating this Agreement pursuant to Section 8.1. Upon termination by buyer, the Purchased Assets
will revert back to Seller. All unvested stock options shall terminate. Additionally, all of the Agreements attached to this Agreement
will also terminate. Notwithstanding anything to the contrary contained in this Agreement, nothing shall limit or prevent any Party
from exercising any rights or remedies it may have under any of the agreements attached as Exhibits to this Agreement, whether
or not this Agreement has been terminated.

 

ARTICLE
IX

 

INDEMNIFICATION
PROVISIONS

 

Section 9.1 Seller’s
Indemnification Obligation.

 

Seller
agrees that, from and after the Closing, it shall indemnify, defend and hold harmless Buyer and their respective officers, directors,
Affiliates, partners, members, managers, employees, agents and other representatives (“Buyer Indemnified Parties”)
from and against any damages, claims, losses, liabilities, costs and expenses (including, without limitation, reasonable attorneys’
fees) (each, a “Liability” and, collectively, “Liabilities”) incurred by any of the foregoing
Persons arising out of (a) any misrepresentation in or breach of any representation or warranty of Seller contained in Article
II of this Agreement and/or (b) any breach of any covenant or agreement of Seller contained in this Agreement, and/or
(c) any action, suit, litigation, proceeding at law or in equity, arbitration or governmental investigation against, or threatened
against, Buyer relating to any pre-Closing matter regarding the Purchased Assets, except in all cases to the extent any Liabilities
arise out of any breach of the Buyer's representations, warranties, covenants or agreements set forth in this Agreement.

 

Section 9.2 Buyer’s
Indemnification Obligation.

 

Buyer
agrees that, from and after the Closing, it shall indemnify, defend and hold harmless Seller and its officers, directors, Affiliates,
partners, members, managers, employees, agents and other representatives (“Seller Indemnified Parties”) from
and against any Liabilities incurred by any of the foregoing Persons arising out of (a) any misrepresentation in or breach
of any representation or warranty of Buyer contained in Article III of this Agreement, (b) any breach of
any covenant or agreement of Buyer contained in this Agreement, (c)  any action, suit, litigation, proceeding at law or in
equity, arbitration or governmental investigation against, or threatened against, Seller relating to any post-Closing matter regarding
the Purchased Assets, except in all cases to the extent any Liabilities arise out of any breach of the Seller's representations,
warranties, covenants or agreements set forth in this Agreement or (d) any action, suit, litigation, proceeding at law or in equity,
arbitration or governmental investigation against, or threatened against, Seller relating to any product liability claim made by
any purchaser of any product sold by Buyer.

 

 

 

    	 	11	 

     

    

 

Section 9.3 Procedures
for Indemnification for Third Party Claims.

 

For
purposes of this Article IX, any Party entitled to be indemnified under Article IX is referred to
herein as an “Indemnified Party,” and any Party obligated to provide indemnification under Article IX is
referred to herein as an “Indemnifying Party.” The obligations and liabilities of the Parties under this Article
IX with respect to, relating to or arising out of claims of third parties (individually, a “Third Party Claim”
and, collectively, the “Third Party Claims”) shall be subject to the following terms and conditions:

 

(a)
The Indemnified Party shall give the Indemnifying Party prompt written notice of any Liability regarding which it seeks indemnification.
In the event a Liability is the result of a Liability asserted against the Indemnified Party by a third-party to this Agreement
(a “Third Party Claim”), the Indemnifying Party may undertake the defense of that claim by representatives chosen by
it with the written consent of the Indemnified Party, which consent may not be unreasonably withheld, conditioned or delayed, provided,
that, in such event, the Indemnified Party will have the right to participate in such defense through counsel of its own choice.
Any such notice of a Liability shall identify with reasonable specificity the basis for the indemnification claimed, the facts
giving rise to the Liability and the amount of the Liability (or, if such amount is not yet known, a reasonable estimate of the
amount of the Liability). The Indemnified Party shall make available to the Indemnifying Party copies of all relevant documents
and records in its possession at the expense of the Indemnifying Party. Failure of an Indemnified Party to give prompt notice shall
not relieve the Indemnifying Party of its obligation to indemnify, except to the extent that the failure to so notify materially
prejudices the Indemnifying Party’s ability to defend such claim against a third party.

 

(b)
If the Indemnifying Party, within ten (10) days after notice from the Indemnified Party of any such Liability, notifies the Indemnified
Party in writing of its election not to, or fails to, assume the defense thereof in accordance with Section 9.3(a) of
this Agreement, the Indemnified Party shall have the right (but not the obligation) to undertake the defense of the Liability.
Any failure on the part of the Indemnifying Party to notify the Indemnified Party within the time period provided above regarding
its election shall be deemed an election by the Indemnifying Party not to assume and control the defense of the Liability.

 

(c)
Anything in this Section 9.3 to the contrary notwithstanding, the Indemnifying Party shall not, and does
not have any authority to, without the prior written consent of the Indemnified Party, settle or compromise any Liability or consent
to the entry of judgment which does not include as an unconditional term thereof the unconditional release of the Indemnified Party,
or consent to the entry of judgment with respect thereto, any Liability regarding which it has delivered notice of a claim for
indemnification to the Indemnifying Party, without first obtaining the written consent of the Indemnifying Party (which shall not
be unreasonably withheld or delayed). An Indemnifying Party shall be deemed to have consented to a settlement, compromise, payment
or judgment by the Indemnified Party if it does not respond to written notice from the Indemnified Party seeking such consent within
ten (10) days after delivery of such notice to the Indemnifying Party.

 

Section 9.4 Indemnification
Limitations.

 

(a) Time
Limits On Indemnification. Except for a claim made under 9.2(d) for which there is no time limit, no claim on account of a
breach or inaccuracy of a representation or warranty shall be made after the expiration of the survival periods referred to in Section 10.1 of
this Agreement. Notwithstanding the foregoing, if a written claim or written notice is given under Article IX with
respect to any representation or warranty prior to the expiration of its survival period, the claim with respect to such representation
or warranty shall continue until such claim is finally resolved.

 

(b) Limitations
on Damages.

 

 

 

    	 	12	 

     

    

 

(i)
In no event shall Seller be liable for indemnification pursuant to Section 9.1(a) unless and until the aggregate
of all Liabilities which are incurred or suffered by the Buyer Indemnified Parties exceeds $50,000 (the “Basket”),
in which case the Buyer Indemnified Parties shall be entitled to indemnification for all such Liabilities including the Basket
(subject to Section 9.4(b)(ii)). Except for a claim made under 9.2(d) for which there is no Basket, in no event
shall Buyer be liable for indemnification pursuant to Section 9.2(a) unless and until the aggregate of all
Liabilities which are incurred or suffered by the Seller Indemnified Parties exceeds the Basket, in which case the Seller Indemnified
Parties shall be entitled to indemnification for all such Liabilities including the Basket (subject to Section 9.4(b)(ii)).

 

(ii)
Notwithstanding anything to the contrary in this Agreement, the maximum aggregate liability of Seller pursuant to Section 9.1(a) shall
not exceed (1) the amount of money actually paid to and received by the Seller from the Buyer or their Affiliates pursuant to the
terms of this Agreement and any of the Agreements attached as Exhibits hereto as of the date the notice of requested indemnification
is delivered to the Seller, less (2) any amounts of money currently due the Seller from the Buyer, Odyssey or their Affiliates
pursuant to the terms of this Agreement and any of the Agreements attached as Exhibits hereto. For purposes of this provision,
the right to purchase Odyssey stock at its par value or the shares, if purchased, shall be valued at the greater of its book value
or its then current market price.

 

Except
for a claim made under 9.2(d) for which there is no limit, the maximum aggregate liability of Buyer pursuant to Section 9.2(a) shall
not exceed $7,500,000.

 

(iii)
Notwithstanding anything to the contrary contained in this Agreement or otherwise, no Party to this Agreement shall be liable to
any Indemnified Party for any special, incidental, punitive, consequential or similar damages except, in the event a Third
Party Claim results in a judgment against an Indemnified Party by the third-party claimant, then such damages shall be included
in the amount of indemnification due the Indemnified Party.

 

Section 9.5 Exclusive
Remedy.

 

The
remedies provided in this Article IX shall be the sole and exclusive remedies of the Parties with respect to the
matters arising from or related to this Agreement or the Transactions, except that nothing herein shall prevent a Party from seeking
specific performance pursuant to Section 10.9, subject to the provisions thereof, including with respect to the
obligations in Section 6.1.

 

ARTICLE
X

 

GENERAL
PROVISIONS

 

Section 10.1 Survival
of Representations and Warranties.

 

Except
for a claim made under 9.2(d) for which there is no time limit, the representations and warranties made by Seller in Article
II of this Agreement shall survive until the date that is fifteen (15) months after the Closing Date. The representations
and warranties made by Buyer in Article III of this Agreement shall survive until the date that is fifteen (15)
months after the Closing Date.

 

Section 10.2 Notices.

 

All
notices and other communications under this Agreement shall be in writing and shall be deemed given (a) when delivered personally
by hand (with written confirmation of receipt) or (b) one Business Day following the day sent by nationally-recognized overnight
courier (with written confirmation of receipt), in each case at the following addresses (or to such other address as a Party may
have specified by notice given to the other Party pursuant to this provision)

 

 

 

    	 	13	 

     

    

 

	 	(a)	if to Buyer:
	 	 	 
	 	 	Odyssey
Group International, Inc.

                                                                          1327
Morse Ave

                                                                          Irvine,
CA 90401

                                                                          Attention: Michael Redmond

	 	 	 
	 	(b)	Seller
	 	 	 
	 	 	James
De Luca.

15
Wendover Road,

Forest
Hills Gardens, NY 11375

	 	 	 
	 	with
a copy to:
	 	 	 
	 	 	Murdock
Capital Partners, Inc.15 West 53rd Street, 24th Floor,

New
York, NY 10019

Attention:

 

Any
notice or other communication that has been given or made as of a date that is not a Business Day shall be deemed to have been
given or made on the next succeeding day that is a Business Day.

 

Section 10.3 Headings.

 

The
headings contained in this Agreement and the disclosure schedules are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement or the disclosure schedules. Unless the context of this Agreement otherwise requires,
words of any gender are deemed to include each other gender and words using the singular or plural number also include the plural
or singular number, respectively.

 

Section 10.4 Entire
Agreement.

 

This
Agreement, together with the exhibits and schedules attached hereto, constitutes the entire agreement, and supersede all prior
agreements and undertakings, both written and oral, between the Parties with respect to the subject matter hereof. There are no
agreements, commitments, promises, or representations that are not contained herein.

 

Section 10.5 Assignment:
Parties in Interest.

 

This
Agreement and any rights or obligations hereunder can be assigned by any Party without the prior written consent of the other Party.
This Agreement shall be binding upon and inure solely to the benefit of each Party hereto and its successors and permitted assigns,
and nothing in this Agreement, express or implied, is intended to confer upon any other Person any rights or remedies of any nature
whatsoever under this Agreement, other than Article IX hereof (which is intended to be for the benefit of the
Persons covered thereby and may be enforced by such Persons).

 

 

 

    	 	14	 

     

    

 

Section 10.6 Governing
Law; Consent to Jurisdiction.

 

This
Agreement shall be governed by, and construed in accordance with, the Laws of the State of California applicable to contracts executed
in and to be performed entirely in that State, without regard to conflicts of Laws principles thereof to the extent that the general
application of the Laws of another jurisdiction would be required thereby.

 

Section 10.7 Counterparts.

 

This
Agreement may be executed and delivered (including by facsimile transmission or .pdf) in one or more counterparts, and by the Parties
hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together
shall constitute one and the same agreement.

 

Section 10.8 Severability.

 

In
case any provision in this Agreement shall be held invalid, illegal or unenforceable in a jurisdiction, such provision shall be
modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable,
and the validity, legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby
nor shall the validity, legality or enforceability of such provision be affected thereby in any other jurisdiction.

 

Section 10.9 Specific
Performance.

 

The
Parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed
in accordance with their specific terms or were otherwise breached. Accordingly, the Parties further agree that each Party shall
be entitled to seek an injunction or restraining order to prevent breaches of this Agreement and to seek to enforce specifically
the terms and provisions hereof, this being in addition to any other right or remedy to which such Party may be entitled under
this Agreement, at law or in equity.

 

Section 10.10 Fees
and Expenses.

 

All
fees, costs and expenses incurred in connection with this Agreement and the Transactions shall be paid by the Party incurring the
same, regardless of the termination, if any, of this Agreement pursuant to Section 8.1. Notwithstanding the foregoing,
in the event the Parties engage in litigation relating to or arising out of this Agreement or the performance thereof, the Parties
agree that the Court shall be asked to determine which Party is the prevailing Party to the proceeding or proceedings, and the
non-prevailing Party or Parties shall, jointly and severally, be liable to the prevailing Party in the amount of all reasonable
attorney’s fees, court costs, and all other expenses, incurred by the prevailing Party to the proceeding in addition to any
other relief to which the prevailing Party may be entitled.

 

Section 10.11 Amendment.

 

This
Agreement may not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed
by Buyer, , and Seller.

 

Section 10.12 Waiver.

 

At
any time prior to the Closing Date, any Party hereto may (a) extend the time for the performance of any of the obligations
or other acts of the other Party hereto, (b) waive any inaccuracies in the representations and warranties contained herein
or in any document delivered pursuant hereto and (c) waive compliance with any of the agreements or conditions contained herein.
Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the Parties hereto. The failure
of any Party hereto to assert any of its rights hereunder shall not constitute a waiver of such rights.

 

 

 

    	 	15	 

     

    

 

ARTICLE
XI

 

CERTAIN
DEFINITIONS

 

For
purposes of this Agreement, the term:

 

“Action”
shall have the meaning ascribed to it in Section 2.4.

 

“Affiliate”
of a Person means a person that directly, or indirectly through one or more
intermediaries, controls or is controlled by, or is under common control with, the person specified. “Agreement”
shall have the meaning ascribed to it in the preamble.

 

“Business
Day” means any calendar day which is not a Saturday, Sunday or federal holiday.

 

“Buyer”
shall have the meaning ascribed to it in the Preamble.

 

“Buyer
Disclosure Schedule” shall have the meaning ascribed to it in the preamble to Article III.

 

“Closing”
shall have the meaning ascribed to it in Section 1.4(a).

 

“Closing
Date” shall have the meaning ascribed to it in Section 1.4(a).

 

“Control”
(including the terms “Controlled by” and “under common Control with”) means the possession, directly or
indirectly or as trustee or executor, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, as trustee or executor, by contract or credit arrangement or otherwise.

 

“Encumbrance”
means any charge, claim, community property interest, condition, easement, covenant, warrant, demand, encumbrance, equitable interest,
lien, mortgage, option, purchase right, pledge, security interest, right of first refusal or other right of third parties or restriction
of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.

 

“Exchange
Act” shall have the meaning ascribed to it in Section 2.3.

 

“Governmental
Authority” means any United States federal, state or local government, governmental, regulatory or administrative authority,
agency, self-regulatory body, instrumentality or commission, and any court, tribunal or judicial or arbitral body (including private
bodies) and any political or other subdivision, department or branch of any of the foregoing.

 

“Indemnified
Party” shall have the meaning ascribed to it in Section 9.3.

 

 

 

    	 	16	 

     

    

 

“Indemnifying
Party” shall have the meaning ascribed to it in Section 9.3.

 

“Intellectual
Property” means all United States and foreign intellectual property and all other similar proprietary rights, including
all (i) patents and patent applications, including divisionals, continuations, continuations-in-part, reissues, reexaminations
and extensions thereof and counterparts claiming priority therefrom; utility models; invention disclosures; and statutory invention
registrations and certificates; (ii) registered, pending and unregistered trademarks, service marks, trade dress, logos, trade
names, corporate names and other source identifiers, domain names, Internet sites and web pages; and registrations and applications
for registration for any of the foregoing, together with all of the goodwill associated therewith; (iii) registered copyrights,
and registrations and applications for registration thereof; rights of publicity; and copyrightable works; (iv) all inventions
and design rights (whether patentable or unpatentable) and all categories of trade secrets as defined in the Uniform Trade Secrets
Act, including business, technical and financial information; and (v) confidential and proprietary information, including
know-how.

 

“Seller’s
Knowledge” shall have the meaning ascribed to it in Section 2.6.

 

“Laws”
means any federal, state or local statute, law, rule, ordinance, code or regulation of any Governmental Authority.

 

“Liability”
and, collectively, “Liabilities” shall have the meaning ascribed to it in Section 9.1.

 

“Order”
shall have the meaning ascribed to it in Section 2.4.

 

“Outside
Date” shall have the meaning ascribed to it in Section 8.1(b).

 

“Parties”
shall have the meaning ascribed to it in the preamble.

 

“Patent(s) means:
The USPTO Patent Number RE45, 535 E issued on June 2, 2015 and Patent Number 8,454,624 B2; issued June 4, 2013, both patents are
related to a Choking Rescue Device.

 

“Patent
Assignment” means the Patent Assignment Agreement whereby, as part of this Agreement, Seller assigns Patent Applications
No. RE 45,535 E and Patent number 8,454,624 B2 issued June 4 2013.

 

“Person”
means an individual, corporation, partnership, limited liability company, association, trust, unincorporated organization or other
entity..

 

“Purchased
Assets” shall have the meaning ascribed to it in Section 1.1.

 

“Seller”
shall have the meaning ascribed to it in the Preamble.

 

“Seller
Disclosure Schedule” shall have the meaning ascribed to it in the preamble to Article II.

 

“Subsidiary”
means any Person with respect to which a specified Person directly or indirectly (A) owns a majority of the equity interests,
(B) has the power to elect a majority of that Person’s board of directors or similar governing body, or (C) otherwise
has the power, directly or indirectly, to direct the business and policies of that Person.

 

 

 

    	 	17	 

     

    

 

“Tax”
or “Taxes” means any and all taxes, fees, levies, duties, tariffs, imposts and other charges of any kind (together
with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any Governmental
Authority, including: taxes or other charges on or with respect to income, franchise, windfall or other profits, gross receipts,
property, sales, use, equity interests, payroll, employment, social security, workers’ compensation, unemployment compensation
or net worth; taxes or other charges in the nature of excise, withholding, ad valorem, stamp, transfer, value-added or gains taxes;
license, registration and documentation fees; and customers’ duties, tariffs and similar charges.

 

“Terminating
Buyer Breach” shall have the meaning ascribed to it in Section 8.1(e).

 

“Terminating
Seller Breach” shall have the meaning ascribed to it in Section 8.1(d).

 

“Third
Party Claim” and, collectively, “Third Party Claims” shall have the meaning ascribed to it in Section 9.3.

 

“Transactions”
shall have the meaning ascribed to it in Section 2.2.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	18	 

     

    

 

IN
WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be duly executed as of the date first written above.

	 	 	 	 
	 	
        SELLER:

         

        De LUCA.

	 	 	 
	 	By:	 	
        /s/James De Luca

	 	Name:	 	James De Luca
	 	Title:	 	Individual

 

	 	 	 	 
	 	
        Seller:

         

        MCP

	 	 	 
	 	By:	 	
        /s/ Luis Mejia

	 	Name:	 	Luis Mejia
	 	Title:	 	/s/ Managing Partner

 

	 	 	 	 
	 	
        ODYSSEY:

         

        ODYSSEY GROUP INTERNATIONAL, INC.

	 	 	 
	 	By:	 	
        /s/ J. Michael Redmond

	 	Name:	 	J. Michael Redmond
	 	Title:	 	President/Chief Executive Officer

 

 

SCHEDULE FOR EXHIBITS

 

		·	EXHIBIT “A” “Common Stock Purchase Agreement”

		·	EXHIBIT “B”“Royalty Agreement”

		·	EXHIBIT “C”“Consulting Agreement”

		·	EXHIBIT “D”“Patent assignment Agreement”

 

 

 

    	 	19	 

     

    

 

EXHIBIT “A”

 

ODYSSEY GROUP INTERNATIONAL, INC.

STOCK OPTION AGREEMENT

FOR

DE LUCA

 

Agreement

 

1.            Grant of Option. Odyssey Group International, Inc., a Nevada corporation (the “Company”),
hereby grants, as of the effective date of this Agreement specified on Schedule I hereof beside the caption “Date
of Grant” (“Date of Grant”), to James De Luca (the “Optionee”) an option (the “Option”)
to purchase an aggregate number of shares set forth on Schedule I hereof beside the caption “Number of Optioned Shares”
(such number being subject to adjustment as provided in Section 10(c) of the Plan) of the Company’s common stock, $.001 par
value per share (the “Shares”), at an exercise price per share set forth on Schedule I hereof beside the caption
“Exercise Price” (such exercise price being subject to adjustment as provided in Section 10(c) of the Plan)(the “Exercise
Price”). The Option shall be subject to the terms and conditions set forth herein. The Option is being issued pursuant to
the Odyssey Group International Inc. 2019 Incentive Compensation Plan (the “Plan”), which is incorporated herein for
all purposes. This Option is designated on Schedule I as either an Incentive Stock Option or a Non-Qualified Stock Option.
If designated on Schedule I hereof as an Incentive Stock Option, this Option is intended to qualify as an Incentive Stock
Option as defined in Section 422 of the Code, and this Agreement shall be interpreted accordingly. Where there is a discrepancy
between this Agreement and the Plan this Agreement shall take precedence

 

2.            Definitions. Unless otherwise provided herein, terms used herein that are defined in the Plan
and not defined herein shall have the meanings attributed thereto in the Plan.

 

3.            Exercise Schedule. Except as otherwise provided in Sections 6 or 10 of this Agreement, or in
the Plan, the Option is exercisable in installments as specified on Schedule I hereof beside the caption “Vesting”,
which shall be cumulative. To the extent that the Option has become exercisable with respect to a percentage of Shares as provided
on Schedule I hereof beside the caption “Vesting” on each date (the “Vesting Date”) upon which the
Optionee shall be entitled to exercise the Option with respect to the percentage of Shares granted as indicated for each Vesting
Date (), the Option may thereafter be exercised by the Optionee, in whole or in part, at any time or from time to time prior to
the expiration of the Option as provided herein. Except as otherwise specifically provided herein, there shall be no proportionate
or partial vesting in the periods prior to each Vesting Date, and all vesting shall occur only on the appropriate Vesting Date.

 

4.            Method of Exercise. The vested portion of this Option shall be exercisable in whole or in part
in accordance with the exercise schedule set forth in Section 3 hereof by written notice which shall state the election to exercise
the Option, the number of Shares in respect of which the Option is being exercised, and such other representations and agreements
as to the holder’s investment intent with respect to such Shares as may be required by the Company pursuant to the provisions
of the Plan. Such written notice shall be signed by the Optionee and shall be delivered in person or by certified mail to the Secretary
of the Company. The written notice shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised
after both (a) receipt by the Company of such written notice accompanied by the Exercise Price and (b) arrangements that are satisfactory
to the Committee in its sole discretion have been made for Optionee’s payment to the Company of the amount, if any, that
is necessary to be withheld in accordance with applicable Federal or state withholding requirements. No Shares shall be issued
pursuant to the Option unless and until such issuance and such exercise shall comply with all relevant provisions of applicable
law, including the requirements of any stock exchange upon which the Shares then may be traded.

 

 

 

    	 	20	 

     

    

 

5.            Method of Payment. Payment of the Exercise Price shall be by any of the following, or a combination
thereof, at the election of the Optionee: (a) cash; (b) check; (c) to the extent permitted by the Committee or as provided on Schedule
I hereof beside the caption “Permission to Pay with Shares”, with Shares owned by the Optionee, or the withholding
of Shares that otherwise would be delivered to the Optionee as a result of the exercise of the Option, or pursuant to a “cashless
exercise” procedure, by delivery of a properly executed exercise notice together with such other documentation, and subject
to such guidelines, as the Committee shall require to effect an exercise of the Option and delivery to the Company by a licensed
broker acceptable to the Company of proceeds from the sale of Shares sufficient to pay the Exercise Price and any applicable income
or employment taxes, or (d) such other consideration or in such other manner as may be determined by the Committee in its absolute
discretion.

 

6.            Termination of Option.

 

(a)       General. Any unexercised portion of the Option shall automatically and without notice terminate and become
null and void at the time of the earliest to occur of the following:

 

(i)         the
tenth anniversary of the date as of which the Option is granted (or, if a different date is shown on Schedule I hereof
beside the caption “Termination Date”, such date).

 

(ii)        Any Options not
vested will terminate upon the termination of the Intellectual Property Purchase Agreement.

 

(b)       Cancellation.
To the extent not previously exercised, (i) the Option shall terminate immediately in the event of (A) the liquidation or dissolution
of the Company, or The Committee shall give written notice of any proposed transaction referred to in this Section 6(b) a reasonable
period of time prior to the closing date for such transaction (which notice may be given either before or after approval of such
transaction), in order that the Optionee may have a reasonable period of time prior to the closing date of such transaction within
which to exercise the Option if and to the extent that it then is exercisable (including any portion of the Option that may become
exercisable upon the closing date of such transaction). The Optionee may condition his exercise of the Option upon the consummation
of a transaction referred to in this Section 6(b).

 

7.            Transferability. Unless (i) transfers are expressly permitted in the language appearing beside
the caption “Expanded Rights to Transfer Option” on Schedule I hereof or (ii) otherwise determined by the Committee,
the Option granted hereby is not transferable otherwise than by will or under the applicable laws of descent and distribution,
and during the lifetime of the Optionee the Option shall be exercisable only by the Optionee, or the Optionee’s guardian
or legal representative. In addition, the Option shall not be assigned, negotiated, pledged or hypothecated in any way (whether
by operation of law or otherwise), and the Option shall not be subject to execution, attachment or similar process. Upon any attempt
to transfer, assign, negotiate, pledge or hypothecate the Option, or in the event of any levy upon the Option by reason of any
execution, attachment or similar process contrary to the provisions hereof, the Option shall immediately become null and void.
The terms of this Option shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee.

 

8.            No Rights of Stockholders. Neither the Optionee nor any personal representative (or beneficiary)
shall be, or shall have any of the rights and privileges of, a stockholder of the Company with respect to any Shares purchasable
or issuable upon the exercise of the Option, in whole or in part, prior to the date on which the Shares are issued.

 

 

 

    	 	21	 

     

    

 

9.            Acceleration of Exercisability of Option.

 

(a)       Acceleration
Upon Certain Terminations or Cancellations of Option. This Option shall become immediately fully exercisable in the event
that, prior to the termination of the Option pursuant to Section 6 hereof, (i) the Option is terminated pursuant to Section 6(b)(i)
hereof, or (ii) the Company exercises its discretion to provide a cancellation notice with respect to the Option pursuant to Section
6(b)(ii) hereof.

 

(b)       Acceleration
Upon Change in Control. This Option shall become immediately fully exercisable in the event that, prior to the termination
of the Option pursuant to Section 6 hereof, and during the Optionee's Continuous Service, there is a “Change in Control”,
as defined in Section 9(b) of the Plan.

 

10.          No Right to Continuous Service. Neither the Option nor this Agreement shall confer upon the
Optionee any right to Continuous Service with the Company or any Related Entity.

 

11.          Information Confidential. As partial consideration for the granting of the Option, the Optionee
agrees with the Company to keep confidential all information and knowledge that the Optionee has relating to the manner and amount
of the Optionee’s participation in the Plan; provided, however, that such information may be disclosed as required by law
and may be given in confidence to the Optionee’s spouse, the Optionee’s tax and financial advisors, or financial institutions
to the extent that such information is necessary to secure a loan.

 

12.          Interpretation / Provisions of Plan Control. This Agreement is subject to all the terms, conditions
and provisions of the Plan, including, without limitation, the amendment provisions thereof, and to such rules, regulations and
interpretations relating to the Plan adopted by the Committee as may be in effect from time to time. If and to the extent that
this Agreement conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and
this Agreement shall be deemed to be modified accordingly. The Optionee accepts the Option subject to all of the terms and provisions
of the Plan and this Agreement. The undersigned Optionee hereby accepts as binding, conclusive and final all decisions or interpretations
of the Committee upon any questions arising under the Plan and this Agreement, unless shown to have been made in an arbitrary and
capricious manner.

 

13.          Notices. All notices, requests, demands, and other communications hereunder shall be in writing
and shall be personally delivered, delivered by facsimile or courier service, or mailed, certified with first class postage prepaid
to the address specified by the person who is to receive the same. Each
such notice, request, demand, or other communication hereunder shall be deemed to have been given (whether actually received or
not) on the date of actual delivery thereof, if personally delivered or delivered by facsimile transmission (if receipt is confirmed
at the time of such transmission by telephone or facsimile-machine-generated confirmation), or on the third day following the date
of mailing, if mailed in accordance with this Section, or on the day specified for delivery to the courier service (if such day
is one on which the courier service will give normal assurances that such specified delivery will be made). Any notice, request,
demand, or other communication given otherwise than in accordance with this Section shall be deemed to have been given on the date
actually received. Each such notice, request, demand, or other communication hereunder shall be addressed, in the case of
the Company, to the Company’s Secretary at Odyssey Group International Inc., 2372 Morse Ave Irvine, CA, or if the Company
should move its principal office, to such principal office, and, in the case of the Optionee, to the Optionee’s last permanent
address as shown on the Company’s records, subject to the right of either party to designate some other address at any time
hereafter in a notice satisfying the requirements of this Section. Any
person entitled to any notice, request, demand, or other communication hereunder may waive the notice, request, demand, or other
communication. 

 

 

 

    	 	22	 

     

    

 

14.           Section
409A.

 

(a)        It is intended that the Option awarded pursuant to this Agreement be exempt from Section 409A of the Code (“Section
409A”) because it is believed that (i) the Exercise Price may never be less than the Fair Market Value of a Share on the
Date of Grant and the number of shares subject to the Option is fixed on the original Date of Grant, (ii) the transfer or exercise
of the Option is subject to taxation under Section 83 of the Code and Treas. Reg. 1.83-7, and (iii) the Option does not include
any feature for the deferral of compensation other than the deferral of recognition of income until the exercise of the Option.
The provisions of this Agreement shall be interpreted in a manner consistent with this intention, and the provisions of this Agreement
may not be amended, adjusted, assumed or substituted for, converted or otherwise modified without the Optionee’s prior written
consent if and to the extent that the Company believes or reasonably should believe that such amendment, adjustment, assumption
or substitution, conversion or modification would cause the award to violate the requirements of Section 409A. In the event that
either the Company or the Optionee believes, at any time, that any benefit or right under this Agreement is subject to Section
409A, then the Committee may (acting alone and without any required consent of the Optionee) amend this Agreement in such manner
as the Committee deems necessary or appropriate to be exempt from or otherwise comply with the requirements of Section 409A (including
without limitation, amending the Agreement to increase the Exercise Price to such amount as may be required in order for the Option
to be exempt from Section 409A).

 

(b)        Notwithstanding the foregoing, the Company does not make any representation to the Optionee that the Option awarded pursuant
to this Agreement is exempt from, or satisfies, the requirements of Section 409A, and the Company shall have no liability or other
obligation to indemnify or hold harmless the Optionee or any Beneficiary for any tax, additional tax, interest or penalties that
the Optionee or any Beneficiary may incur in the event that any provision of this Agreement, or any amendment or modification thereof
or any other action taken with respect thereto, that either is consented to by the Optionee or that the Company reasonably believes
should not result in a violation of Section 409A, is deemed to violate any of the requirements of Section 409A.

 

15.           Incentive Stock Option Treatment. If designated on Schedule I hereof as an Incentive
Stock Option: (a) the terms of this Option shall be interpreted in a manner consistent with the intent of the Company and the
Optionee that the Option qualify as an Incentive Stock Option under Section 422 of the Code; (b) if any provision of the Plan
or this Agreement shall be impermissible in order for the Option to qualify as an Incentive Stock Option, then the Option shall
be construed and enforced as if such provision had never been included in the Plan or the Option; and (c) if and to the extent
that the number of Options granted pursuant to this Agreement exceeds the limitations contained in Section 422 of the Code on
the value of Shares with respect to which this Option may qualify as an Incentive Stock Option, this Option shall be a Non-Qualified
Stock Option.

 

16.           Section Headings. The Section headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

17.           Governing
Law and Venue. THIS AGREEMENT SHALL AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEVADA WITHOUT GIVING
EFFECT TO ANY CHOICE OR CONFLICT OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF NEVADA OR ANY OTHER JURISDICTION) THAT WOULD
CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF NEVADA. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO
THE PERSONAL JURISDICTION OF THE COURTS LOCATED IN THE STATE OF CALIFORNIA AND AGREES THAT ANY LITIGATION BETWEEN THE PARTIES
WILL BE FILED IN COURTS LOCATED IN LOS ANGELES, CALIFORNIA.

 

 

 

    	 	23	 

     

    

 

18.           Arbitration.
By execution hereof, the parties hereto expressly agree that upon the request of any party, whether made before or after
the institution of any legal proceeding, any action, dispute, claim or controversy of any kind, whether in contract or in tort,
statutory or common law, legal or equitable, arising between the parties in any way arising out of any of the provisions contained
in this Agreement shall be resolved by binding arbitration administered by the American Arbitration Association (the “AAA”)
and in Los Angeles, California. Such arbitration shall be conducted in accordance with the Commercial Arbitration Rules of the
AAA and, to the maximum extent applicable, the Federal Arbitration Act (Title 9 of the United States Code) except as otherwise
specified herein. Judgment upon the award rendered by the arbitrator may be entered in any court having competent jurisdiction.
The arbitrator shall resolve all disputes in accordance with the applicable substantive law. A single arbitrator shall be chosen
and shall decide the dispute, unless the amount sought in the dispute exceeds $100,000, in which case a panel of three arbitrators
shall decide the dispute. In all arbitration proceedings in which the amount of any award exceeds $100,000, in the aggregate,
the arbitrator(s) shall make specific, written findings of fact and conclusions of law. In all arbitration proceedings in which
the amount of any award exceeds $100,000, in the aggregate, the parties shall have, in addition to the limited statutory right
to seek a vacation or modification of an award pursuant to applicable law, the right to vacation or modification of any award
that is based, in whole or in part, on an incorrect or erroneous ruling of law by appeal to an appropriate court having jurisdiction;
provided, however, that any such application for a vacation or modification of such an award based on an incorrect ruling of law
must be filed in a court having jurisdiction over the dispute within 15 days from the date the award is rendered. The findings
of fact of the arbitrator(s) shall be binding on all parties and shall not be subject to further review except as otherwise allowed
by applicable law. No provision of this Agreement nor the exercise of any rights hereunder shall limit the right of any party,
and any party shall have the right during any dispute, to seek, use, and employ ancillary or preliminary remedies, such as injunctive
relief (including, without limitation, specific performance), from a court having jurisdiction before, during, or after the pendency
of any arbitration. The institution and maintenance of any action for judicial relief or pursuit of provisional or ancillary remedies
shall not constitute a waiver of the right of any party to submit any dispute to arbitration nor render inapplicable the compulsory
arbitration provisions hereof.

 

19.           Attorney’s
Fees. If any action is brought to enforce or interpret the terms of this Agreement (including through arbitration),
the prevailing party shall be entitled to reasonable attorneys’ fees, costs, and necessary disbursements in addition to
any other relief to which such party may be entitled.

 

20.           Counterparts.
This Agreement may be executed in any number of counterparts and shall be effective when each party hereto has executed
at least one counterpart, with the same effect as if all signing parties had signed the same document. All counterparts will be
construed together and evidence only one agreement, which, notwithstanding the actual date of execution of any counterpart, shall
be deemed to be dated the day and year first written above. In making proof of this Agreement, it shall not be necessary to account
for a counterpart executed by any party other than the party against whom enforcement is sought or to account for more than one
counterpart executed by the party against whom enforcement is sought.

 

21.           Execution
by Facsimile. The manual signature of any party hereto that is transmitted to any other party by facsimile or in portable
document format (PDF) shall be deemed for all purposes to be an original signature.

 

 

 

 

 

 

Remainder of page intentionally left
blank; signature page follows.

 

 

 

 

 

 

 

    	 	24	 

     

    

 

IN WITNESS WHEREOF, the undersigned
have executed this Agreement as of the 26th day of June 2019.

 

	 	COMPANY:
	 	Odyssey Group International, Inc.
	 	 
	 	By:	/s/ J. Michael Redmond
	 	 	Name: J. Michael Redmond
Title: CEO

 

 

The Optionee acknowledges
receipt of a copy of the Plan and represents that he or she has reviewed the provisions of the Plan and this Agreement in their
entirety, is familiar with and understands their terms and provisions, and hereby accepts this Option subject to all of the terms
and provisions of the Plan and this Agreement. The Optionee further represents that he or she has had an opportunity to obtain
the advice of counsel prior to executing this Agreement.

 

 

 

	 	OPTIONEE:
	 	 
	Dated: 6-27-19	/s/ James De Luca

Name: James De Luca

15 Wendover Road,

Forest Hills Gardens, NY 11375

 

 

 

 

    	 	25	 

     

    

 

SCHEDULE I

 

 

	NAME OF OPTIONEE:	James De Luca
	DATE OF GRANT:	June 26, 2019
	TYPE OF OPTION:	Incentive Stock Option        No
	 	Non-Qualified Stock Option         Yes
	NUMBER OF OPTIONED SHARES:	360,000
	EXERCISE PRICE:	$1.25 per Share
	TERMINATION DATE:	None 
	VESTING:	
        150,000 vest immediately

        60,000 vest upon the first anniversary date of the Intellectual
        Property Purchase Agreement

        150,000 vest on the second anniversary date of the Intellectual
        Property Purchase Agreement or upon FDA submission which ever occurs first.

	PERMISSION TO PAY WITH SHARES:	__X_ Granted _____Denied 
	EXPANDED RIGHTS TO TRANSFER OPTION:	Options may be transferred to a family
member

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	26	 

     

    

 

ODYSSEY GROUP INTERNATIONAL, INC.

STOCK OPTION AGREEMENT

FOR

Murdock Capital Partners

 

Agreement

 

22.             
Grant of Option. Odyssey Group International, Inc., a Nevada corporation (the “Company”),
hereby grants, as of the effective date of this Agreement specified on Schedule I hereof beside the caption “Date
of Grant” (“Date of Grant”), to Murdock Capital Partners (the “Optionee”) an option (the “Option”)
to purchase an aggregate number of shares set forth on Schedule I hereof beside the caption “Number of Optioned Shares”
(such number being subject to adjustment as provided in Section 10(c) of the Plan) of the Company’s common stock, $.001 par
value per share (the “Shares”), at an exercise price per share set forth on Schedule I hereof beside the caption
“Exercise Price” (such exercise price being subject to adjustment as provided in Section 10(c) of the Plan)(the “Exercise
Price”). The Option shall be subject to the terms and conditions set forth herein. The Option is being issued pursuant to
the Odyssey Group International Inc. 2019 Incentive Compensation Plan (the “Plan”), which is incorporated herein for
all purposes. This Option is designated on Schedule I as either an Incentive Stock Option or a Non-Qualified Stock Option.
If designated on Schedule I hereof as an Incentive Stock Option, this Option is intended to qualify as an Incentive Stock
Option as defined in Section 422 of the Code, and this Agreement shall be interpreted accordingly. Where there is a discrepancy
between this Agreement and the Plan this Agreement shall take precedence

 

23.             
Definitions. Unless otherwise provided herein, terms used herein that are defined in the Plan
and not defined herein shall have the meanings attributed thereto in the Plan.

 

24.             
Exercise Schedule. Except as otherwise provided in Sections 6 or 10 of this Agreement, or in
the Plan, the Option is exercisable in installments as specified on Schedule I hereof beside the caption “Vesting”,
which shall be cumulative. To the extent that the Option has become exercisable with respect to a percentage of Shares as provided
on Schedule I hereof beside the caption “Vesting” on each date (the “Vesting Date”) upon which the
Optionee shall be entitled to exercise the Option with respect to the percentage of Shares granted as indicated for each Vesting
Date (), the Option may thereafter be exercised by the Optionee, in whole or in part, at any time or from time to time prior to
the expiration of the Option as provided herein. Except as otherwise specifically provided herein, there shall be no proportionate
or partial vesting in the periods prior to each Vesting Date, and all vesting shall occur only on the appropriate Vesting Date.

 

25.             
Method of Exercise. The vested portion of this Option shall be exercisable in whole or in part
in accordance with the exercise schedule set forth in Section 3 hereof by written notice which shall state the election to exercise
the Option, the number of Shares in respect of which the Option is being exercised, and such other representations and agreements
as to the holder’s investment intent with respect to such Shares as may be required by the Company pursuant to the provisions
of the Plan. Such written notice shall be signed by the Optionee and shall be delivered in person or by certified mail to the Secretary
of the Company. The written notice shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised
after both (a) receipt by the Company of such written notice accompanied by the Exercise Price and (b) arrangements that are satisfactory
to the Committee in its sole discretion have been made for Optionee’s payment to the Company of the amount, if any, that
is necessary to be withheld in accordance with applicable Federal or state withholding requirements. No Shares shall be issued
pursuant to the Option unless and until such issuance and such exercise shall comply with all relevant provisions of applicable
law, including the requirements of any stock exchange upon which the Shares then may be traded.

 

 

 

    	 	27	 

     

    

 

26.              Method
of Payment. Payment of the Exercise Price shall be by any of the following, or a combination thereof, at the election
of the Optionee: (a) cash; (b) check; (c) to the extent permitted by the Committee or as provided on Schedule I hereof
beside the caption “Permission to Pay with Shares”, with Shares owned by the Optionee, or the withholding of
Shares that otherwise would be delivered to the Optionee as a result of the exercise of the Option, or pursuant to a
“cashless exercise” procedure, by delivery of a properly executed exercise notice together with such other
documentation, and subject to such guidelines, as the Committee shall require to effect an exercise of the Option and
delivery to the Company by a licensed broker acceptable to the Company of proceeds from the sale of Shares sufficient to pay
the Exercise Price and any applicable income or employment taxes, or (d) such other consideration or in such other manner as
may be determined by the Committee in its absolute discretion.

 

27.             
Termination of Option.

 

(a)        General.
Any unexercised portion of the Option shall automatically and without notice terminate and become null and void at the time of
the earliest to occur of the following:

 

(i)        the tenth anniversary of the date as of which the Option is granted (or, if a different date is shown on Schedule I
hereof beside the caption “Termination Date”, such date).

 

(ii)        Any Options not
vested will terminate upon the termination of the Intellectual Property Purchase Agreement.

 

(b)       Cancellation.
To the extent not previously exercised, (i) the Option shall terminate immediately in the event of (A) the liquidation or dissolution
of the Company, or The Committee shall give written notice of any proposed transaction referred to in this Section 6(b) a reasonable
period of time prior to the closing date for such transaction (which notice may be given either before or after approval of such
transaction), in order that the Optionee may have a reasonable period of time prior to the closing date of such transaction within
which to exercise the Option if and to the extent that it then is exercisable (including any portion of the Option that may become
exercisable upon the closing date of such transaction). The Optionee may condition his exercise of the Option upon the consummation
of a transaction referred to in this Section 6(b).

 

28.             
Transferability. Unless (i) transfers are expressly permitted in the language appearing beside
the caption “Expanded Rights to Transfer Option” on Schedule I hereof or (ii) otherwise determined by the Committee,
the Option granted hereby is not transferable otherwise than by will or under the applicable laws of descent and distribution,
and during the lifetime of the Optionee the Option shall be exercisable only by the Optionee, or the Optionee’s guardian
or legal representative. In addition, the Option shall not be assigned, negotiated, pledged or hypothecated in any way (whether
by operation of law or otherwise), and the Option shall not be subject to execution, attachment or similar process. Upon any attempt
to transfer, assign, negotiate, pledge or hypothecate the Option, or in the event of any levy upon the Option by reason of any
execution, attachment or similar process contrary to the provisions hereof, the Option shall immediately become null and void.
The terms of this Option shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee.

 

29.             
No Rights of Stockholders. Neither the Optionee nor any personal representative (or beneficiary)
shall be, or shall have any of the rights and privileges of, a stockholder of the Company with respect to any Shares purchasable
or issuable upon the exercise of the Option, in whole or in part, prior to the date on which the Shares are issued.

 

 

 

    	 	28	 

     

    

 

30.             
Acceleration of Exercisability of Option.

 

(a)       Acceleration
Upon Certain Terminations or Cancellations of Option. This Option shall become immediately fully exercisable in the event
that, prior to the termination of the Option pursuant to Section 6 hereof, (i) the Option is terminated pursuant to Section 6(b)(i)
hereof, or (ii) the Company exercises its discretion to provide a cancellation notice with respect to the Option pursuant to Section
6(b)(ii) hereof.

 

(b)       Acceleration
Upon Change in Control. This Option shall become immediately fully exercisable in the event that, prior to the termination
of the Option pursuant to Section 6 hereof, and during the Optionee's Continuous Service, there is a “Change in Control”,
as defined in Section 9(b) of the Plan.

 

31.             
No Right to Continuous Service. Neither the Option nor this Agreement shall confer upon the
Optionee any right to Continuous Service with the Company or any Related Entity.

 

32.             
Information Confidential. As partial consideration for the granting of the Option, the Optionee
agrees with the Company to keep confidential all information and knowledge that the Optionee has relating to the manner and amount
of the Optionee’s participation in the Plan; provided, however, that such information may be disclosed as required by law
and may be given in confidence to the Optionee’s spouse, the Optionee’s tax and financial advisors, or financial institutions
to the extent that such information is necessary to secure a loan.

 

33.             
Interpretation / Provisions of Plan Control. This Agreement is subject to all the terms, conditions
and provisions of the Plan, including, without limitation, the amendment provisions thereof, and to such rules, regulations and
interpretations relating to the Plan adopted by the Committee as may be in effect from time to time. If and to the extent that
this Agreement conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and
this Agreement shall be deemed to be modified accordingly. The Optionee accepts the Option subject to all of the terms and provisions
of the Plan and this Agreement. The undersigned Optionee hereby accepts as binding, conclusive and final all decisions or interpretations
of the Committee upon any questions arising under the Plan and this Agreement, unless shown to have been made in an arbitrary and
capricious manner.

 

34.             
Notices. All notices, requests, demands,
and other communications hereunder shall be in writing and shall be personally delivered, delivered by facsimile or courier service,
or mailed, certified with first class postage prepaid to the address specified by the person who is to receive the same. Each such
notice, request, demand, or other communication hereunder shall be deemed to have been given (whether actually received or not)
on the date of actual delivery thereof, if personally delivered or delivered by facsimile transmission (if receipt is confirmed
at the time of such transmission by telephone or facsimile-machine-generated confirmation), or on the third day following the date
of mailing, if mailed in accordance with this Section, or on the day specified for delivery to the courier service (if such day
is one on which the courier service will give normal assurances that such specified delivery will be made). Any notice, request,
demand, or other communication given otherwise than in accordance with this Section shall be deemed to have been given on the date
actually received. Each such notice, request, demand, or other communication hereunder shall be addressed, in the case of the Company,
to the Company’s Secretary at Odyssey Group International Inc., 2372 Morse Ave Irvine, CA, or if the Company should move
its principal office, to such principal office, and, in the case of the Optionee, to the Optionee’s last permanent address
as shown on the Company’s records, subject to the right of either party to designate some other address at any time hereafter
in a notice satisfying the requirements of this Section. Any person entitled to any notice, request, demand, or other communication
hereunder may waive the notice, request, demand, or other communication. 

 

 

 

    	 	29	 

     

    

 

35.             
Section 409A.

 

(a)              
It is intended that the Option awarded pursuant to this Agreement be exempt from Section 409A of the Code (“Section
409A”) because it is believed that (i) the Exercise Price may never be less than the Fair Market Value of a Share on the
Date of Grant and the number of shares subject to the Option is fixed on the original Date of Grant, (ii) the transfer or exercise
of the Option is subject to taxation under Section 83 of the Code and Treas. Reg. 1.83-7, and (iii) the Option does not include
any feature for the deferral of compensation other than the deferral of recognition of income until the exercise of the Option.
The provisions of this Agreement shall be interpreted in a manner consistent with this intention, and the provisions of this Agreement
may not be amended, adjusted, assumed or substituted for, converted or otherwise modified without the Optionee’s prior written
consent if and to the extent that the Company believes or reasonably should believe that such amendment, adjustment, assumption
or substitution, conversion or modification would cause the award to violate the requirements of Section 409A. In the event that
either the Company or the Optionee believes, at any time, that any benefit or right under this Agreement is subject to Section
409A, then the Committee may (acting alone and without any required consent of the Optionee) amend this Agreement in such manner
as the Committee deems necessary or appropriate to be exempt from or otherwise comply with the requirements of Section 409A (including
without limitation, amending the Agreement to increase the Exercise Price to such amount as may be required in order for the Option
to be exempt from Section 409A).

 

(b)              
Notwithstanding the foregoing, the Company does not make any representation to the Optionee that the Option awarded pursuant
to this Agreement is exempt from, or satisfies, the requirements of Section 409A, and the Company shall have no liability or other
obligation to indemnify or hold harmless the Optionee or any Beneficiary for any tax, additional tax, interest or penalties that
the Optionee or any Beneficiary may incur in the event that any provision of this Agreement, or any amendment or modification thereof
or any other action taken with respect thereto, that either is consented to by the Optionee or that the Company reasonably believes
should not result in a violation of Section 409A, is deemed to violate any of the requirements of Section 409A.

 

36.             
Incentive Stock Option Treatment. If designated on Schedule I hereof as an Incentive
Stock Option: (a) the terms of this Option shall be interpreted in a manner consistent with the intent of the Company and the
Optionee that the Option qualify as an Incentive Stock Option under Section 422 of the Code; (b) if any provision of the Plan
or this Agreement shall be impermissible in order for the Option to qualify as an Incentive Stock Option, then the Option shall
be construed and enforced as if such provision had never been included in the Plan or the Option; and (c) if and to the extent
that the number of Options granted pursuant to this Agreement exceeds the limitations contained in Section 422 of the Code on
the value of Shares with respect to which this Option may qualify as an Incentive Stock Option, this Option shall be a Non-Qualified
Stock Option.

 

37.             
Section Headings. The Section headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

38.             
Governing Law and Venue. THIS AGREEMENT SHALL AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEVADA WITHOUT GIVING EFFECT TO ANY CHOICE OR CONFLICT OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF
NEVADA OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF NEVADA.
EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF THE COURTS LOCATED IN THE STATE OF CALIFORNIA AND AGREES
THAT ANY LITIGATION BETWEEN THE PARTIES WILL BE FILED IN COURTS LOCATED IN LOS ANGELES, CALIFORNIA.

 

 

 

    	 	30	 

     

    

 

39.             
Arbitration. By execution hereof, the parties hereto expressly agree that upon the
request of any party, whether made before or after the institution of any legal proceeding, any action, dispute, claim or controversy
of any kind, whether in contract or in tort, statutory or common law, legal or equitable, arising between the parties in any way
arising out of any of the provisions contained in this Agreement shall be resolved by binding arbitration administered by the
American Arbitration Association (the “AAA”) and in Los Angeles, California. Such arbitration shall be conducted in
accordance with the Commercial Arbitration Rules of the AAA and, to the maximum extent applicable, the Federal Arbitration Act
(Title 9 of the United States Code) except as otherwise specified herein. Judgment upon the award rendered by the arbitrator may
be entered in any court having competent jurisdiction. The arbitrator shall resolve all disputes in accordance with the applicable
substantive law. A single arbitrator shall be chosen and shall decide the dispute, unless the amount sought in the dispute exceeds
$100,000, in which case a panel of three arbitrators shall decide the dispute. In all arbitration proceedings in which the amount
of any award exceeds $100,000, in the aggregate, the arbitrator(s) shall make specific, written findings of fact and conclusions
of law. In all arbitration proceedings in which the amount of any award exceeds $100,000, in the aggregate, the parties shall
have, in addition to the limited statutory right to seek a vacation or modification of an award pursuant to applicable law, the
right to vacation or modification of any award that is based, in whole or in part, on an incorrect or erroneous ruling of law
by appeal to an appropriate court having jurisdiction; provided, however, that any such application for a vacation or modification
of such an award based on an incorrect ruling of law must be filed in a court having jurisdiction over the dispute within 15 days
from the date the award is rendered. The findings of fact of the arbitrator(s) shall be binding on all parties and shall not be
subject to further review except as otherwise allowed by applicable law. No provision of this Agreement nor the exercise of any
rights hereunder shall limit the right of any party, and any party shall have the right during any dispute, to seek, use, and
employ ancillary or preliminary remedies, such as injunctive relief (including, without limitation, specific performance), from
a court having jurisdiction before, during, or after the pendency of any arbitration. The institution and maintenance of any action
for judicial relief or pursuit of provisional or ancillary remedies shall not constitute a waiver of the right of any party to
submit any dispute to arbitration nor render inapplicable the compulsory arbitration provisions hereof.

 

40.             
Attorney’s Fees. If any action is brought to enforce or interpret the terms of
this Agreement (including through arbitration), the prevailing party shall be entitled to reasonable attorneys’ fees, costs,
and necessary disbursements in addition to any other relief to which such party may be entitled.

 

41.             
Counterparts. This Agreement may be executed in any number of counterparts and shall
be effective when each party hereto has executed at least one counterpart, with the same effect as if all signing parties had
signed the same document. All counterparts will be construed together and evidence only one agreement, which, notwithstanding
the actual date of execution of any counterpart, shall be deemed to be dated the day and year first written above. In making proof
of this Agreement, it shall not be necessary to account for a counterpart executed by any party other than the party against whom
enforcement is sought or to account for more than one counterpart executed by the party against whom enforcement is sought.

 

42.             
Execution by Facsimile. The manual signature of any party hereto that is transmitted
to any other party by facsimile or in portable document format (PDF) shall be deemed for all purposes to be an original signature.

 

 

 

 

 

 

Remainder of page intentionally left
blank; signature page follows.

 

 

    	 	31	 

     

    

 

IN WITNESS WHEREOF, the undersigned
have executed this Agreement as of the 26th day of June 2019.

 

	 	COMPANY:
	 	Odyssey Group International, Inc.
	 	 
	 	By:	/s/ J. Michael Redmond
	 	 	Name: J. Michael Redmond
Title: CEO

 

The Optionee acknowledges
receipt of a copy of the Plan and represents that he or she has reviewed the provisions of the Plan and this Agreement in their
entirety, is familiar with and understands their terms and provisions, and hereby accepts this Option subject to all of the terms
and provisions of the Plan and this Agreement. The Optionee further represents that he or she has had an opportunity to obtain
the advice of counsel prior to executing this Agreement.

 

 

	 	OPTIONEE:
	 	 
	Dated: 07-11-19	/s/ Luis J. Mejia

        Luis J. Mejia, Managing Partner

        Name: Murdock Capital Partners

        15 W. 53rd St.

        New York, NY 10019

 

 

 

 

 

 

 

 

 

    	 	32	 

     

    

 

SCHEDULE I

 

	NAME OF OPTIONEE:	Murdock Capital Partners
	DATE OF GRANT:	June 26, 2019
	TYPE OF OPTION:	Incentive Stock Option          No
	 	Non-Qualified Stock Option          Yes
	NUMBER OF OPTIONED SHARES:	240,000
	EXERCISE PRICE:	$1.25 per Share
	TERMINATION DATE:	None 
	VESTING:	
        100,000 vest immediately

        40,000 vest upon the first anniversary date of the Intellectual
        Property Purchase Agreement

        100,000 vest on the second anniversary date of the Intellectual
        Property Purchase Agreement or upon FDA submission whichever occurs first.

	PERMISSION TO PAY WITH SHARES:	__X_  Granted ____ Denied 
	EXPANDED RIGHTS TO TRANSFER OPTION:	Options may be transferred to a family
member

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	33	 

     

    

 

EXHIBIT “B”

 

ROYALTY AGREEMENT

 

THIS AGREEMENT (this "Agreement")
is entered into as of June 26, 2019 by and between Odyssey Group International Inc., Inc. a corporation organized under the laws
of the State of Nevada (“Odyssey”), Murdock Capital Partners a New York corporation, (“MCP”) and James
De Luca an individual (“De Luca”) are hereinafter collectively referred to as the Parties.

 

WHEREAS, the Parties have
entered into an Intellectual Property Purchase Agreement and other related agreements pursuant to which Odyssey is purchasing certain
intellectual property and related assets from De Luca as set forth therein (the "Acquisition Agreement");

 

WHEREAS, as part of the
consideration of the Acquisition Agreement, De Luca shall assign, and Odyssey shall acquire, all right, title, and interest in
and to patents that are owned by De Luca pursuant to that certain “Patent Assignment” (defined herein below) in exchange
for payment of certain royalties to De Luca and MCP, among other consideration.

 

NOW, THEREFORE, for and
in consideration of the Parties’ Acquisition Agreement, Patent Assignment and the mutual covenants contained herein, and
for other good and valuable consideration receipt of which each party hereby acknowledges, the Parties, intending to be legally
bound hereby, agree as follows:

 

1. DEFINITIONS

 

1.1 "AFFILIATE" shall mean any entity
in which Odyssey or De Luca or MCP (as the case may be), directly or indirectly, or through one or more intermediaries, holds the
beneficial ownership of more than fifty percent (50%) or the equity securities or interests, and only so long as such ownership
continues.

 

1.2 "ASSIGNED PATENTS" shall mean
the patent “USPTO Patents Number RE45, 535 E issued on June 2, 2015 and Patent Number 8,454,624 B2; issued June 4, 2013,
both patents are related to a Choking Rescue Device a copy of which is attached as Exhibit “A” to this Agreement.

 

1.3 “PATENT ASSIGNMENT” shall mean
the Patent Assignment Agreement attached as Exhibit “G” to the Acquisition Agreement.

 

2. GRANT OF RIGHTS.

 

2.1 De Luca shall assign all of De Luca's right,
title and interest in the Assigned Patents, subject to the conditions set forth in Section 2.3 of this Agreement and pursuant to
the terms of the Patent Assignment. In order to affect such ownership transfer, contemporaneously with the execution of this Agreement,
De Luca has executed that certain separate assignment document, to be recorded with the United States Patent and Trademark Office
in a form determined by Odyssey to be appropriate. De Luca shall reasonably cooperate with Odyssey, at Odyssey’s sole expense,
in the filing and prosecution of the Assigned Patent.

 

2.2 De Luca promptly shall deliver to Odyssey
(or provide access to) all documentation in its possession or control pertaining to the Assigned Patents, including, to the extent
possessed, copies of all correspondence to or from examining authorities regarding such Assigned Patents, patents and prior art
searches pertaining to such Assigned Patent, and all correspondence with any attorney involved in the preparation and/or prosecution
of the Assigned Patents.

 

 

 

    	 	34	 

     

    

 

3. ROYALTY 

 

3.1 Odyssey shall pay De Luca and MCP an amount
equal to a total of three percent (3%) of all net profits accounted by Odyssey from any sale, use, derivation, license, grant or
transfer of any rights in, to or regarding the Assigned Patents,, the commercial exploitation of the Assigned Patents, (the “Royalty”).
Odyssey will pay De Luca sixty (60) percent of the Royalty and Odyssey will pay forty (40) percent of the Royalty to MCP. Net Royalty
shall be determined by GAAP

 

3.2 After FDA approval or the first commercial
exploitation of the Assigned Patents whichever occurs first, during each calendar quarter this Agreement is in effect (January
through March being the First Quarter, April through June being the Second Quarter, July through September being the Third Quarter
and October through December being the Fourth Quarter) commencing with the end of the first calendar quarter after the date of
first commercial sale of any product sold by Odyssey that contains the Assigned Patents. Odyssey shall deliver to De Luca and MCP,
within thirty (30) days from the last day of the calendar quarter, an accurate and complete written statement setting forth Odyssey’s
calculations of all Royalty payments due De Luca and MCP from net profits accounted during such calendar quarter, including all
amounts of net profits accounted from whatever sources related to the Royalty during the quarter, certified as to accuracy by an
appropriate representative of Odyssey. Time is of the essence of this provision. Odyssey hereby grants De Luca the right to audit
and inspect Odyssey’s records and operations relating to the Royalty (including the right to access Odyssey’s proprietary
or confidential business information to the extent reasonably necessary, provided that De Luca agrees to keep all such information
confidential when identified as such by Odyssey), one time per year and upon reasonable notice, to insure the amount of the Royalty
paid to De Luca under the terms of this Agreement is accurate and appropriate. The costs of the audit will be at De Luca’s
expense. However, in the event that the audit reveals an underpayment of a royalty by Odyssey, Odyssey shall pay any undisputed
difference within fifteen (15) calendar days following written notice of the underpayment. If the underpayment is in excess of
three percent of the royalty due De Luca and MCP, then Odyssey shall reimburse De Luca and MCP for the reasonable, actual and documented
cost of the audit.

 

3.3 All payments of Royalty amounts shall be
paid within thirty (30) days of the last day of the calendar quarter during which revenues are accounted. De Luca and MCP shall
be entitled to Royalty payment commencing on the date of this Agreement and ending at such time Odyssey is no longer able to generate
revenues from the sale, use, derivation, license, grant or transfer of any rights in, to or regarding the Assigned Patent.

 

4. WARRANTIES AND LIMITATION OF LIABILITY

 

4.1 WARRANTIES.

 

4.1.1 MCP represents and warrants that: (a)
it is a corporation duly organized, validly existing, and in good standing under the laws of the State of New York and has full
power and authority to enter into this Agreement and perform its obligations hereunder; (b) immediately prior to the execution
of this Agreement (and subject to such licenses as have been disclosed to Odyssey in writing), De Luca has full power and authority
to enter into this Agreement and perform its obligations and owns all right, title and interest in and to the Assigned Patent;
and (c) it has the legal right to grant all the rights it purports to grant and to convey all the rights it purports to convey
pursuant to Section 2.1 above.

 

4.1.2 Odyssey represents and warrants that:
(a) Odyssey Group International, Inc. it is a corporation duly organized, validly existing, and in good standing under the laws
of the State of Nevada; (b) Odyssey has full power and authority to enter into this Agreement and perform its obligations hereunder.

 

4.1.3 EXCEPT AS PROVIDED IN THIS SECTION 4.1
AND UNDER THE TERMS OF THE ACQUISITION AGREEMENT AND ANY AGREEMENTS ATACHED THERETO AS EXHIBITS, EACH PARTY DISCLAIMS ALL WARRANTIES,
EITHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO ANY (IF ANY) IMPLIED WARRANTIES OF MERCHANTABILITY, OF FITNESS
FOR A PARTICULAR PURPOSE, AND OF LACK OF NEGLIGENCE OR LACK OF WORKMANLIKE CONDUCT OR EFFORT. ALL PATENTS ASSIGNED UNDER THIS AGREEMENT
ARE PROVIDED AS IS WITH ALL FAULTS, AND NO WARRANTIES OR PROMISES ARE MADE THAT THE SAME WILL WORK OR WORK FOR ANY PARTICULAR PURPOSE.
EXCEPT AS PROVIDED IN THIS SECTION 4.1, THERE IS NO WARRANTY OF TITLE, AUTHORITY OR NON-INFRINGEMENT IN ANY SUCH PATENT.

 

 

 

    	 	35	 

     

    

 

4.2 LIMITATION OF LIABILITY. TO THE MAXIMUM
EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL ANY PARTY BE LIABLE FOR ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES
WHATSOEVER ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THE IMMEDIATELY PRECEDING SENTENCE SHALL HAVE NO APPLICABILITY TO ANY LEGAL CAUSE OF ACTION ARISING FROM ANY PARTY'S ACTIVITIES
OUTSIDE THE SCOPE OF THIS AGREEMENT.

 

5. GENERAL

 

5.1 ENTIRE AGREEMENT. This Agreement constitutes
the entire agreement of the Parties with respect to the subject matter hereof, and to the extent that this agreement is inconsistent
with any other agreement(s) between the Parties, the terms of this agreement are to control.

 

5.2 AMENDMENT. This Agreement shall not be
amended or otherwise modified except by a written agreement dated after the date of this Agreement and signed on behalf of Odyssey,
MCP and De Luca by their respective duly authorized representatives.

 

5.3 GOVERNING LAW. This Agreement shall be
governed by and construed in accordance with the laws of California.

 

5.4 ASSIGNMENT. This Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and assigns.

 

5.5 NO WAIVER. No waiver of any breach of any
provision of this Agreement shall constitute a waiver of any prior, concurrent or subsequent breach of the same or any other provisions
hereof, and no waiver shall be effective unless made in writing and signed by an authorized representative of the waiving party.

 

5.6 SAVINGS CLAUSE. If any provision of this
Agreement shall be held by a court of competent jurisdiction to be illegal, invalid or unenforceable, the remaining provisions
shall remain in full force and effect.

 

5.7 FURTHER ASSURANCES. Each party agrees to
take such further action and execute, deliver and/or file such documents or instruments as are reasonably necessary to carry out
the terms and purposes of this Agreement.

 

5.8 SECTION HEADINGS. The section headings
used in this Agreement are intended for convenience only and shall not be deemed to supersede or modify any provisions.

 

5.9 FEES AND EXPENSES. All fees, costs and
expenses incurred in connection with this Agreement shall be paid by the Party incurring the same. Notwithstanding the foregoing,
in the event the Parties engage in litigation relating to or arising out of this Agreement or the performance thereof, the Parties
agree that the Court shall be asked to determine which Party is the prevailing Party to the proceeding or proceedings, and the
non-prevailing Party or Parties shall, jointly and severally, be liable to the prevailing Party in the amount of all reasonable
attorney’s fees, court costs, and all other expenses, incurred by the prevailing Party to the proceeding in addition to any
other relief to which the prevailing Party may be entitled.

 

 

 

 

    	 	36	 

     

    

 

IN WITNESS, WHEREOF, the parties have executed
this Agreement as of the Effective Date.

 

 

 

ODYSSEY GROUP INTERNATIONAL, INC.

 

 

/s/ J. Michael Redmond                 June 27, 2019

J. Michael Redmond                      Date

President/CEO

 

 

 

 

DE LUCA, INC.

 

 

/s/ James De Luca                          June 27,2019

James De Luca                               Date

 

 

 

 

MURDOCK CAPITAL PARTNERS

 

 

/s/ Luis Mejia                                  July 11, 2019

By:                                                    Date

 

 

 

    	 	37	 

     

    

 

Exhibit A

Assigned Patents

 

 

“USPTO Patents Number RE45, 535 E issued on June 2, 2015 and
Patent Number 8,454,624 B2; issued June 4, 2013, both patents are related to a Choking Rescue Device

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	38	 

     

    

 

EXHIBIT “C”

 

CONSULTING AGREEMENT

This Consulting Agreement (the "Agreement")
is entered into as of this 26th day of June 2019 (the "Effective Date"), by and between Odyssey Group International,
Inc. a Nevada corporation with offices at 2372 Morse Ave., Irvine, CA 92614 (the "Company") and James De Luca at 15 Wendover
Road, Forest Hills Gardens, NY 11375 ("Consultant") and Murdock Capital Partners (“Consultant”). James De
Luca and Murdock Capital Partners may be collectively referred to as “Consultants”. Together, the Company and Consultants
may be referred to as the "Parties".

 

WHEREAS, Consultants possesses
certain skills and expertise;

 

WHEREAS, Company wishes to retain
the services of Consultants on the terms and conditions set forth below, and

 

WHEREAS, Consultants are willing
to provide services to the Company, on the terms and conditions set forth below,

 

NOW, THEREFORE, the Parties agree
as follows:

 

		1.	Services. Consultants will perform the services set forth on Exhibit B, or as amended by mutual written agreement. It
is agreed and understood that the nature and manner of services provided hereunder shall be within Consultant’s area of professional
expertise and/or historical experience.

 

		(a)	Direction. Consultant shall be directed by and shall report to Company’s President or his successor as requested
by the Company.

 

		(b)	Start Date. Consultant's consulting obligations to Company shall begin when the Company has raised a minimum of six
hundred thousand dollars ($600,000.00) for the development of the anti choking device. Term. This Agreement shall commence
on the Start Date and, unless earlier terminated in accordance with Section 15, shall continue for one year thereafter (the "Term").

 

		2.	Method of Performance. The Consultant shall determine the method, details, and means of performing and fulfilling the
duties hereunder.

 

		3.	Other Employment. The Company acknowledges and agrees that Consultant may assume other commitments, and has ongoing
or intends to obtain engagements outside of Consultant's work for Company during the Term ("Other Engagements"); provided
that Consultant fully complies with the confidentiality and non-compete obligations contained in this Agreement. Consultant shall
reasonably notify Company of any Other Engagements, which may pose a conflict of interest prior to undertaking such Engagements,
it being understood that such notice shall allow Company sufficient basis to proceed in accordance with Section 15(b)(2), below
if necessary.

 

		4.	Status as Independent Contractor; Nature of Relationship. It is agreed and understood that the Consultant is an independent
contractor and will not act as an agent nor shall he or she be deemed an employee of Consultant for the purposes of any employee
benefit programs, income tax withholding, FICA taxes, unemployment benefits, and worker’s compensation insurance, or otherwise.
Consultant shall not enter into any agreement or incur any obligations on Company’s behalf, or commit Company in any manner
without Company’s prior written consent.

 

		5.	Resources. Upon Consultant's reasonable request, the Company shall provide such incidental resources to Consultant as
the Company in its discretion believes may be warranted.

 

 

 

    	 	39	 

     

    

 

		6.	Compensation. It is agreed and understood, that subject to the Term and performance and under Section 1, the Consultant
shall be paid as set forth in Exhibit A. Consultant shall be solely responsible for and agrees that he or she will in a timely
fashion pay all federal, state and other taxes on the amounts set forth in this Section.

 

		7.	Expenses. Consultant will be reimbursed for the reasonable expenses, pre-approved by the Company that Consultant incurs
directly in connection with services provided under this Agreement, following the submission of documentation evidencing and confirming
such expenses.

 

		8.	Compliance with all Laws. Consultant agrees that in the course of providing his services to the Company, he or she will
not knowingly engage in any practice or commit any acts in violation of any federal, state or local law or ordinance.

 

		9.	Non-Disclosure Obligations.

 

		(a)	Definition of "Information." “Information” shall mean materials, data, or information in any form,
whether written, oral, digital, or otherwise, provided by or obtained from Company, Company's agents, or Company's contractors
in connection with the Consultant's engagement by Company. Technical or business information of a third person furnished or disclosed
to the Consultant under this Agreement shall constitute Information of Company unless otherwise specifically indicated in writing.

 

		(b)	Confidential Information. For purposes of this Agreement, the term "Confidential Information" shall mean Information
regarding Company's business including, but not limited to, Information regarding medical device products, software, processing
and manufacturing capabilities, copyrighted or patentable subject matter, research, development, innovations, inventions, designs,
technology, improvements, trade secrets, business affairs and finances, customers, employees, operations, facilities, consumer
markets, products, capacities, systems, procedures, security practices, data formats, and business methodologies. Confidential
Information dies not include information which: (i) is in the public domain at the time of disclosure; (ii) was in the possession
of Consultant free of any obligation of confidence prior to the time of disclosure by the Company; (iii) though originally Confidential
Information, subsequently becomes part of the public knowledge through no fault of Consultant, as of the date of its becoming part
of the public knowledge; (iv) though originally Confidential Information, subsequently is rightfully received by Consultant without
obligations of confidence from a third party who is free to disclose the information, as of the date of such third-party disclosure;
or (v) is independently developed by Consultant without the use of any Confidential Information, as of the date of such independent
development.

 

		(c)	Consultant's Obligations. All Confidential Information relating to or obtained from Company by the Consultant shall
be maintained in confidence by the Consultant, and the Consultant shall use best efforts to protect and safeguard the Confidential
Information.

 

		(d)	Use of Confidential Information. Without Company's prior written approval, the Consultant: (a) shall not use Confidential
Information directly or indirectly for any purpose except in connection with the services the Consultant performs on behalf of
Company; and (b) shall not disclose, sell, assign, transfer, share or lease Confidential Information of Company, or make such Confidential
Information available to, or make it available for the use or benefit of, any third party.

 

		10.	Former Engagement Information. The Consultant shall not, during the Consultant's engagement with the Company, improperly
use or disclose any proprietary information or trade secrets of any former employer, hiring party, or other person or entity with
which the Consultant has an agreement or duty to keep in confidence, if any, and shall not bring onto the premises of the Company
any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing
by such employer, person, hiring party, or entity.

 

 

 

    	 	40	 

     

    

 

		11.	Court or Agency Order. In the event the Consultant receives a subpoena or order of a court or administrative body requesting
disclosure of Company’s Confidential Information, the Consultant agrees (a) that, as promptly as possible after learning
of such disclosure obligation and before making such disclosure, the Consultant shall notify Company of such obligation to make
such disclosure, to allow Company an opportunity to object to such disclosure or to obtain a protective order or other appropriate
relief; (b) that the Consultant shall provide such cooperation and assistance, at Company's expense, as Company may reasonably
request in any effort by Company to obtain such relief; and (c) that the Consultant shall take all appropriate steps to limit the
amount and scope of Confidential Information so disclosed and to protect its confidentiality.

 

		12.	Non-Solicitation and Non-Compete. The Consultant agrees not to solicit or encourage employees of Consultant to work
for a Competitor during the Term, and for a period of one year after expiration of the Term. "Competitor" means any person
or organization, including the Consultant him or herself, engaged in, or about to become engaged in, research on or the acquisition,
development, production, distribution, marketing or providing of a Competing Product. "Competing Product" means any product,
process, or service of any person or organization other than the Company, in existence or under development, which both (A) is
identical to, substantially the same as, or an adequate substitute for any product, process, or service of the Company, in existence
or under development, on which the Consultant works during the Term or about which the Consultant acquires Confidential Information,
and (B) is (or could reasonably be anticipated to be) marketed or distributed in such a manner and in such a geographic area as
to actually compete with such product, process or service of the Company.

 

		13.	Inventions. For purposes of this Agreement, the term "Inventions" shall mean any and all inventions, original
works of authorship, developments, concepts, improvements, or trade secrets (whether or not patentable or registrable under copyright
or similar laws) which relate to the business of the Company and which the Consultant either (i) solely or jointly conceives, develops,
or reduces to practice during Company time, at the Company's direction, or using Company equipment or resources; or (ii) solely
or jointly conceives, develops, or reduces to practice based on Company Confidential Information. The Consultant will promptly
make full written disclosure of Inventions to the Company and will hold such Inventions in trust for the sole right and benefit
of the Company. The Consultant hereby assigns to the Company all the Consultant's right, title and interest in and to Inventions.
Without limiting the foregoing, the Consultant further acknowledges that all Inventions (x) which are original works of authorship;
(y) which are made by the Consultant (solely or jointly with others) within the scope of the Consultant's engagement hereunder;
and (z) which are protectable by copyright, shall be deemed, to the extent applicable, “works made for hire,” as that
term is defined in the United States Copyright Act.

 

		14.	Patent and Copyright Registration. The Consultant agrees to assist the Company, or its designee, at the Company’s
expense, in every reasonable way to secure the Company’s rights in the Inventions and any copyrights, patents, mask work
rights or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company
of all pertinent information and data with respect thereto and the execution of all applications, specifications, oaths, assignments
and all other instruments which the Company shall deem necessary in order to apply for and obtain such rights and in order to assign
and convey to the Company, its successors, assigns and nominees the sole and exclusive rights, title and interest in and to such
Inventions, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto.

 

		15.	Termination. This Agreement may be terminated without liability as follows:

 

		(a)	For Cause. If either Party is in material breach, the non-breaching party may terminate this Agreement upon providing
the breaching party (a) with written notice, specifying the breach, and (b) with a ten (10) day opportunity to cure, commencing
upon the effective date of such notice.

 

		(b)	For Convenience. Either Party may terminate this agreement upon fifteen (15) days notice except that if the Company
terminates this Consulting agreement under this provision 15(b) Consultant shall be paid the amounts set forth in Exhibit B up
to and including the end of the term of this agreement.

 

 

 

    	 	41	 

     

    

 

		16.	Survival. The following provisions shall survive the expiration or termination of this Agreement: Sections 9, 11, 12,
14, and 17.

 

		17.	Return of Property. Consultant expressly agrees that upon completion of his or her consulting services under this Agreement,
or at any time prior to that time upon request of the Company, Consultant will return to the Company all property of the Company
obtained or received by Consultant during the Term of this Agreement including, but not limited to, any and all files, computers,
computer equipment, software, diskettes or other storage media, documents, papers, records, notes, agenda, memoranda, plans, calendars
and other books and records of any kind and nature whatsoever containing Confidential Information concerning the Company or its
customers or operations.

 

		18.	No Oral Modification. This Agreement may not be changed orally, and no modification, amendment, or waiver of any provision
contained in this Agreement, or any future representation, promise, or condition in connection with the subject matter of this
Agreement shall be binding upon any party hereto, unless made in writing and signed by such party.

 

		19.	Entire Agreement. This Agreement contains the entire agreement between the Parties and supersedes any and all previous
agreements of any kind whatsoever between them, whether written or oral, and all prior and contemporaneous discussions and negotiations
have been and are merged and integrated into, and are superseded by, this Agreement. This is an integrated document.

 

		20.	Severability. In the event that any provision of this Agreement or the application thereof should be held to be void,
voidable, unlawful or, for any reason, unenforceable, the remaining portion and application shall remain in full force and effect,
and to that end the provisions of this Agreement are declared to be severable.

 

		21.	Governing Law. This Agreement is made and entered into, and shall be subject to, governed by, and interpreted in accordance
with the laws of the California and shall be fully enforceable in the courts of that state, without regard to principles of conflict
of laws. The Parties (i) agree that any suit, action or other legal proceeding arising out of this Agreement may be brought
in the United States District Court for the District of California, or if such court does not have jurisdiction or will not accept
jurisdiction, in any court of general jurisdiction in California; (ii) consent to the jurisdiction of any such court; and
(iii) waive any objection which they may have to the laying of venue in any such court. The Parties also consent to the service
of process, pleadings, notices or other papers by regular mail, addressed to the party to be served, postage prepaid, and registered
or certified with return receipt requested.

 

		22.	Notices. All notices, requests, consents, approvals and other communications required or permitted under this Agreement
("Notices") shall be in writing and shall be delivered to the addresses listed above, by a overnight courier service,
by hand, or by facsimile transmission, unless otherwise provided in this Agreement. Such Notices shall be effective (i) if sent
by overnight courier service, three business days after mailing; (ii) if sent by hand, on the date of delivery; and (iii) if sent
by facsimile, on the date indicated on the facsimile confirmation. Any party may change its address or facsimile number for notification
purposes by giving all of the individuals and entities noted above notice, in accordance with the notice provisions set forth in
this Section, of the new address or facsimile number and the date upon which it will become effective.

 

		23.	Assignment. Either Party may assign this Agreement. No party may assign either this Agreement or any of its rights,
interests, or obligations hereunder without the prior written approval of the other parties and such approval shall not unreasonably
be withheld. Subject to the preceding sentence, this Agreement shall be binding upon and shall inure to the benefit of the parties
hereto and their respective successors and permitted assigns.

 

		24.	Counterparts. This Agreement may be executed in counterparts, and each counterpart, when executed, shall have the effect
of a signed original.

 

 

 

 

    	 	42	 

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have caused this Agreement to be executed by the undersigned duly authorized persons as of the day and year above stated.

 

Odyssey Group International, Inc.

 

 

By:/s/ J. Michael Redmond

Name: J. Michael Redmond

Title: President and CEO

 

 

 

 

CONSULTANT

 

/s/ James De Luca 

James De Luca

 

DATE: June 27, 2019

 

 

 

 

CONSULTANT

 

/s/ Luis J. Mejia 

Luis J. Mejia

Murdock Capital Partners

 

DATE: July 11, 2019

 

 

 

 

    	 	43	 

     

    

 

EXHIBIT “A”

 

 

CONSULTANT SERVICES

AND

PAYMENT SCHEDULE

 

 

 

 

  

PAYMENT SCHEDULE

 

		1.	Monthly Cash Compensation will begin at a time when the Company has raised a minimum of six hundred thousand dollars ($600,000.00)
for the development of the anti choking device and will continue for one year thereafter. The monthly cash compensation will be
a total of $10,000.00 per month, six thousand dollars ($6,000.00) of which will be paid directly to De Luca and four thousand ($4,000.00)
will be paid directly to MCP.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	44	 

     

    

 

EXHIBIT B

 

SERVICES

 

Consultant shall assist in all technology transfer related
to the Purchased Assets as defined in the Intellectual Property Purchase Agreement.

 

Consultant shall assist with the development and commercialization
efforts of the Purchased Assets.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	45	 

     

    

 

EXHIBIT “D”

 

PATENT ASSIGNMENT AGREEMENT

 

Effective June
26, 2019 (the “Effective Date”) De Luca an individual whose address is 15
Wendover Road, Forest Hills Gardens, NY 11375 (“Assignor”), with its principal address at and Odyssey Group
International, Inc., a Nevada corporation (“Assignee”) with its principle address at 2372 Morse Ave Irvine, CA 92614.

 

ARTICLE I

BACKGROUND

 

WHEREAS, Assignor
has developed and deployed a certain technology and known as “anti choking” and a “choking rescue” device
(the “Platform”); and

 

		a)	WHEREAS, Assignor is the owner of all intellectual property rights in or to the Platform and two
US Patents, The USPTO Patent Number RE45, 535 E issued on June 2, 2015 and Patent Number 8,454,624
B2; issued June 4, 2013, both patents are related to a Choking Rescue Device.

 

WHEREAS, Assignee
is engaged in the development of medical products for commercial use and application, and desires to own the Platform and Assignor’s
intellectual property rights in and to the same; and

 

WHEREAS, Assignor
and Assignee, are parties to that certain Intellectual Property Purchase Agreement whereby Assignor agreed to assign The
USPTO Patent Number RE45, 535 E issued on June 2, 2015 and Patent Number 8,454,624 B2; issued June 4, 2013, both patents are related
to a Choking Rescue Device, and

 

In consideration
of the Intellectual Property Purchase Agreement and other good and valuable consideration, the receipt and adequacy of which is
hereby acknowledged, Assignor does hereby transfer and assign to Assignee, its successors, assigns and legal representatives all
its right, title and interest in and to the patents and the invention entitled:

 

“Device for Removing a Lodged
Mass”

 

Invented
by James De Luca and described in the:

The USPTO
Patent Number RE45, 535 E issued on June 2, 2015 and Patent Number 8,454,624 B2; issued June 4, 2013, both patents are related
to a Choking Rescue Device.

 

and all United
States Letters Patent which may be granted therefor, and all divisions, reissues, continuations and extensions thereof, the said
interest being the entire ownership of the said Patents when granted, to be held and enjoyed by the said Assignee, its successors,
assigns or other legal representatives, to the full end of the term for which said Patent may be granted, as fully and entirely
as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made;

 

And I hereby authorize and request
the Commissioner of Patents and Trademarks to transfer and assign said Patent to the said Assignee.

 

ASSIGNOR

 

By: /s/ James T. De Luca           6/27/19

James De Luca                            Date

 

 

 

    	 	46	 

     

    

 

STATE OF NEW YORK:

: to wit:

CITY OF SUFFOLK:

 

I HEREBY CERTIFY
that on this 27TH day of JUNE, 2019, before me, the undersigned Notary Public of the jurisdiction aforesaid personally
appeared James DE LUCA, and acknowledged himself to be the individual owner of the Platform and that he, being authorized so to
do, executed the foregoing instrument for the purposes therein contained.

 

IN WITNESS MY Hand and
Notarial Seal.

 

	 	Gerald T. Bodner (SEAL)
	 	Notary Public
	 	 
	GERALD T. BODNER

Notary Public, state of New York

NO. 02BO4937733

Qualified in Nassau and Suffolk Counties

My Commission expires: June 30, 2022

	Registration
# : ______________
	 	 
	ACKNOWLEDGED AND ACCEPTED:	 
	 	 
	Odyssey Group International, Inc.	 
	 	 
	By: /s/ J. Michael Redmond

J. Michael Redmon

President/CEO

Odyssey Group international Inc.

	6-27-19

        
Date

 

 

 

 

 

    	 	47

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]